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ABSTRACT 
Allogeneic stem cell transplantation (SCT) is currently the curative therapy of choice for a 
majority of haematological malignancies and primary immune disorders. SCT harnesses 
the multipotent, proliferative potential of haematopoietic stem cells (HSC) to reconstitute 
the recipient’s immune system following myeloablative treatment to eradicate their 
diseased cells. HSC are capable of giving rise to all three lineages that constitute healthy 
mature blood and as such are critical for the success of SCT as a therapy.  
SCT is limited by serious complications including graft failure and graft-versus-host 
disease (GVHD). HSC Engraftment requires that the ingoing HSC to home to and take up 
residence in the bone marrow (BM) microenvironment where they proliferate to 
reconstitute the haematopoietic system. Failure of this initial engraftment results in primary 
graft failure and leaves the recipient without a functional immune system and in a severely 
immunocompromised state. Graft failure may occur as a result of insufficient transplanted 
HSC or failure of the donor HSC to survive the transplant process.  
An additional complication that is closely associated with allogeneic SCT is GVHD, which 
occurs when the donor immune cells recognise recipient tissue as foreign and mount an 
immune response resulting in multi-organ tissue damage associated with significant 
morbidity and mortality. GVHD is driven by the presence of alloreactive T cells included in 
the donor graft. The therapeutic intent of SCT incorporates these T cells for their ability to 
target and destroy residual malignant cells within the patient. Unfortunately they also 
respond to injury signals from host tissue and instigate further tissue damage through 
similar mechanisms. A key primary initiator of GVHD is the cytokine milieu, which is 
triggered in series by tissue damage, injury signals and donor / host antigen presentation 
in the gastrointestinal tract and is characterized by the release of pro-inflammatory 
cytokines. Thus allogeneic SCT elicits a highly inflammatory environment that the 
incoming donor graft must survive and negotiate in order to carry out its intended 
haematopoietic recovery. 
Autophagy is an intracellular survival process that has an established role in the long-term 
survival and function of HSC. We investigated the contribution of autophagy to HSC in the 
setting of allogeneic transplantation and the T cell derived cytokine storm characteristic of 
GVHD. We demonstrate in vitro that both TNF and IL-1 synergistically promote 
autophagy in both HSC and their more mature haematopoietic stem progenitor cells 
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(HSPC). In vivo we demonstrate that autophagy is increased in donor HSC and HSPC in 
the setting of GVHD compared to non-GVHD controls. Competitive transplant experiments 
demonstrated that autophagy deficient cells display reduced capacity to reconstitute the 
haematopoietic system compared to WT counterparts. In an MHC mismatch model of 
GVHD we demonstrated that in the presence of alloreactive T cells and the subsequent 
cytokine milieu, autophagy-deficient HSC / HSPC are overcome and undergo primary graft 
failure. Using several different models we confirm that autophagy activity is increased in 
early progenitor and HSC populations in the presence of T cell derived cytokine stressors; 
that these HSC populations critically require autophagy to survive the inflammatory 
conditions present during GHVD onset and that in the absence of autophagy HSC and 
early progenitor populations fail to provide short term reconstitution leading to primary graft 
failure and mortality. Thus autophagy serves as a key survival mechanism in HSC and 
HSPC populations that is critically required during the process of allogeneic SCT to ensure 
successful engraftment and haematopoiesis in the setting of GVHD. 
An important pathway that mediates aGVHD pathophysiology involves the priming of 
myeloid and lymphoid cells by cytokine signals, which may be released locally or 
systemically, and result in the activation of cognate receptor signalling pathways on a 
variety of target cells. This thesis examines the role of three cytokines that share a 
common beta (c) signalling subunit and are well known for their role in haematopoiesis. 
We demonstrate that c signalling is required by both haematopoietic and non-
haematopoietic compartments. When c signalling is ablated in the recipient, systemic 
levels of Csf2, IL-3 and IL-5 are significantly increased demonstrating that recipient 
signalling serves as a reservoir for these cytokines during the early post-transplant period. 
Recipients lacking c signalling succumb to GVHD more rapidly than WT groups but 
interestingly this outcome can be rescued through the ablation of c signalling in the donor 
graft, suggesting that the elevated c cytokines that accrue in the c-/- recipient are 
signalling a pathogenic population within the donor graft. Interestingly, in a model of 
subclinical aGVHD, where animals survive out long term to a chronic GVHD (cGVHD) 
stage, we observed improved clinical scores in recipients given a WT BM graft together 
with c-/- T cells. This suggests a previously underappreciated role for c signalling in the 
donor T cell graft and suggests that these T cells indeed play a persistent role in cGVHD 
pathology. In total, our data suggests a duplicitous role for c signalling that is both 
pathogenic (in the donor graft) and protective in the recipient. 
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Acute GVHD (aGVHD) occurs during the early post-transplant period and initiates with 
tissue damage and the cytokine storm described earlier. In the second phase of aGVHD 
pathophysiology cytokine signalling plays a key role in driving the differentiation and 
expansion of naïve T cells toward differing maturation lineages and pathophysiological 
outcomes. The final effector phase of aGVHD is typically associated with recipient tissue 
damage in the gastrointestinal tract, liver and skin. Here, cognate T cell-MHC interactions 
evoke effector T cell expansion and cytolytic activity. We have previously identified that 
non-haematopoietic antigen presenting cells (APC) are sufficient to induce lethal aGVHD. 
Here we identify a novel role for the MARCH-family ubiquitin ligases, in particular 
MARCH8, in trafficking MHC II from the surface of non-haematopoietic epithelial APC in 
the gastrointestinal (GI) tract during aGVHD onset. Ablation of MARCH8 results in 
increased surface expression of MHC II in epithelial cells of the GI tract and a subsequent 
expansion of donor T cells within the GI tract, lung, liver and spleen during aGVHD onset. 
In SCT recipients, the ablation of MARCH8 entirely or in non-haematopoietic cells alone, 
results in exacerbated GVHD and reduced survival. This highlights the role of non-
haematopoietic APC in the initiation of aGHVD and identifies MARCH8 as candidate for 
therapeutic control of MHC II surface trafficking. 
Overall, the data presented in this thesis identifies multiple novel aspects that contribute to 
the complications associated with allogeneic SCT, from the health and functional 
engraftment of the primary donor HSC graft to key initiation pathways that mediate the 
onset and severity of GVHD. 
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CHAPTER 1.  INTRODUCTION 
 
 Stem Cell Transplantation 1.1
Stem Cell transplantation (SCT) is currently the primary curative therapy for the majority of 
haematological malignancies, primary immune deficiencies and disorders. Transplantation 
uses a stem cell graft from a healthy, genetically similar individual to reconstitute the 
recipient’s immune system following a process of myeloablative pre-conditioning.  
The success of SCT relies on a unique population of cells called Haematopoietic Stem 
Cells (HSC), which possess the unique capacity to give rise to all of the different 
haematopoietic lineages required for functional immunity [1, 2]. In this way, HSC are 
critical for lifelong blood production, a role that they are uniquely equipped to carry out due 
to their ability to both self-renew and to generate daughter stem cells. As HSC differentiate 
they give rise to subsequent intermediate lineages termed progenitor cells, the fate of 
which become increasingly restricted until they eventually give rise to one of the many 
mature blood cell types [3]. 
 Allogeneic SCT therapy in the clinic 1.2
A donor stem cell graft may be derived from two sources: A patient may be given an 
autologous transplant, meaning that the stem cell graft was harvested from their own bone 
marrow tissue. The alternative is an allogeneic transplant where the donor graft is taken 
from a healthy donor. Autologous transplantation is the standard of choice for diseases 
that do not involve haematopoietic malignancies as they harbour lower risk for rejection, 
GVHD and the patient’s immunity recovers more rapidly which in turn reduces their risk of 
infection. However, patients with haematological malignancies are at risk of relapse from 
residual tumour cells and as such require a healthy donor graft from a genetically matched 
individual. 
The therapeutic potential of SCT for treating haematological malignancy lies with the graft-
versus-leukaemia (GVL) response, which relies on donor T cells in the graft being able to 
identify and eradicate residual leukaemia cells within the recipient. Unfortunately GVL 
responses are closely intertwined with detrimental graft-versus-host disease (GVHD). 
GHVD occurs when these same donor T cells, incorporated for their role in the beneficial 
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GVL response, recognise recipient antigens as foreign and elicit an immune response. 
GHVD results in inflammation and tissue damage within the recipient.  
While allogeneic SCT incorporates selection of a genetically compatible (based on blood 
human leukocyte antigen (HLA) matching) donor for the recipient, inevitable HLA (MHC in 
mouse) mismatches remain and form the driving factor for rapid graft rejection and T cell 
mediated GVHD following transplantation [4]. Despite this, and following on from promising 
advances in the management of acute GVHD in the clinic, the use of haplo-identical 
allografts, for their superior GVL effect, is now a preferred clinical approach to treating 
haematological malignancies [5, 6]. As such, ongoing study into methods to reduce 
alloreactive side effects and improve patient outcomes is required. 
 Pathophysiology of graft-versus-host disease 1.3
Graft-versus-Host Disease (GVHD) affects between 50-70% of patients who receive an 
allogeneic SCT. It occurs in both acute and chronic forms and accounts for the majority of 
morbidity and mortality (around 20%) associated with SCT [7, 8]. 
1.3.1 Acute GVHD 
Acute GVHD (aGVHD) occurs early, within 100 days following HSCT and is unequivocally 
dependent on the presence and function of donor T cells in the donor inoculum [9, 10]. 
Target organs include the gastrointestinal tract, lung and liver. The pathogenesis of 
aGVHD can be divided into three major phases (Figure 1.1): 
1. Conditioning induced inflammatory responses; 
2. Activation of donor T cells by APCs; and 
3. Host target tissue damage. 
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Figure 1.1 Pathophysiology of acute graft versus host disease. Adapted from [11]. 
1. Pre-transplant myeloablative conditioning causes tissue damage 
Prior to transplantation, recipients undergo myeloablative conditioning 
(radiation/chemotherapy), to reduce malignant disease to a minimal residual level and to 
ablate the patients existing immune system. This ablation allows the donor inoculum to 
engraft and reconstitute haematopoiesis and immunity. This conditioning treatment is also 
toxic and causes both tissue damage and associated loss of mucosal barrier function, 
primarily in the gastrointestinal tract [12]. The resultant cellular damage triggers the 
release of bacterial products such as lipopolysaccharide (LPS) and danger-associated 
molecular patterns (DAMPS) arising from GI microbiota. These agents contribute to 
inflammation within the GI tract and the “cytokine storm” which is typically characterized by 
pro-inflammatory cytokines such as TNF, IL-1 and IL-6 [12, 13]. Thus, the GI tract is the 
site of origin for aGVHD pathogenesis and is considered the principal target organ [11, 14].  
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2. Activation of donor T cells by APCs 
Following SCT, the cytokine storm plays a crucial role in donor T cell and APC interactions 
that drive naïve T cell differentiation and expansion [15]. The early dogma prescribed that 
antigen presentation was restricted to host haematopoietic APC, reporting MHC I 
presentation by conventional DC (cDC) as the most efficient APC for CD8+ T cell activation 
in aGVHD [16-19]. However, recent studies using both MHC I and II dependent models 
demonstrate not only that cDC are dispensable for aGHVD onset but additionally that non-
haematopoietic APC alone are sufficient to induce lethal CD4+ mediated aGVHD [20-22]. 
Strikingly, although the GI tract is considered the initiation site for the cytokine storm and 
subsequent aGVHD little has been reported on the role of antigen presentation by host 
non-haematopoietic cells during this early initiation phase of aGVHD. Chapter 5 of this 
thesis examines the role of non-haematopoietic APC in the GI tract as APC during 
aGVHD.   
3. Host target tissue damage 
The final effector phase of aGVHD is characterized by host tissue damage. The organs 
primarily targeted during aGVHD are the skin (81%), the GI tract (54%) and the liver (50%) 
[23]. The infiltration of alloreactive cells and the production of pro-inflammatory cytokines 
result in hallmark apoptosis [12]. CD4+ and CD8+ T cells and natural killer (NK) cells 
infiltrate GVHD target organs and induce injury through the perforin/granzyme B pathway, 
Fas/FasL pathway, TNF and/or TRAIL pathways or direct cytokine mediated injury [24]. As 
previously mentioned, tissue damage driven by pre-conditioning results in elevated pro-
inflammatory cytokines including IL-1 and TNF which are both critical promoters of 
aGVHD and their neutralisation prevents target organ damage [25, 26]. This process is 
regulated by the action of regulatory T cells (Treg) and natural killer T (NKT) cells in 
addition to anti-inflammatory cytokines such as IL-10 and TGF-[27]. 
1.3.2 Chronic GVHD 
Around half of patients treated with allogeneic HSCT develop cGVHD, which is the major 
cause of late non-relapse death following SCT. Chronic GVHD (cGVHD) typically develops 
from 100 days post-transplant but can take as long as 2-5 years for symptoms to become 
evident. It may present de novo (without prior clinical signs of aGVHD) or set in 
progressively as active or aGVHD merging into the chronic form. Older recipient age and 
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prior aGVHD are the greatest risk factors for cGHVD [28] and therefore improved 
strategies to prevent and/or treat aGVHD may in turn help to prevent onset of cGVHD. 
The pathophysiology of cGVHD is complex and less defined than that of aGVHD. It affects 
multiple organs including skin, secretory glands, liver, lungs, oesophagus, joints and the 
gastrointestinal tract. Pathology is characterized by skin dyspigmentation, scleroderma, 
lichenoid oral or vaginal findings, ocular sicca, fibrosis, bronchiolitis obliterans and 
oesophageal web formation [29, 30]. The features of cGVHD are similar to auto-immune 
diseases like scleroderma and systemic lupus erythematosus (SLE). In many cases 
cGVHD can be directly preceded by aGVHD (20-30%) or follow a period of interruption 
(30-40%). In addition, around 35% of patients develop cGVHD despite no prior aGVHD 
symptoms [30]. The incidence of cGVHD remains high in recipients receiving T-cell 
depleted transplants suggesting that non-T cell pathways contribute or that bone marrow 
derived and pathogenic auto-reactive T cell development occurs [31]. Today the majority 
of SCT use G-CSF mobilised peripheral blood as a stem cell source and this has now 
been associated with a significant increase in cGVHD [32]. Importantly, there is currently 
no satisfactory treatment for cGVHD although Csf-1 has emerged as a candidate target for 
the treatment of scleroderma in cGVHD setting [33].  
 Haematopoietic Stem Cells 1.4
Haematopoietic stem cells (HSC) are a rare population that reside in specialized niches 
within the adult bone marrow (BM) and are critical for haematopoiesis. Haematopoiesis 
begins during embryogenesis in the yolk sac at around 6-8 weeks of gestation. HSC 
continue developing in the foetal liver, then the spleen and finally take up residence in the 
bone marrow (BM) where they reside in close association with osteoblasts to provide life-
long haematopoiesis [34]. 
In order to sustain their long life span, HSC possess a unique set of characteristics. The 
BM microenvironment is a hypoxic and low nutrient microenvironment. To survive here, 
HSC enter quiescence; where they are reversibly arrested in the G0/G1 phase of cell 
cycling [35]. This low metabolic, predominantly glycolytic, state of arrest enables HSC to 
remain relatively dormant, and to self-renew at a slow rate and avoid metabolic 
exhaustion. Studies have demonstrated that the ability to enter a quiescent state is a 
critical factor enabling LT-HSC to maintain their lifelong capacity for self-renewal [36-39]. 
Even in a quiescent state, HSC remain poised to transition into active proliferation, 
capable of rapidly giving rise to all haematopoietic cell lineages.   
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The hierarchy of the haematopoietic system is well defined (Figure 1.2). Long-term HSC 
(LT-HSC) represent the most primitive HSC population and possess the ability to both self-
renew and to produce multipotent daughter cells called short-term HSC (ST-HSC). ST-
HSC produce multipotent progeny (MPP) which give rise to the common lymphoid 
progenitors (CLP) and the common myeloid progenitors (CMP). CMP differentiate further 
into granulocyte-monocyte progenitors (GMP), which give rise to granulocytes and 
macrophages and megakaryocyte-erythroid progenitors (MEP), which give rise to 
erythrocytes and platelets. The CLP give rise to mature B and T lymphocytes and natural 
killer (NK) cells. 
 
Figure 1.2 The hierarchical model of haematopoiesis. Adapted from [40]. 
As such, the HSC pool is collectively referred to as a heterogeneous population and for the 
purposes of this thesis LT-HSC and ST-HSC are distinguished from the more 
mature/differentiated progenitor populations which are collectively referred to as 
haematopoietic stem progenitor cells (HSPC).  
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1.4.1 HSC function 
Lifelong haematopoiesis relies on the continued health and function of an organism’s HSC 
compartment. Ultimately, as an organism ages so too does the HSC pool resulting in a 
decline in normal cell function and the onset of haematopoietic-related disease. 
Remarkably, a single purified LT-HSC is capable of indefinite self-renewal together with 
the capacity to give rise to all of the mature haematopoietic lineages that constitute whole 
blood [41-45]. This capacity for self-renewal diminishes as you progress down the 
haematopoietic hierarchy. ST-HSC exhibit limited capacity for self-renewal while 
subsequent HSPC lack this ability entirely. As such, HSPC are primarily responsible for 
short-term haematopoiesis and are rapidly exhausted. Several triggers stimulate HSC to 
enter active cycling and egress from the BM niche including cytokines (IFN and G-CSF) 
and myeloablative agents (5-FU, cyclophosphamide) [46, 47]. As mentioned earlier, G-
CSF–mobilised HSC are currently routinely used as a source for SCT. Another rich source 
of embryonic HSC is the foetal liver (FL). FL-HSC are highly proliferative, capable of 
efficient haematopoiesis and therefore provide a rich source of HSC for SCT [48, 49]. 
Multiple studies have demonstrated that in order both maintain their own health and to 
perform the rigorous requirements for ongoing haematopoiesis, HSC employ a cell survive 
mechanism known as autophagy. 
 Autophagy 1.5
Macroautophagy (herein referred to as autophagy) is considered a cell survival pathway 
and is the most comprehensively described autophagy process in eukaryotic cells. This 
process involves the sequestration of cytoplasmic components into specific cytosolic 
vesicles that deliver them to lysosomes for degradation [50]. It serves to protect cells from 
an accumulation of potentially toxic cytoplasmic aggregates and provide and intrinsic 
source of energy through recycling intracellular constituents [51]. This pathway is highly 
conserved in eukaryotes and is regulated by both developmental and environmental 
factors including nutrient starvation, hypoxia and reactive oxygen species (ROS) [52]. 
Autophagy is employed throughout various stages of cell lifecycle, including development, 
immunity, intracellular quality control, tumour suppression, stress responses and even cell 
death [53-57] [58, 59]. This process serves to maintain healthy function and long-term 
survival of HSC and their progeny during homeostatic blood production and also plays a 
role during the dysregulated production of leukemic cells.  
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1.5.1 The autophagy process 
The autophagic process requires the co-ordinated interaction of more than 30 autophagy-
related genes (Atg). Autophagy activity is repressed by the Mechanistic Target Of 
Rapamycin Complex 1 (mTORC1). However, mTORc1 activity is inhibited by cellular 
stressors such as nutrient deprivation (cellular starvation), cytokines or growth factors and 
this subsequently results in the activation of autophagy within the cell. Upon induction of 
autophagy, a membrane structure referred to as the isolation membrane, forms a cup-
shaped structure that expands to sequester cytoplasmic materials that have been marked 
for degradation. In a series of highly controlled processes, which will be detailed below, 
this membrane eventually seals to form the well-described double membrane-bound 
autophagosome which eventually fuses with a lytic compartment [55, 60, 61]. To follow, 
the autophagy process is described and illustrated in Figure 1.3. 
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Figure 1.3 The autophagy process. 
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Autophagy initiation 
In mammalian cells, the earliest autophagy specific structure forming de novo is a small 
punctum of the ULK1 (UNC-51-like kinase) complex [62]. The ULK complex comprises 
ULK1/2-ATG13-FIP200-ATG101 proteins and has recently been identified to emerge from 
regions where ATG9 vesicles cluster and align with the endoplasmic reticulum (ER). This 
association between ATG9 and early ATG13 structures precedes any isolation membrane 
structure. High-resolution imaging revealed that these ATG13 assemblies already assume 
quasi-spherical morphology suggesting that the ULK1 complex may provide early 
membrane organization function and that ULK1 may act by usurping membrane from the 
ATG9 compartment in a nucleation step that gives rise to an omegasome [62]. ULK1 is 
known to associate uniquely with the early autophagy machinery and genetic ablation of 
ULK1 components has been demonstrated to disarm autophagy entirely [63, 64]. Thus the 
expanding omegasome provides an early membrane platform, coalesced with the ER, to 
which the remaining core autophagy machinery is recruited. 
Autophagosome formation requires sequential translocation of autophagy-specific proteins 
to membrane regions attached to the ER and enriched in phosphatidylinositol 3-phospate 
(PI3P) [62]. Following mTORc1 inactivation, increased ULK1 kinase activity 
phosphorylates Ambra1 protein and stimulates Beclin-1 (Atg6) activation, two components 
of the class III PI3K (Phospholnositide-3-Kinase) complex. Beclin-1 activates the catalytic 
subunit of the PI3K complex, the lipid kinase VPS34 (vacuolar protein sorting 15 and 34). 
VPS34 acts in complex with BECLIN1 and ATG14 to stimulate synthesis of PI3P at the 
periphery of budding phagophore membrane.  
Membrane Elongation 
Following the initiation of autophagy, elongation and closure of the phagophore membrane 
enables formation of the autophagosome. This process requires two ubiquitin-like 
conjugation systems: Atg12-Atg5-Atg16L and LC3-PE (microtubule associated Light Chain 
3-Phosphatidyl Ethanolamine / Atg8). Formation of the Atg12-Atg5-Atg16L complex begins 
with covalent association between Atg12 and Atg5, a union that is activated by Atg7 and 
Atg10.  The lipidation machinery Atg16L, attracted to the PI3P enriched regions of the 
phagophore membrane, then links with Atg5-Atg12. The Atg5-Atg12-Atg16L complex 
plays a key role in expansion of the phagophore membrane and also acts as a ligase 
stimulating the LC3-PE interaction with the phagophore membrane [65].  
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Formation of the LC3-PE complex begins with cleavage of the LC3 precursor, pro-LC3 to 
the cytosolic form LC3-I by the protease Atg4B. Atg7 and Atg3 together with the Atg5-
Atg12-Atg16L complex induce the conjugation of LC3-1 to PE to form LC3-II, a lipidation 
process that also incorporates LC3-II into the phagophore membrane. As the 
autophagosome matures, Atg4B cleaves LC3-II from the outer membrane, which enables 
the phagophore membrane to fuse upon itself. This leaves LC3-II intact on the inner 
membrane of the autophagosome. The quantification of LC3-II protein serves as the 
signature protein for identification of a functional autophagosome [66, 67]. 
Fusion and lysosomal degradation 
The mature autophagosome has engulfed its target material and must not deliver its cargo 
to a lytic compartment for degradation. The targeting and fusion process that occurs 
between the autophagosome and lysosome has not been well characterized. However, 
autophagosome maturation may involve fusion with multivesicular bodies (MVB) or 
endosomes to form amphisomes, prior to their fusion with lysosomes to form the 
autolysosome [68]. Several proteins that regulate fusion between the autophagosome and 
lysosome have been identified, these include: ESCRT (Endosomal Sorting Complex 
Required for Transport), the Rubicon-UVRAG complex, SNAREs (soluble N-
ethylmalmemide sensitive factor attachment protein receptor), Rab (Ras [rat sarcoma] like 
in rate brain), LAMP2 (lysosome associated membrane protein 2) and LC3 [69]. In the final 
step, lysosomal enzymes, in particular hydrolases, complete the breakdown of the 
autolysosomal contents and the degraded contents are released back into the cytosol 
where they are recycled and reused by the cell to form new macromolecules and amino 
acids. 
1.5.2 Approaches to studying autophagy 
In the last decade, new techniques have emerged to monitor autophagic activity and also 
to modulate its function in specific cell types. Targeted genetic ablation of ATG genes in 
mice has led to a range of phenotypes ranging from embryonic (BECLIN-/- and AMBRA-/-) 
to neonatal lethality (ATG5-/- and ATG7-/-). Both global and lineage specific models for the 
ablation of autophagy are available. The transgenic mouse models currently employed to 
study the role of autophagy in HSC have been extensively reviewed in Leveque et al. 
(2015). 
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Detection of autophagy 
The quantification of autophagosomes within a cell is the definitive assay for measuring 
autophagy function. Multiple methods have been developed to identify and quantify 
autophagosome formation within the cell. Autophagic flux refers to the dynamic process of 
autophagosome formation, delivery to the lysosome and subsequent degradation of the 
autophagic substrates. The autophagosome component LC3, is currently widely used as a 
marker of autophagosomes[70]. During the maturation and fusion of the autophagosome 
LC3-II is incorporated into the inner membrane of the autophagosome while any LC3 
proteins remaining on the outer membrane are degraded. Thus the ratio of LC3-II / LC3-I 
within a cell, as determined by western blot (WB), serves as a measure of autophagic flux 
[71]. The measure of autophagic flux is considered the most reliable indicator of 
autophagic activity. Endogenous LC3 can also be examined by means of intra-cellular 
staining and in addition, LC3-GFP transgenic mice are widely used to identify fluorescent 
autophagosomes within the cell [72]. LC3 proteins are identifiable by microscopy as 
punctae within the cell or alternatively, the measure of total LC3-GFP intensity can be 
measured by flow cytometry [73]. Recently, imaging flow cytometry has facilitated the 
visualisation and quantification of LC3 punctae within individual cells [74]. 
 
Pharmacologic manipulation 
Autophagosome formation can be pharmacologically inhibited in vitro by class III PI3-
kinase inhibitors such as wortmannin, LY294002 and 3-MA [75, 76]. Importantly, these 
reagents are not specific to autophagy and can also impact non-autophagy related 
pathways. Fusion between the mature autophagosome and the lysosome can be inhibited 
both in vitro and in vivo by several reagents including bafilomycin A1 (BAF 1), chloroquine 
(CQ), ammonium chloride and lysosomal protease inhibitors such as E64d and pepstatin A 
[77, 78]. More specifically CQ is a lysosomotropic weak base, which can diffuse into the 
lysosome where it changes the lysosomal pH in turn, inhibiting autophagic degradation 
within the lysosome [79]. As such it results in an accumulation of mature autophagosomes, 
and thus LC3-II, and has been used to monitor autophagy flux. 
 Autophagy in the HSC pool 1.6
Autophagy has been described to play a central role during haematopoiesis (Figure 1.4). 
This includes an important role in the maintenance and function of stem cells in addition to 
multiple mature immune cells [80, 81]. HSC utilize autophagy in order to maintain 
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characteristics that ensure their pluripotency and longevity in the steady state [82]. 
Chapter 4 on this thesis focuses on the critical requirement for autophagy in the HSC 
donor graft and extends analysis into the highly inflammatory setting of SCT.  
 
Figure 1.4 The role of autophagy in haematopoiesis. Adapted from [80]. 
1.6.1 Autophagy in HSC quiescence 
In the BM niche, quiescent HSC are in a state of altered metabolic activity [83]. 
Quiescence is achieved by cyclin-dependent kinase inhibition and the action of the PI3K-
mTORC1 pathway [84-86]. A recent study demonstrated that autophagy actively 
suppresses HSC metabolism by clearing healthy, active mitochondria in order to maintain 
the HSC in a quiescent state [87]. During quiescence HSC utilize autophagy to clear 
cellular waste and recycle broken down amino acid components to provide energy.  
1.6.2 Autophagy in active HSC  
Several publications in recent years have demonstrated that autophagy is a key 
intracellular survival mechanism active in HSC and critical for their long-term survival and 
self-renewal [88, 89].  
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During active oxidative metabolism, mitochondria produce reactive oxygen species (ROS), 
which are rapidly released into the cytoplasm but are unable to escape from the cell and 
must therefore be detoxified in the cytoplasm. As HSC exit from a quiescent state they 
also increase their mitochondrial activity and production of ROS [90]. The accumulation of 
ROS is toxic and as such, cells utilize internal disposal mechanisms to control ROS levels 
and protect the cell from damage [91]. In this activated HSC setting, autophagy serves to 
both prevent the accumulation of intracellular ROS levels and to remove damaged 
mitochondria [89, 92]. A recent study by Bigarella et al. (2016), found that FOXO3, a 
regulator of autophagy, plays a protective role in HSC genomic stability and that FOXO3-/- 
mice display HSC with elevated ROS levels and defective HSC cycling [93]. Furthermore, 
these mice displayed DNA damage in primitive HSC and HSPC, associated with reduced 
expression of DNA damage repair genes. In vivo treatment with N-acetyl-cysteine (NAC) 
at least partially reversed DNA damage suggesting that elevated ROS was driving this 
damage [94-96]. In HSCs, several studies have reported compromised capacity for self-
renewal in the absence of autophagy. In vitro analysis using serial CFU assays 
demonstrated that Atg7-/- HSC lost the ability to form colonies in vitro upon re-plating  
suggesting that the self-renewal capacity of HSCs in the absence of autophagy is limited 
or compromised [89]. Thus autophagy plays a protective role in HSC and HSPC genomic 
stability and health. 
1.6.3 Autophagy in HSC differentiation and lineage commitment 
While a number of studies have reported the critical requirement for autophagy in the long-
term repopulating function of HSCs, studies using both ATG5- and ATG7-deficient mouse 
models have also confirmed that autophagy plays an active role in HSPCs [89, 97]. More 
recent publications suggest that while autophagy is actively employed in both HSC and 
HSPC, the environmental conditions / cellular stressors that trigger autophagy in these 
different populations may differ.  
Autophagy may serve a critical role in the nutrient-dependent modulation of HSCs and 
HSPCs during steady state haematopoiesis. It was recently reported that under normal 
nutrient-rich conditions autophagy promotes the entry of HSC into active cell cycling while 
under poor nutrient conditions HSC are directed to remain quiescent while their more 
mature HSPC are directed to proliferate [98]. When HSCs leave quiescence and become 
activated they, together with their more committed HSPCs, have an increased requirement 
for metabolic activity in order to mature and divide. Warr et al. (2015) demonstrated that 
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while long-lived HSC are able to mount a robust autophagic response following metabolic 
stress (nutrient starvation), their short-lived myeloid progeny do not display the same 
autophagic response [99]. Interestingly, Granulocyte/macrophage progenitor (GMP) cells 
cultured in the presence of cytokine rich media (containing: interleukin-3 (IL-3), Colony 
stimulating factor2 (Csf2), stem cell factor (SCF), interleukin-11 (IL-11), FMS-like tyrosine 
kinase-3 (Flt-3), Thrombopoietin (Tpo) and Erythropoietin (Epo)) demonstrated LC3-GFP 
punctae whose turnover (autophagic flux) was not altered when cytokines were withdrawn. 
In contrast, HSCs displayed no detectable LC3-GFP punctae in cytokine culture conditions 
but exhibited robust puncta formation when cytokines were withdrawn indicating that while 
both HSCs and their more mature myeloid progenitors both employ autophagy, they do so 
in response to different environmental cues [99].  Further to this, studies involving the 
disruption of mTORC1 through ablation of the glucose sensing RagA demonstrated that 
autophagy was dispensable for HSC glucose metabolism yet resulted in markedly altered 
HSPC function and differentiation [100]. Thus, the conditional requirement for autophagy 
under nutritional stress may differ between HSC and their more mature HSPC.  
1.6.4 Autophagy in conditions of non-homeostatic stress 
In addition to the homeostatic stressors (hypoxia, nutrient starvation and protein damage) 
that are known to induce autophagy, studies have demonstrated that this cell survival 
mechanism is also involved in non-homeostatic stress responses, such as: irradiation 
[101], infection [102-104], pharmacological treatment and disease [105]. Autophagy is 
employed, predominantly under conditions of stress, for the disposal of mutated proteins 
and non-functional proteasomes [106, 107]. In mesenchymal stem cells (MSC), chronic 
stress is demonstrated to inhibit autophagy, induce apoptosis, to alter differentiation and 
proliferation and to transform morphology [108]. A recent study demonstrated that 
autophagy is most critical for HSCs under conditions of stress including the setting of 
transplantation, where intense regenerative stress is required [87]. Two separate studies 
using murine HSCs deficient in either ATG7 or FIP200 showed that these autophagy-
deficient HSCs failed to reconstitute lethally irradiated recipients following primary 
transplantation [88, 89]. However, our own primary bone marrow transplantation studies in 
murine models demonstrate that ATG7-/- HSC administered in T cell depleted grafts, are 
capable of reconstituting lethally irradiated allogeneic recipients and that these recipients 
survive long term (unpublished data).  Thus, the mechanisms by which HSCs require 
autophagy for survival post-transplant remain largely undefined. 
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In addition to the requirement for the autophagy process in HSC to replicate and 
repopulate following transplantation, the ingoing HSC and HSPC graft is immersed in 
tissue microenvironments that are highly inflamed. Pre-transplant conditioning regimes, 
including irradiation and chemotherapy, result in damage to multiple tissues including the 
BM stem cell niche and the systemic release of pro-inflammatory cytokines [14]. In vitro 
experiments confirm that HSCs cultured for 21 hours in cytokine rich media increased 
LC3-GFP protein expression levels, indicating increased levels of autophagy, and that 
these treated HSCs switch to a highly activated, mitochondria-driven oxidative 
phosphorylation (OXPHOS) state compared to freshly isolated, quiescent HSCs [87]. In 
vivo, granulocyte colony-stimulating factor (G-CSF) activates autophagy in HSCs and 
neutrophils from both human and mouse donors. Furthermore, G-CSF mobilization of 
HSCs and neutrophils from the BM niche was impaired in the absence of autophagy. Thus 
autophagy is induced in HSCs and their myeloid progeny in response to cytokine-induced 
stress/signals and is likely required for their survival in the periphery [109]. In the absence 
of autophagy, HSC display reduced reconstitution potential and a bias toward myeloid 
lineages after transplantation, which was further exacerbated upon secondary 
transplantation [87]. Thus, autophagy plays an important role in maintaining healthy HSC 
function and differentiation. In a recent review we proposed that autophagy was likely a 
key mechanism employed by the donor HSC graft to survive and thrive in the inflammatory 
conditions of allogeneic stem cell transplantation (SCT) [82]. However, studies examining 
the role of autophagy in HSCs and HSPCs in the setting of SCT do not encompass GVHD. 
Chapter 3 of this thesis will explore the requirement for autophagy in HSC and HSPC 
during allogeneic SCT and engraftment in the setting of GVHD.  
 The importance of cytokine signalling during GVHD 1.7
Cytokine signalling is critical for the development and maintenance of multiple immune cell 
populations, some of which serve to protect host tissue from inflammation and others that 
promote inflammation and drive host tissue damage. The role of cytokines during the 
initiation and pathogenicity of GVHD have been comprehensively described in two recent 
reviews [13, 110]. 
As previously described, conditioning-induced injury to the GI tract plays a critical role in 
the onset of GVHD [26]. Most therapeutic interventions during this early phase use 
immunosuppressive drugs that predominantly target donor T cells but not exclusively, and 
their impact on myeloid populations, particularly DCs should also be considered [111, 
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112]. DCs are known to be critical for initiation of GVHD [113] but multiple studies also 
demonstrate that in the early phase of GVHD, patient conditioning regimes lead to the 
activation of myeloid cells, including neutrophils and monocytes [114-117] prior to the 
expansion of alloreactive cytotoxic T cells. Indeed, a recent study confirmed that 
neutrophils are the first population to reach tissue injury sites in the GI tract and 
subsequently migrate to the mesenteric lymph node (mLN) where they participate in allo-
antigen presentation [118]. This same study demonstrated that pharmacological inhibition 
of the intracellular, non-receptor tyrosine kinases Janus Kinase-1 and -2 (JAK1/2), which 
are central mediators of cytokine signalling, reduced both neutrophil influx and aGVHD 
pathogenesis. This finding highlights the therapeutic potential in targeting activated 
myeloid cells during the early initiation of GVHD. 
Additionally, monocytes and macrophages play an important role following SCT. In steady 
state, monocytes do not contribute significantly to tissue-resident macrophage populations. 
Macrophages populate most tissues during foetal development and then maintain 
themselves, independently of adult haematopoiesis, through their limited capacity for self-
renewal and longevity [119-122]. As such, despite being derived from common precursors, 
tissue macrophage compartments tend to develop independently of other tissue 
populations, within their own local microenvironment [123-125]. 
Following SCT, host macrophages are typically replaced by colony stimulating factor-1 
(Csf1) and colony stimulating factor-2 (Csf2)-driven proliferation of donor macrophages 
[120]. Although in the event that donor macrophage development is compromised, host 
macrophages also retain the ability to expand. Previous studies by our lab demonstrate 
that Csf1 receptor (Csf1R) blocking antibody (M279, AMGEN), reduces tissue resident 
macrophage precursors (CD115+ Gr-1-) leading to the almost complete depletion of 
resident macrophage populations in several tissues including the peritoneum, GI tract, 
liver, kidney and skin [126]. Furthermore, depletion of these resident macrophages in 
recipients following SCT led to accelerated GHVD pathology attributed to decreased CD4+ 
regulatory T cells and increased donor T cell activation together with enhanced pro-
inflammatory TNF and IFN cytokine release. 
Using a similar approach, Mortha et al. (2014) used Csf1 to block macrophages in the GI 
tract and observed a subsequent decrease in Csf2. This study identified an important 
interactive role between Csf2 producing type three innate lymphoid cells (RORt+ ILC3), 
and tissue resident phagocytic macrophages, which respond to the gut microenvironment 
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and present antigen to ILC3 in the small intestine. In this setting, Csf2 was associated with 
colonic CD103+CD11b+DC production of TGF-beta and macrophage production of IL-10 
[127]. Interestingly, an additional study reported two separate subsets of CD103+ migratory 
murine DCs, in both the skin and GI tract, that appear to be Csf2 dependent and are 
proposed to provide immune protection [128]. Despite the established role of Csf2 
signalling in myeloid development and recruitment, little has been reported on its role in 
the gastrointestinal tract in the setting of GVHD. 
Taken together, it is apparent that myeloid populations contribute to both homeostatic 
health in the GI tract and conversely toward the initial inflammation associated with GVHD 
onset. The significant impact of JAK1/2 inhibition during GHVD initiation draws comparable 
interest to Csf2 considering that binding of Csf2 to its receptor leads directly to the 
recruitment and activation of JAK2 [129]. Importantly, this intracellular signalling occurs 
through a signalling receptor subunit that Csf2 shares with interleukin-3 (IL-3) and 
interleukin-5 (IL-5), known as the common beta chain (c). Csf2, IL-3 and IL-5 are thus 
known as the beta common (c) family of cytokines, and are well established mediators of 
haematopoiesis and act on multiple immune cells. However their role in the setting of 
GVHD remains largely unexplored. 
1.7.1 Beta common (c) receptor cytokines 
Although originally identified for their role in haematopoiesis the c cytokines are known to 
be pleiotropic factors that act upon multiple cell types and impact heavily on health and 
disease) [130]. Collectively, c signalling cytokines are not only important in the 
development and maintenance of multiple immune populations but they appear to play a 
dichotomous role in both the promotion of inflammatory populations and protection from T-
cell dependent diseases. Chapter 4 of this thesis examines the role of c signalling 
cytokines in both haematopoietic and non-haematopoietic compartments in the 
inflammatory setting of GVHD.   
1.7.2 Beta common (c) receptor signalling 
Each of the three c cytokines signals through its own receptor heterodimer formed 
between a specific -subunit (IL-3R, IL-5R, Csf2R), and the shared transmembrane 
signalling beta (c) subunit (Figure 1.5). 
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Figure 1.5 Common beta (c) cytokine receptors 
Cytokine (Csf2, IL-5 or IL-3) binding to a c heterodimer results in the phosphorylation of 
at least two distinct domains in the c subunit [131]. One domain induces the activation of 
mitogen-activated protein (MAP) kinases and the PI3K / Akt pathway while the second 
domain mediates the activation of the JAK2 / STAT5 signalling pathway [132, 133]. 
1.7.3 Haematopoiesis in mice lacking c expression 
As previously described, the beta common (c) subunit signals three major haematopoietic 
cytokines produced by activated T cells, including: IL-3, IL-5 and Csf2 [129]. Our own 
studies demonstrate that naïve mice deficient in c signalling capacity develop equal 
frequencies and numbers of Ly6Chi and Ly6Clo monocytes / macrophages compared to 
wild-type C57Bl/6 animals [33]. Mice deficient for the c demonstrate pulmonary-alveolar 
disorders and reduced peripheral eosinophils, attributed to a lack of IL-5 and Csf2 
signalling [134].  
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Initially, mice lacking Csf2rb were reported to have normal haematopoiesis [135] which 
was subsequently attributed to the presence of an alternate IL-3 beta subunit (IL3) (Figure 
1.5) in the murine system [136]. However, more recent studies have confirmed differences 
in migratory murine DC subsets in mice lacking Csf2R[137]. Of note, these publications 
did not examine the targeted ablation of c cytokines individually. 
Certainly, c family cytokines display a degree of overlap with regard to their cellular 
sources and targets and a comprehensive review of their role in health and disease was 
recently published [130]. Despite this, their direct influence in the setting of SCT and 
GVHD remains largely undefined. Chapter 4 of this thesis will focus on the impact of 
ablating the c signalling component utilised by all three c cytokines (Csf2, IL-3 and IL-5) 
and examine the impact on recipients in the post-transplant GVHD setting.  
1.7.4 Interleukin 3 (IL-3)  
IL-3 is well recognised as a survival and growth factor in haematopoietic cells in both 
health and disease [133]. It primarily derived from activated CD4+ T cells and mast cells 
and can stimulate the differentiation of BM progenitor cells and the survival and activation 
of mature myeloid cells including: Mast cells, basophils, eosinophils, neutrophils, 
macrophages, DC, erythrocytes and megakaryocytes [138]. Mice lacking the IL-3 gene (IL-
3-/-) display normal steady-state haematopoiesis suggesting that either IL-3 is not involved 
in early haematopoietic cell development or is dispensable in place of synergistic cytokines 
[139]. Mice in which, the alternate IL-3 beta chain (IL-3R) is functionally inactivated (by 
replacement of exons 9-13 with a neomycin resistance cassette) are hyporesponsive to IL-
3 and display normal haematopoiesis [140]. This study suggested that both the c and IL-
3 receptor subunits are co-expressed on IL-3 responsive cells and have equal signalling 
capacity. Considering this, the extent to which IL-3 signalling is perturbed in mice lacking 
the c receptor subunit remains to be confirmed. 
Studies on parasite immunity and host defence report a role for IL-3 in promoting the 
expansion of haematopoietic effector populations including mast cells and basophils [141, 
142]. In addition, IL-3 enhanced the secretory function of mast cells and inhibited the 
accumulation of eosinophils in a murine model of allergic peritonitis [143]. In humans, IL-3 
is additionally shown to modulate the development of regulatory T cells during collagen-
induced arthritis [144]. Thus while IL-3 may not be essential for early haematopoiesis it 
appears to play a role during inflammatory responses. 
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Due to its promotion of HSC and megakaryocyte differentiation and survival, IL-3 is an 
important factor in BM reconstitution although studies report that it’s clinical application has 
been restricted due to its concurrent role in stimulating basophils and mast cells[145]. IL-3 
promotes both normal and malignant haematopoietic cell expansion and expression of the 
IL-3R alpha (IL-3Ra / CD123) subunit has been identified on leukemic stem-like cells, 
basophils and human plasmacytoid DC (pDC) [133]. The overexpression of IL-3Ra in 
acute myeloid leukaemia strongly correlate with reduced patient survival [146-148] and as 
such targeting of IL-3Ra via several approaches is currently being exploited therapeutically 
[149-152]. 
1.7.5 Interleukin 5 (IL-5)  
IL-5 is produced in both the steady state and during inflammation and exerts effects on 
both proliferation and differentiation [153, 154]. Major cellular sources of IL-5 include: Th2 
cells, mast cells, group 2 innate lymphoid cells (ILC2), CD34+progenitor cells, invariant 
natural killer (NK) T cells and eosinophils [155]. The primary cellular targets of IL-5 include 
B cells, eosinophils and basophils, although expression of IL-5R on eosinophils is 
reported to be threefold higher than that of basophils [156]. Although IL-5 deficient mice do 
produce basal levels of eosinophils that appear morphologically and functionally normal, 
they are unable to mount a pronounced eosinophilia response following allergen challenge 
or parasite infection and thus display compromised defence against infection [157, 158]. In 
addition these mice display functional deficiency in lymphocytes and Immunoglobulin A 
(IgA) production. Similarly, IL-5R deficient mice display defective B cell and IgA 
production associated with impaired immunity against infection [159, 160] and as such IL-5 
signalling is critically implicated in mucosal immunity. In addition, several studies report a 
role for IL-5 producing innate cell populations located in fat-associated lymphoid clusters in 
the mesentery (termed natural helper cells) [161] and also in mesenteric lymph nodes and 
the GI tract (termed nuocytes and MPPtype2) [162, 163] that are required for immunity 
against gastrointestinal infections.  
Not surprisingly, the action of IL-5 signalling is directly linked to hypereosinophilic 
syndrome [130, 164] and severe allergic asthma [165, 166]. Recent studies have 
demonstrated a key role for excessive IL-5-production by ILC2 in eosinophil activation and 
the pathogenesis of allergic disease, thus highlighting the therapeutic potential role for 
anti-IL-5 and anti-IL-5R treatments in the clinic [154].  
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1.7.6 Colony Stimulating Factor 2 (Csf2) 
Csf2 is well known as a haematopoietic growth factor that controls the differentiation of 
myeloid haematopoietic progenitor cells and DC precursors, which give rise to a range of 
mature DC subsets. Csf2 modulates survival, proliferation, differentiation, and function of 
other mature myeloid cells including granulocytes (eosinophils and neutrophils), 
monocytes and macrophages [135, 167, 168]. Importantly, these cell types serve an 
essential role in the initiation and propagation of cell-mediated immune responses.  
Both CD4+ and CD8+ T cells produce Csf2, and expression is up-regulated in response to 
stimulation of the T cell receptor (TCR) and co-stimulation molecules such as CD28 [169]. 
In addition, Type 17 helper T cells (Th17) have been shown to produce Csf2 in response 
to ROR-t (retinoic acid receptor-related orphan receptor gamma t) and IL-23 [170]. More 
recently, our group identified that in addition to Th17, a pathogenic population of Tc17 cells 
produce large amounts Csf2 [171, 172]. Interestingly, mice that are unable to generate 
Th17 cells, display reduced Csf2 levels in the GI tract, almost as low as those seen in 
CSF2-/- [127]. Thus, alloreactive T cells provide a likely source for elevated Csf2 levels in 
the setting of GVHD.  
Despite being prolific producers of Csf2, T cells are largely considered to lack expression 
of the Csf2 receptor rendering them unable to respond directly to this cytokine [173, 174]. 
Interestingly, transgenic overexpression of Csf2, specifically in T cells, resulted in 
increased inflammatory infiltrate in both lymphoid and non-lymphoid organs together with 
elevated Th17 cytokines including: IL-1, IL-2, IL12p40, Csf2 and IL-17A [175]. In 
comparison, Csf2 deficient mice are protected from several T cell-dependent experimental 
disease models including multiple sclerosis (MS) and arthritis [176, 177] attributed to the a 
requirement for Csf2 in controlling the functional balance between effector and regulatory 
T cell subsets during disease [178]. Furthermore, Csf2 inhibition provides a promising 
approach to the treatment of inflammatory disease of the lung and GI tract, including 
chronic obstructive pulmonary disease [179, 180], asthma [181, 182] and has already 
demonstrated therapeutic effect in an IL-23-dependent, eosinophil-driven murine model of 
sterile, chronic colitis [183]. These studies emphasise the potential impact of targeted Csf2 
blockade in the treatment of inflammatory disease particularly at mucosal barrier sites 
such as the GI tract and lung which have already been described as target organs. 
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1.7.7 Haematopoietic c signalling in the GI tract 
As described above, multiple haematopoietic populations either actively produce or 
actively respond to c family cytokines [130]. Of note, heavily responsive populations 
either reside in or are recruited to mucosal barrier sites including the GI tract and the lung.  
Csf2 produced by activated T cells has an important role in crosstalk between antigen 
presenting cells (APC) and T cells in the GI tract [127]. Macrophages are also known to 
play a critical role in wound repair in the intestinal tract and in vitro studies confirm that 
Csf2 receptor (Csf2R) signalling is required for macrophages to promote epithelial repair. 
In addition, macrophages from Crohn’s disease (CD) patients with active disease display 
deficient repair capabilities, which are reversed by Csf2 treatment [184]. Thus, Csf2 
signalling is required for both mouse and human macrophage driven intestinal repair.  
Eosinophil priming is an important in vivo phenomenon in patients with allergic 
inflammation and studies report exposure to c cytokines as a likely initiator of this priming 
[185-187]. In the gut, eosinophils normally reside in the colonic mucosa and studies 
demonstrate that they play a protective role in acute colitis via production of anti-
inflammatory lipid mediators [188]. This study demonstrated that mice deficient in 
eosinophils succumb to greater colonic inflammation, associated with increased 
neutrophilic inflammation and elevated proinflammatory cytokines.  
Innate Lymphoid Cells (ILC) form a small population in the GI tract that contribute to host 
defence and tissue repair but also induce tissue-specific immunopathology. Several ILC 
populations have been shown to both produce and respond to c cytokines. ILC2 recruit 
and maintain intestinal inflammatory monocytes but also respond dynamically to Csf2 
signalling and their mobilization precedes inflammation in the SI [189]. In addition, resident 
ILC2 constitutively secrete IL-5 resulting in local production of eotaxin and the 
accumulation of eosinophils in the local tissue [155]. A third population of RORt ILC 
(ILC3) produce Csf2 in response to MyD88 driven, IL-1 signals from tissue-resident 
macrophages stimulated by gut microbial signals [127]. Thus multiple haematopoietic cell 
types in the GI tract both produce and respond to c cytokine family members. 
1.7.8 Non-haematopoietic c signalling 
In addition to haematopoietic signalling there is growing evidence that supports a critical 
role for Csf2 signalling in non-haematopoietic populations, particularly in the 
gastrointestinal tract. 
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Csf2 is known to promote epithelial barrier integrity and to stimulate myeloid cell 
antimicrobial function [190, 191]. In the setting of disease, patients with ileal Crohn’s 
disease (CD) demonstrated high levels of endogenous neutralising Csf2 antibody which is 
associated with reduced Csf2 bioactivity and neutrophil antimicrobial function [192]. In 
addition to patient samples, mice administered Csf2 neutralising antibody also displayed 
reduced ileal epithelial barrier function and an increased susceptibility to nonsteroidal anti-
inflammatory drug (NSAID)-induced ileitis [192]. Thus, Csf2 signalling appears critical for 
healthy intestinal epithelial barrier function in the setting of inflammation and disease. 
Csf2 signalling in non-haematopoietic cells is essential for the homeostatic maintenance of 
healthy intestinal barrier function. This signalling regulates epithelial homeostasis via 
STAT5 activation in IEC and a loss of Csf2 signalling in non-haematopoietic cells 
increases ileal injury in response to NSAID treatment [193]. Colon epithelial cells produce 
Csf2, and this endogenous epithelial cell-derived Csf2 has a non-redundant role in 
facilitating the proliferation of epithelial cells and ulcer healing following injury to the colonic 
crypt epithelium [194]. 
In addition, Csf2 has been shown to regulate alveolar epithelial barrier integrity via direct 
signalling on epithelial cells [195]. In vitro autocrine Csf2 signalling stimulated crypt cell 
proliferation in IEC [196] and systemic in vivo Csf2 treatment resulted in reduced epithelial 
apoptosis in lungs exposed to hyperoxic conditions [197]. Thus Csf2 appears to perform a 
proliferative/ stimulatory role in epithelial cell barrier function both in the steady state and in 
response to insult. 
Considering that the intestinal tract and the lung are primary target organs for acute GVHD 
and that the activation of alloreactive T cells is known to initiate in the gut, the mechanisms 
by which Csf2 signalling promotes mucosal integrity and adaptive immune responses to 
injury are of paramount importance to the field of transplantation. 
 MHC antigen presentation 1.8
Major histocompatibility complexes (MHC) are the cell machinery that bind and present 
antigen peptides at the cell surface to activate naïve T lymphocytes. These glycoproteins 
are encoded by a large multigene family known as the major histocompatibility complex 
(MHC), which includes two pathways for antigen presentation: MHC class I and MHC class 
II [198]. In mice, there are three MHC class I (K, D, and L) and two MHC class II (A and E) 
loci, each encoding highly polymorphic genes. 
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1.8.1 MHC class I presentation 
MHC class I molecules are expressed by all nucleated cells with the exception of red blood 
cells and germinal cells. They are responsible for presenting endogenously-synthesised 
self-peptides to CD8+ cytolytic T lymphocytes (CTLs)[199]. For MHC class I presentation, 
endogenous antigens are degraded by the proteasome into short peptides that are 
transported into the endoplasmic reticulum (ER). When a peptide binds to the MHC I 
complex with high affinity, it forms a stable complex and triggers the final folding and 
dissociation of the peptide loading complex so that the loaded MHC I can exit the ER and 
be transported to the cell surface. Although primarily responsible for endogenous antigen 
presentation, studies demonstrate that following phagocytic or endocytic uptake, some 
exogenous antigens can escape the vacuolar system and access MHC I presentation 
through the cytosol, a process known as cross-presentation [200]. Cross-presentation is a 
key alternate approach employed by phagocytic APC that plays a central role in immune 
surveillance. It allows DC to acquire antigens from other cellular sources in the periphery 
and to report their presence to naïve CD8+ T cells in lymphoid tissues [201, 202].  
1.8.2 MHC class II presentation  
In contrast, MHC class II molecules present exogenously synthesized peptides to CD4+ T 
helper (Th) cells [203]. Numerous haematopoietic APC are reported to express MHC II 
molecules including mast cells, basophils, eosinophils, neutrophils, ILC and CD4+ T cells 
themselves. In addition however, peripheral non-haematopoietic cells also express MHC II 
including: Endothelial and lymph node stromal cells, where MHC II expression is inducible; 
and intestinal epithelial cells (IEC) and thymic epithelial cells (TEC), where MHC II is 
constitutively expressed [204, 205]. This is important in the context of transplantation and 
immunity as epithelial cells are uniquely positioned at the interface between the host 
immune system and environmental antigens and may be poised to regulate T cell 
responses to mucosal antigens. Of note, IEC isolated from patients with inflammatory 
bowel disease (IBD) express higher MHC II and in vitro studies demonstrate increased 
MHC II expression in colorectal carcinoma tumours in response to IFN[206]. In the 
setting of allogeneic SCT we have previously demonstrated that recipient non-
haematopoietic APC are sufficient to induce expansion of donor T cells in the GI tract and 
concomitant inflammatory cytokines [22]. 
Of course, haematopoietic APC are also present and actively present MHC II during 
GHVD initiation in the GI tract. A key distinction, however, is that MHC II membrane 
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trafficking and surface expression in monocytes, macrophages and DC, is not constitutive. 
DC activation both promotes and stabilises MHC II membrane expression meaning that 
activated DC can express high levels of MHC II for extended periods. Inhibition of MHC II 
expression or loading can be driven by external factors such as pathogens but also by 
internal regulatory factors including the expression of ubiquitin ligase membrane-
associated RING-CH family members. In human monocytes, the rapid internalization and 
degradation of MHC II from the surface is signalled via a process called ubiquitination 
[207].    
1.8.3 Ubiquitination 
Ubiquitination is a post-translational modification that ‘marks’ proteins with ubiquitin 
molecules to signal cell trafficking events [208]. It is well known for degradation but is also 
involved in signalling trafficking both toward the plasma membrane (PM) via secretory 
pathways as well as their subsequent removal via endocytic pathways [209]. Overall, 
ubiquitination serves as an essential part of the complex maintenance system that controls 
the quality, quantity, and localization of integral membrane proteins being trafficked to and 
from the plasma membrane.  
Ubiquitination is achieved through the action of three enzymes: 
• E1: Ubiquitin-activating enzyme E1 primes the ubiquitin to make it active. This 
involves the hydrolysis of ATP to link the carboxyl end of ubiquitin to the E1 
enzyme. 
• E2: Ubiquitin-conjugating enzyme E2 acts as an escort to deliver the ubiquitin to the 
next enzyme, E3. 
• E3: Ubiquitin-protein ligase E3 serves as a platform for interaction. E3 is selective 
about which E2 complexes it will permit to interact with the different proteins.  
E3 ubiquitin ligases typically form non-catalytic scaffolds that orchestrates the positioning 
of a loaded E2 ubiquitin-conjugating enzyme in close proximity to a target protein, allowing 
the transfer of ubiquitin to occur [210]. Thus E3 ultimately selects the target protein by 
specific selection of the lysine residue that is used to generate an isopeptide bond to the 
carboxyl group of ubiquitin. 
Ubiquitination is critical for regulating MHC II trafficking and surface expression levels 
[211, 212]. The majority of research to date has focused on DC populations where cell 
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surface levels of MHC II differ between steady state and activated cells [213]. These 
studies have identified an important role for the MARCH-RING family E3-ubiquitin-ligases 
in membrane trafficking of MHC II. 
 MARCH-RING family E3-ubiquitin-ligases 1.9
Membrane associated really interesting new gene (RING) -CH (MARCH) family of 
membrane-bound E3 ubiquitin ligases are enzymes that add ubiquitin to target lysines in 
substrate proteins, thereby signaling their vesicular transport between membrane 
compartments. There are several members of the MARCH-RING family which have been 
extensively reviewed [214].  
1.9.1 MARCH8 
The first mammalian MARCH protein identified was MARCH8, also known as c-MIR [215, 
216]. MARCH8 has been demonstrated to downregulate several transmembrane 
glycoproteins including MHC II [217], CD86 [218], IL-1 receptor accessory protein [219], 
TNF-related apoptosis-inducing ligand (TRAIL) receptor 1 [220] and the transferrin 
receptor [221]. MARCH8 has additionally been identified as a potent antiviral protein that is 
highly expressed in terminally differentiated myeloid cells and responsible for targeting 
viral envelope glycoproteins to reduce their incorporation into virions [222]. The related 
ligase MARCH8 has recently been demonstrated to be responsible for regulating surface 
MHC II expression in thymic epithelial cells (TECs). This ubiquitination of MHC II by 
MARCH8 is controlled by CD83 and ultimately plays a major role in CD4+ T cell selection 
in the thymus [217, 223]. 
Chapter 5 of this thesis focuses on the role of MARCH8 in MHC II presentation by non-
haematopoietic APC during acute GVHD onset in brief comparison to its most closely 
related family member MARCH1.  
1.9.2 MARCH1 
MARCH1 is the family member most closely related to MARCH8 and is expressed at very 
low levels in most tissues, but is highly expressed in both the spleen and lymph nodes 
[216]. MARCH1 regulates the ubiquitin-dependent trafficking of MHC II and CD86 and as 
such plays a critical role in APCs including DC, B cells and monocytes [207, 224-226]. 
MARCH1 deficiency in vivo results in a substantial reduction in the number of thymus-
derived regulatory T cells (Treg) in mice. DCs that were deficient in either MARCH1 
expression or in MHC II ubiquitination both displayed increased surface MHC II but failed 
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to generate antigen-specific Treg in vivo and in vitro demonstrating that MARCH1-
mediated MHCII-ubiquitination in DCs is required for the generation of naturally occurring 
Treg cells in vivo [227]. IL-10 production by Treg has been shown to promote MARCH1 
expression and subsequently suppresses antigen presentation in activated macrophages 
[207, 228, 229]. 
The stabilisation of peptide-MHC-II complexes (pMHC II) at the cell surface by removal of 
its ubiquitination is one event that defines the activation of conventional dendritic cells 
(cDCs). A study found that cDCs generated from mice whose MHC II ubiquitination is 
inhibited had a reduced ability to activate naïve CD4 T cells and thus reduced Th1/Th17 
differentiation [230]. Considering the important role that APC MHC II presentation plays in 
the initiation of GVHD the role of MARCH-family ubiquitinases in this setting should be 
explored. 
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CHAPTER 2. AIMS OF THESIS 
The aim of this thesis was to understand the role of cellular signalling mechanisms such as 
autophagy, c cytokine signals and antigen presentation during early engraftment and 
allogeneic T-cell mediated GVHD onset in order to improve patient outcomes following 
SCT to ameliorate graft failure and GVHD complications.  
Autophagy is critical for survival and engraftment of haematopoietic stem and progenitor 
cells in the highly inflammatory setting of allogeneic (Chapter 4) 
This project examined a novel role for autophagy in HSPC during the primary engraftment 
period using Atg5 deficient mice and mice with a haematopoietic cell-specific loss of ATG7 
to examine the requirement for autophagy in HSC and HSPC survival and engraftment 
following allogeneic SCT in the presence of alloreactive T cell cytokines. 
The role of common beta chain cytokine signals in GVHD (Chapter 5) 
This project examined the impact of ablating the common beta chain receptor subunit in 
the context of aGVHD onset. Using mice deficient in the common c receptor signalling 
subunit this study compared the requirement for signalling in both the donor graft and the 
recipient haematopoietic and non-haematopoietic compartments.  
The role of the E3-Ubiquitin-Ligase MARCH8 in non-haematopoietic MHC II trafficking 
during aGVHD (Chapter 6) 
This project examined the impact of ablating the E3-ubiquitin ligase MARCH8 in the 
context of aGVHD onset. Using mice deficient in MARCH8 we compared cell surface 
expression of MHC II with a focus on non-haematopoietic epithelial cells, particularly in the 
GI tract. In a model of aGVHD we compared the impact of MARCH8 ablation on donor T 
cell expansion and aGVHD pathology. 
This thesis identifies multiple novel targets for the treatment and management of 
complications associated with SCT. 
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CHAPTER 3. METHODS 
 Mouse strains 3.1
All procedures were approved by the QIMR Berghofer Medical Research Institute animal 
ethics committee (A1503-603M P2096). Female C57Bl/6j (B6.WT, CD45.2, H-2b), Ptprca 
(B6.Ptprc, CD45.1, H-2b), BALB/c (BALB/c.WT, CD45.2, H-2d), B6D2F1 (H-2b/d) mice were 
purchased from the Animal Resources Centre (W.A., Australia).  
3.1.1 Transgenic mouse strains 
LC3 GFP (B6) and Atg5-/- mice were originally provided by Noboru Mizushima 
(Department of Physiology and Cell Biology, Tokyo Medical and Dental University, Tokyo, 
Japan) and subsequently housed and bred in the QIMR animal facility. Atg5 Fetal liver 
(FL) cells were harvested and genotyped at E17.5 before being used for experiments 
(methods detailed below). Common β chain–/– (Csf2rbtm1Cgh) [231] were provided mice 
were provided by Angel Lopez (Centre for Cancer Biology, Adelaide, Australia). MARCH8–
/– mice [217] were provided by Justine Mintern (University of Melbourne, Melbourne, 
Australia). RAG-1 KO, TNFR1/2 KO (B6), IL-1R KO (B6), MacGreen (B6), BALB/c .45.1+ 
and BALB/cGFP+Luciferase+ mice [232] were generated in house (QIMR Berghofer 
Medical Research Institute), housed in sterilised microisolator cages and received acidified 
autoclaved water (pH 2.5) during experimental housing. 
 Graft preparation 3.2
BM was prepared by flushing tibiae and femora of donor mice with RPMI + 2% FBS media 
administered through a 10mL syringe and 23 gauge needle. T-cell depletion of BM was 
carried out by incubating the cells with hybridoma supernatants containing CD4 (RL172.4), 
CD8 (TIB211), and anti-Thy1.2 (HO-13-4) monoclonal antibodies, followed by incubation 
with rabbit complement (Cedarlane Laboratories) as previously described [233]. The 
resulting BM suspension contained less than 1% contamination of viable CD3+ T cells. 
T cells were isolated from whole spleen using magnetic bead depletion of non-T-cell 
splenocytes. Whole donor spleen was mashed using sterile autoclaved glass microscope 
slides and passed through a cell sieved (company). Following red cell lysis this single cell 
suspension was incubated with purified mAb (CD19 [HB305], CD11b [TIB128], anti-B220 
[RQ36B2], anti-Gr1 [RB6-8C5], and anti-Ly76 [TER119]) for 20 minutes on ice. Cells were 
subsequently incubated with goat anti-rat IgG BioMag beads (QIAGEN) for 20 minutes on 
 31 
 
ice followed by depletion of the antibody-bound cells by magnetic separation. The purified 
CD3+ T-cell preparation was stained with anti-CD3-PE (Biolegend or BD Biosciences), 
CD4-APC (Biolegend) and CD8-Pacific Blue (Biolegend) and confirmed to be more than 
80% pure. 
 Peripheral blood sampling and analysis 3.3
Peripheral blood (PB) was collected by retro-orbital venous blood sampling into EDTA-
coated tubes, and total cell counts analysed on a Hemavet 950 analyser (Drew Scientific). 
 Flow cytometry 3.4
All fluorescence-activated cell sorting (FACS) experiments were performed on an LSRII 
Fortessa flow cytometer (BD Biosciences) unless otherwise specified. Flow cytometry data 
was analysed with Flowjo software (TreeStar). All antibodies were diluted at 1:100 in 
phosphate-buffered saline (PBS) supplemented with 2% fetal calf serum (FCS). Antibodies 
were obtained from Biolegend, BD Biosciences or MBL as listed in Table 2.1. 
3.4.1 Haematopoietic stem and progenitor cell (HSPC) staining 
Lineage positive cells were identified by staining with a lineage cocktail comprised of 
biotinylated antibodies against B220 (RA3-6B2), Cd3e (145-2C11), Cd5 (53-7.3), Gr-1 
(GB6-8C5), Mac-1 (M1/70) and Ter-119 (TER-119) and tertiary staining with streptavidin 
alexa (SA) PE/Cy7. LKS (Lineage-Kit+Sca-1+) cells were identified from the lineage 
negative/low gate and stained with streptavidin, anti-c-Kit (2B8) and anti-Sca-1 (D7) or, for 
post-transplant analysis anti-ESAM1 antibodies to identify c-Kit+Sca-1+ (or ESAM1+) 
herein referred to as HSC from c-Kit+Sca-1- (or ESAM1-) herein referred to as HSPC. 
Common-myeloid progenitor, Granulocyte-macrophage progenitor (GMP) and 
megakaryocyte-erythroid progenitor (MEP) cells were identified from LKS- with the 
addition of anti-Cd34 (RAM34) and anti-Cd16/32 (93) antibodies. Long-term 
haematopoietic stem cells (LT-HSC) were stained as described for LKS with the addition 
of anti-Cd48 (HM48-1) and anti-Cd150 (TC15-12F12.2) antibodies. Antibody incubations 
were performed for 20-30 minutes at 4oC prior to analysis. 
 Imaging flow cytometry 3.5
Imaging flow cytometry was used to identify and simultaneously image single cells in real 
time. Again BM cells were stained with lineage markers (as previously stated in 2.8.1) and 
the negative population stained for cKit+ESAM+ to separate HSC and HSPC populations. 
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In these studies, LC3 GFP mice, which express GFP driven off the LC3 promoter, are 
used to measure LC3 protein on the autophagosome membrane (as a readout of 
autophagy activity). Using the ImagestreamX (Amnis) imaging software we were able to 
quantify the number and distribution of LC3-GFP punctae in each cell and use this as a 
measure of autophagy activity in different cellular subpopulations. The magnification was 
60X and the maximum power was set for each laser in use. The images and statistics 
were processed using the IDEAS software (version 6.0, AMNIS). 
 Bioluminescent imaging 3.6
Mice were imaged using the Xenogen, IVIS 100 Bioluminescent Imaging System (Caliper 
Life Sciences). Anaesthetised mice were injected subcutaneously with 200g firefly 
luciferin (Caliper Life Sciences), which was allowed to circulate for 5 minutes before image 
acquisition commenced. Bioluminescent images were captured for 5 minutes for whole 
body images and 2 minutes for excised organs. Light emission is presented as photons 
per second per cm2 per steer radiant (ph s-1 cm-2 sf-1). Data was analysed with Living 
Image software Version 4 (Xenogen). 
 Generation of chimeric mice 3.7
3.7.1 Atg5-/- FL chimeras 
To generate foetal liver chimeras, mice heterozygous for the Atg5 deficiency were time 
mated and sacrificed at E17.5. Foetal livers were harvested into a single cell suspension. 
A tail sample was harvested into Quick Extract DNA extraction solution (Epicentre 
Biotechnologies) for genomic DNA extraction and PCR was performed on each pup 
sample to determine both the Atg5 genotype (WT, heterozygote or homozygote) and the 
sex of each pup.  Atg5 genotyping used the following three primer sequences: – 5’-
ACAACGTCGAGCACAGCTGCGCAAGG-3’, 5’-GAATATGAAGGCACACCCCTGAAATG-
3’ and 5’-GTACTGCATAATGGTTTAACTCTTGC-3’. To avoid sex chromosome 
histocompatibility issues for transplantation experiments sex differentiation genotyping was 
performed using the following primer sequences:  X chrom F – 5’ 
GTTCTTTCGTTTTCCCCTCTC 3’ , X chrom  R – 5’ GGCATTATCTAAGGAGAAGCATC 
3’, Y chrom(a)  – 5’ GACTAGACATGTCTTAACATCTGTCC 3’ , Y chrom(b) – 5’ 
CCTATTGCATGGACAGCAGCTTATG 3’.  Female Atg5 KO and WT pups were identified 
and 1-3x106 foetal liver cells from each were injected separately into lethally irradiated 
(1000cGy) Ptprca recipient mice. Chimeric (Ptprca) mice were left for three months to 
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allow reconstitution of the immune system and mice were confirmed to have donor 
engraftment >98% before being used for transplant experiments.  
3.7.2 Common beta chain KO (c-/-) chimeras 
Chimeric recipients were generated using WT (B6 or Ptprca) and c-/- (B6) mice as both 
donor and recipient cohorts. Recipients were lethally irradiated (1000 cGy) and 
transplanted with 10x106 BM. Chimeras were left to reconstitute for three months before 
donor engraftment >98% was confirmed by analysis of donor CD45+ congenic markers in 
peripheral blood. Animals were subsequently used for transplant experiments. 
3.7.3 March8-/- and K>R (KR-/-) chimeras 
Chimeric recipients were generated using WT (B6), March8-/- and KR-/- recipient mice. 
Recipients were lethally irradiated (1000 cGy) and transplanted with 10x106 Ptprca BM 
and left to reconstitute for a minimum of 8 weeks before donor engraftment >98% was 
confirmed by analysis of donor CD45+ congenic markers in peripheral blood. Animals were 
subsequently used for transplant experiments 
 Competitive FL transplantation 3.8
Atg5-/-  FL cells (expressing CD45.2) were combined in a 1:1 ratio with congenic 
competitor Ptprca FL cells (expressing CD45.1) and injected into the lateral tail vein of 
lethally irradiated (1000 cGy) RAG-KO recipient mice (Animal Resource Centre, Western 
Australia). PB was sampled and counted as described (2.3) at six weeks post-transplant to 
determine haematopoietic chimerism. PB samples were subjected to red blood cell lysis 
using Gey’s solution (made in house) and stained with anti-CD45.1 (A20) and anti-CD45.2 
(104) for 20-30 minutes at 4oC and analysed by flow cytometry. 
 Transplantation models 3.9
Well established GVHD models were used to study the impact of donor CD3+ T cells 
under different transplant conditions. These studies employed both major-
histocompatibility mismatch models and minor-histocompatibility mismatch models as 
detailed in Table 2.2. 
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3.9.1 Cyclosporine administration 
Recipients of Atg5-/- and control grafts were treated with cyclosporine (CsA) or saline 
based on animal weight (25 g/gram; Novartis Pharma, Switzerland) daily from day+0 to 
day+14 via intra-peritoneal injection. 
 Assessment of GVHD 3.10
The degree of systemic GVHD was assessed by weekly scoring based on five physical 
characteristics. Mice scores are generated based on animal movement, posture, fur 
ruffling, skin integrity, and weight loss Table 2-3 [234].  
 Statistical analysis 3.11
Survival curves were plotted using Kaplan-Meier estimates and compared by log-rank 
analysis using PRISM 6 (GraphPad software). A P value less than .05 was considered 
statistically significant. A 2-tailed Mann-Whitney U test or an unpaired t test was used to 
evaluate significant differences between groups and all data is represented as mean ± 
SEM. 
 Histology analysis 3.12
Formalin-preserved lung, liver, small intestine and colon were embedded in paraffin, and 
5-m-thick sections were stained with hematoxylin and eosin (H&E) for histological 
analysis and scoring. Slides were coded and examined in a blinded fashion using a 
semiquantitative scoring system [233]. Each H&E labelled section was assigned a score 
between 0 and 4 based on the extent of cellular apoptosis and inflammatory infiltrate. 
Images of GVHD target tissue damage were acquired on a Brightfield slide scanner 
(Aperio Scanscope XT) and Imagescope software. 
 Serum cytokine analysis 3.13
Serum cytokine concentrations were determined using the BD Cytometric Bead Array 
system (BD Biosciences Pharmingen) according to the manufacturer's protocol. 
 In vitro cytokine stimulation 3.14
Whole bone marrow (BM) was isolated from B6.LC3-GFP mice and counted. 5 X 106 
whole BM cells per well were cultured in 6 well plates at 37oC in media either 
supplemented with 10 mg/mL cytokine (IL-1, TNF, IFN, G-CSF, MCP-1, IL-6 or IL-1+TNF) 
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or non-supplemented media.  After 4 hours of incubation cells were washed and surface 
stained with haematopoietic stem and progenitor cell (HSPC) staining panels (see 2.8.1) 
and analysed by flow cytometry.  
 RNA extraction 3.15
Ribonucleic acid (RNA) from whole tissue was extracted by homogenisation in Trizol 
(Invitrogen, Life Technologies, Carlsbad, CA). 200µL chloroform was added to 1mL 
homogenized tissue, shaken vigorously and incubated at room temperature for three 
minutes followed by centrifugation (12,000xg for 15 min) at 4oC). The aqueous (upper) 
phase was transferred into a fresh eppendorf tube, taking care to avoid the white 
Deoxyribonucleic Acid (DNA) interphase. Whole tissue provided ample RNA however 
where sorted cellular RNA volumes were low, 1 µL of diluted glycogen (5 µg/µL) was 
added to the aqueous RNA solution. 500µL isopropanol was added to the aqueous RNA 
solution and tubes were stored for a minimum of 30 minutes at -20oC or overnight at -70oC 
to induce RNA precipitation. Finally, the solution was centrifuged at 4oC for 15 mins at 
12,000×g. The supernatant was carefully removed and discarded and the RNA pellet air-
dried and re-suspended in between 10-50 µl of RNase-free water (depending on expected 
RNA volume). RNA concentration and purity was determined (Nanodrop 2000) and RNA 
stock was stored at −80oC until cDNA preparation. 
 Reverse transcription cDNA amplification 3.16
To eliminate DNA contamination, a DNAse treatment was performed on RNA samples 
(maximum 2 μg/ 7 l). 2 µl of a master mix containing 1 µl Invitrogen 10X DNAse Buffer 
and 1 µl Invitrogen DNAse I Enzyme was added to each sample. The tubes were vortexed 
and spun down before incubation at room temperature for 15 mins. Next, 2 µl of 12.5 mM 
EDTA was added to each sample and samples were incubated in a 65ºC water bath for 10 
minutes, removed and immediately placed on ice for at least 1 minute. Reverse 
transcription (RT) of the RNA was performed as follows: Firstly, Promega Oligo dT 5 g/l 
(1 µl per sample) together with dNTPs at 10 mM (1 µl per sample) was added to each 
RNA sample and subsequently incubated at 65ºC for 5 mins and then immediately placed 
in ice. Next, 7 µl of a master mix solution containing: 4 µl of 5X 1st strand buffer; 1 µl of 
100mM DTT; 1 µl of Promega RNAsin enzyme (40U/µl); and 1 µl Superscript III enzyme 
(50U, Invitrogen Life Technologies, Carlsbad, CA) was added to each sample. The 
samples were placed in a thermal cycler (applied biosystems) and RT was performed 
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using the following conditions: 50ºC for 60 minutes followed by 70ºC for 15 minutes. The 
cDNA generated was stored at -80ºC. 
 Quantitative real-time PCR 3.17
Forward and reverse primers were resuspended in DNAse/RNAse free water at a 
concentration of 100nmol/mL. Primer master mix solutions were prepared by pooling 
forward and reverse primers at a 1/10 dilution in DNAse/RNAse free water; final working 
primer solution was [10nmol/mL]. The RT-qPCR reaction was performed in 96 well 
reaction plates (1 well per test sample, in duplicate) using SYBR Green PCR reaction mix 
(Thermo Fisher) according to the manufacturer’s instructions. The SYBR green dye is 
detected and quantified by the Real-Time PCR machine (ViiA™ 7 Real-Time PCR System, 
Applied Biosystems CA, USA). The ViiA 7 software (QuantStudioTM Real-Time PCR 
Software) automatically determines the threshold (in the linear amplification phase) to 
provide Ct values for each sample, representative of the number of cycles required to 
reach the threshold intensity of fluorescence. All qPCR assays included reactions using 
the housekeeping gene Hypoxanthine-guanine phosphoribosyltransferase (HPRT) as an 
endogenous control to normalise for variations in the amount of cDNA present in each 
reaction. The relative expression of the transcript was expressed in arbitrary units and 
calculated following the 2−ΔΔCt method [235]. The 2−ΔΔCt values were plotted using 
GraphPad software 7.0 (GraphPad Software Inc., San Diego, CA, USA) to generate the 
graphic of the transcript expression. 
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Table 2.1 List of antibodies 
 
Antibody Catalogue No. 
B220-biotin 103204; Biolegend 
B220-Pacific Blue 103227; Biolegend 
c-Kit (CD117)-APC 105812; Biolegend 
c-Kit (CD117)-APC/Cy7 105826; Biolegend 
c-Kit (CD117)-PE/Cy7 105814; Biolegend 
CD107a-V450 560648; BD Biosciences 
CD16/32-APC/Cy7 101328; Biolegend 
CD16/32-PE 101308; Biolegend 
CD25-PE 101904; Biolegend 
CD3-CF594 562286; BD Horizon 
CD3e-Pacific Blue 100334; Biolegend 
CD3-PE 100308; Biolegend 
CD326-PE/Cy7 118216; Biolegend 
CD4-Pacific Blue 100428; Biolegend 
CD4-PerCP-Cy5.5 550954; BD Pharminogen 
CD4-APC 100412; Biolegend 
CD8-Pacific Blue 558106; BD Pharminogen 
CD8-PE/Cy7 100722; Biolegend 
CD115 (CSFR1)-PE 135506; Biolegend 
CD11b-APC/Cy7 101226; Biolegend 
CD11c-APC 117310; Biolegend 
CD11c-PerCP/Cy5.5 117328; Biolegend 
CD14-FITC 123308; Biolegend 
CD150-PE 115904; Biolegend 
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CD34-e660 50-0341-80; eBioscience 
CD34-FITC 11-0341-85; eBioscience 
Cd3e-biotin 100304; Biolegend 
CD45.1-Alexa Fluor 700 561235; Biolegend 
CD45.2-AF700 109822; Biolegend 
CD45.2-Horizon V500 562129; BD Biosciences 
CD48-APC/Cy7 103432; Biolegend 
Cd5-biotin 100604; Biolegend 
ESAM1-PE 136204; Biolegend 
F4/80-PE 123110; Biolegend 
F4/80-PE/Cy7 123114; Biolegend 
Flt3-PECF594 562537; BD Biosciences 
Foxp3-AF647 320014; Biolegend 
Gr-1-biotin 79750; Biolegend 
Gr-1-Pacific Blue 108430; Biolegend 
IA/IE (MHC II)-FITC 107607; Biolegend 
IA/IE (MHC II)-PE/Cy7 107630; Biolegend 
IA/IE (MHC II)-Pacific Blue 107620; Biolegend 
IL7Ra (CD127)-biotin 135006; Biolegend 
(anti) LC3 mab (purified IgG)  (clone 4E12) MBL 
Ly6C-BV605 128036; Biolegend 
Ly6G-APC/Cy7 127628; Biolegend 
Mac-1 (Cd11b)-biotin 101204; Biolegend 
Mac-1 (Cd11b)-BV605 563015; BD Pharminogen 
Mac-1 (Cd11b)-Pacific Blue 101224; Biolegend 
Mac-1 (CD11b)-PerCP/Cy5.5 101228; Biolegend 
NK1.1-APC 108710; Biolegend 
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Streptavidin-PE/Cy7 405206; Biolegend 
Streptavidin-AF700 S21383; Invitrogen 
SiglecF-AF647 562680; BD Pharminogen 
Sca-1-PE/Cy7 122514; Biolegend 
Ter-119-biotin 116204; Biolegend 
Ter-119-Pacific Blue 116232; Biolegend 
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Table 2.2Transplantation models 
 
 
DONOR 
 
 
RECIPIENT 
 
Antigen 
Mismatch 
 
Radiation 
dose (cGy) 
 
BM 
dose 
 
T cell 
dose 
Strain Haplotype Strain Haplotype 
 
C57Bl/6 
 
 
H-2b 
 
B6D2F1 
 
H-2d/b 
 
MHC/MiHA 
Parent 
 
1100 
 
5 x 106 
 
1-3 x 106 
 
BALB/c 
 
 
H-2d 
 
C57Bl/6 
 
H-2b 
 
MHC/miHA 
 
1000 
 
10 x 
106 
 
3-5 x 106 
 
C57Bl/6 
Foetal Liver 
 
H-2b 
 
RAG-1 KO 
 
H-2b 
 
NIL 
 
1000 
 
1-3 x 
106 
 
N/A 
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Table 2.3 Assessment of clinical GVHD in transplanted mice 
 
Reproduced from [234] 
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CHAPTER 4. AUTOPHAGY IS CRITICAL FOR 
SURVIVAL AND ENGRAFTMENT OF 
HAEMATOPOIETIC STEM AND PROGENITOR 
CELLS IN THE HIGHLY INFLAMMATORY 
SETTING OF ALLOGENEIC 
TRANSPLANTATION 
 Introduction 4.1
Allogeneic stem cell transplantation (SCT) is a well-established treatment for a number 
of haematopoietic malignancies that cannot be cured by conventional chemotherapy. 
The success of transplantation relies on the proliferative potential of donor 
haematopoietic stem cells (HSC) and their unique ability to reconstitute the recipient’s 
entire haematopoietic system and restore immunity. The curative property of SCT 
relies on naïve donor T cells within the graft being able to recognise recipient antigens 
as foreign and target residual malignant cells for destruction. This is referred to as the 
graft versus leukaemia (GVL) effect. For this reason, donor T cells are an important 
component within the graft. In addition however, these T cells are the primary 
mediators of an early cytokine storm which drives graft versus host disease (GVHD), a 
life-threatening complication of SCT. Establishing transplant protocols that maximise 
the efficiency of HSC engraftment, while maximizing GVL and minimizing GVHD has 
been a long-term goal in the field. 
The stem cell graft contains a variety of pluripotent cell types, including the haematopoietic 
stem cells (HSC) in addition to more differentiated haematopoietic progenitor cells (HSPC) 
[236-238]. HSPC and HSCs are responsible for providing almost immediate, short-term 
haematopoiesis to protect the host following myeloablation and stem cell 
transplantation[239]. Studies have reported that following acute lethal irradiation, bone 
marrow (BM) reconstitution is primarily mediated by committed myeloid progenitors [240]. 
Allogeneic SCT represents perhaps the most stressf therapeutic procedure undertaken 
in regard to bone marrow stem cells and the bone marrow microenvironment. There are 
three major limitations to the success of SCT and these include: Graft rejection or failure, 
graft versus host disease (GVHD), and infection. Graft failure following allogeneic SCT can 
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manifest in two forms: Either a lack of initial donor cell engraftment (primary graft failure), 
or a loss of donor cells after initial engraftment (secondary graft failure) [241]. Secondary 
graft dysfunction in particular is common during GVHD with devastating, often fatal 
consequences. The mechanisms that promote GVHD-associated graft dysfunction remain 
poorly defined. 
The paucity of donor HSC is a major limitation when it comes to clinical application and the 
success of SCT in patients. Research to develop protocols to expand transplantable HSC 
ex-vivo has explored a variety of approaches including the identification of transcriptional 
regulators of factors that support BM stroma and also small molecules to promote stem 
cell expansion [242]. An alternative to these approaches is to enhance the ability of the 
ingoing cells to successfully engraft. The process of successful engraftment relies on 
ingoing donor HSCs and HSPCs trafficking to the BM niche and then engaging with the 
appropriate supporting cells in order to survive and differentiate into all of the mature 
lineages that constitute whole blood [82]. Cells within the transplanted graft encounter 
numerous stresses initiated by factors including recipient myelotoxic conditioning, which 
ablates the tumour burden but also causes additional tissue damage impacting the BM 
niche and other tissues such as the gut[26, 243]. The graft also incurs the additional stress 
of ex-vivo manipulation prior to transplantation and the requirement for these cells to 
undergo supraphysiological haematopoietic expansion post-transplant [244]. Rossi et al. 
(2012) determined that distinct biological regulation is required for stress haematopoiesis, 
which includes that following HSCT, compared to the baseline turnover that is ongoing in 
healthy individuals [245]. Furthermore, recent studies have identified that the HSPCs that 
maintain haematopoiesis following a HSCT may indeed differ from those required to 
sustain naïve haematopoiesis [246, 247]. 
Allogeneic transplantation is associated with a highly inflammatory milieu. Recipient 
conditioning contributes to tissue damage, typically in the gut, resulting in the release of 
inflammatory cytokines such as interleukin (IL)-1, IL-6, and tumour necrosis factor (TNF) 
together with LPS which are all known to trigger autophagy [248, 249]. Additionally, this 
inflammatory milieu promotes the activation of antigen presenting cells (APC) which prime 
donor alloreactive CD3+ T cells, which are required to  These alloreactive T cells further 
contribute to the release of pro-inflammatory cytokines, and thus drive GVHD as part of a 
process described as the cytokine storm [243]. 
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Macroautophagy (herein referred to as autophagy) is a highly conserved and tightly 
regulated catabolic process that involves the sequestration and lysosomal degradation of 
cellular components including mitochondria, endoplasmic reticulum, peroxisomes, 
misfolded proteins and damaged organelles [250-253]. Autophagy is characterized by the 
formation of a double-membrane structure called a phagophore, which elongates and 
engulfs cellular material and fuses upon itself to form an autophagosome [254]. More than 
30 autophagy related genes (Atg) are known to contribute to this process [255]. During this 
maturation, Atg7 and Atg5 activate LC3 lipidation allowing the incorporation of 
phospholipids into the autophagosome membrane and as such, lipidated LC3 (LC3-II) is 
routinely used as a specific marker of autophagosome formation.  
Studies to date have demonstrated that autophagy is required the survival and function of 
HSC in the steady state [88]. Conditional ablation of Atg7 in all haematopoietic cells, using 
the VAVcre system, led to an accumulation of mitochondria and ROS in HSC. VAVcreAtg7fl/fl 
mice displayed a significant reduction in HSC number within the LinnegSca-1+c-Kit+ (LSK+) 
compartment. Furthermore, production of both lymphoid and myeloid progenitors was 
impaired [89, 256]. Of note, little has been described with regard to HSC and HSPC in the 
setting of allogeneic SCT and GVHD. 
 Results 4.2
4.2.1 Autophagy is active in haematopoietic and progenitor cells in the 
steady state 
To determine whether autophagy is an active process in HSPC we used flow cytometry 
and multispectral imaging flow cytometry to compare autophagosome formation in HSC 
and HSPC. Using BM from LC3-GFP mice, which express GFP driven off the LC3 
promoter and permit the identification of LC3-GFP autophagosomes, we were able to 
quantify the number of autophagosomes as a measure of autophagic activity in subsets of 
cells. Gating on lineage negative BM cells, these were divided into HSC LKS+ 
(LinnegcKit+Sca-1+) and HSPC LKSneg (LinnegcKit+Sca-1neg) populations (Figure 4.1A). The 
expression of LC3-GFP was greater in HSC (84.3%) than HSPC cells (23.6%) in the 
steady state (Figure 4.1B). Furthermore, imaging flow cytometry analysis permitted the 
intracellular localization of LC3 and its accumulation on the autophagosome membrane, 
thus confirming the constitutive activity of this pathway in both HSC and HSPC.  
Quantification of these LC3-GFP punctae revealed that there were significantly more 
autophagosomes present in HSC compared to HSPC in the steady state (Figure 4.1C+D). 
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Thus, in the steady state HSC demonstrate a significantly greater level of autophagy than 
their myeloid progenitor counterparts. 
4.2.2 Autophagy is dispensable for development of HSC and HSPC 
Haematopoietic ablation of Atg7, under the VAVcre promoter, was previously shown to 
impair production of HSC and progenitor populations [256]. In order to examine whether 
ablation of Atg5 also impacted the development of HSC and progenitor cells we utilized 
mice harbouring a global deficiency in Atg5 [51]. Previous studies have demonstrated that 
systemic deletion of Atg5, one of the core autophagy genes, is lethal in neonates [257]. 
We therefore examined the impact of Atg5 deficiency on the HSC compartment in foetal 
liver (FL) harvested from pups at embryonic day 18 (E18.5). Although, the absolute cell 
numbers in Atg5-/- FL were significantly reduced compared to WT littermates (Figure 4.2A), 
the absolute number of LT-HSC (LKS+, LinnegcKitmidSca-1+) and common lymphoid 
progenitors (CLP) did not differ between WT and Atg5-/- foetal livers (Figure 4.2B). 
Similarly, HSPC cell numbers and the subsets within this population: granulocyte 
macrophage progenitors (GMP), common myeloid progenitors (CMP) and megakaryocyte 
erythroid progenitors (MEP) did not differ between WT and Atg5-/- in the steady state 
(Figure 4.2C). Thus we confirmed that autophagy is not required for the development of 
HSC or HSPC in FL. 
4.2.3 Autophagy deficient cells display delayed engraftment and 
reduced competitive fitness 
Having established that autophagy was not required for the generation of FL HSC and 
HSPC, we next examined the functional requirement for autophagy in these cells. Previous 
studies report that HSC from conditional FIP200-/- and Atg7-/- mice are not capable of 
reconstituting lethally irradiated recipient mice[88, 89]. To determine whether Atg5-/- FL 
were capable of functional engraftment we transplanted Atg5-/- or WT (CD45.2+) FL cells 
into lethally irradiated syngeneic Ptprca (CD45.1+) recipients and monitored engraftment in 
the BM, spleen and peripheral blood at six weeks post-transplant (Figure 4.2D). These 
experiments showed that Atg5-/- FL cells are capable of engrafting and reconstituting the 
recipient haematopoietic system. Engraftment by Atg5-/- FL cells was however mildly 
reduced, suggesting they have reduced efficiency in comparison to recipients receiving 
WT littermate FL grafts. Having demonstrated that autophagy in HSC and progenitor 
populations is not critical for their development but that they exhibited slightly reduced 
engraftment potential post-transplant we next compared the competitive fitness of 
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autophagy deficient HSC with WT cells. Thus, lethally irradiated RAG-1-deficient 
recipients, which lack mature B and T lymphocytes [258], were transplanted with a grafts 
containing equivalent numbers of 50:50 ratio of WT (CD45.1+) and autophagy-deficient 
Atg5-/- or Atg5+/- (CD45.2+) FL (Figure 4.2E). Six weeks post-transplant, we used flow 
cytometry to differentiate CD45.1+ WT cells from CD45.2+ Atg5-deficient cells and 
observed a significantly reduced frequency of donor CD45.2+ cells for both Atg5-/- and 
Atg+/- compared to WT. The ratio between Atg5-/- to WT was reduced compared to that 
between Atg5+/- and WT cells demonstrating that there is a dose response to the level of 
autophagy required for these cells to engraft during this six week period. This superior 
engraftment by WT cells demonstrates that following syngeneic transplantation autophagy 
is required for optimal engraftment. 
4.2.4 Autophagy is upregulated following allogeneic transplant in the 
setting of GVHD 
Following allogeneic transplantation the inflammatory milieu that ensues may elicit 
additional requirements for autophagy within HSC and HSPC to facilitate engraftment. To 
determine the requirement for autophagy in this setting we used the well-established 
C57Bl/6 into B6D2F1 model of GVHD to examine autophagic activity in HSC and HSPC at 
d7 post-transplant. Here we utilized the transgenic B6.LC3-GFP reporter mice, and 
transplanted 5x106 LC3-GFP BM together with or without 2x106 LC3-GFP CD3+ T cells to 
induce GVHD. At day 7 post-transplant we analysed the level of autophagy in HSC and 
HSPC in the BM (Figure 4.3A). BM resident lineage negative cells of donor origin were 
selected and divided into, HSC and HSPC populations (see methods). We quantified the 
level of autophagy in these populations by measuring the intensity of LC3-GFP 
fluorescence (FACS) and the number of LC3-GFP punctae in individual cells (AMNIS). 
Flow cytometry confirmed that LC3-GFP mean fluorescent intensity was significantly 
higher in the setting of GVHD compared to that of non-GVHD recipient BM (Figure 4.3B). 
Furthermore, AMNIS imaging flow cytometry enabled us to image individual cells and 
quantify the number of LC3-GFP+ punctae as a measure of autophagic flux (Figure 4.3C). 
Quantification of these punctae revealed that autophagy is elevated in both HSC and 
HSPC in the setting of GVHD. Additionally, autophagy was significantly increased in the 
common myeloid progenitor (CMP) and megakaryocyte erythroid progenitor (MEP) 
subsets in the setting of GVHD while there was no difference observed in the granulocyte 
macrophage progenitor (GMP) subset (Figure 4.3D). This data demonstrates that in the 
setting of GVHD, induced by allogeneic CD3+ T cells, autophagy is increased compared to 
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non-GVHD suggesting that autophagy is required by HSC and progenitor populations in 
this highly inflammatory environment. 
4.2.5 Following allogeneic transplantation, autophagy is required for 
survival and engraftment of HSPC 
Considering the elevated autophagic activity observed in donor cells in the setting of 
GVHD we next examined the impact of ablating autophagy within the donor graft in the 
context of allogeneic SCT. Again, using the C57Bl/6 into B6D2F1 GVHD model we 
transplanted recipients with 1.5-3x106 FL cells from WT or Atg5-/- FL together with 1x106 
Ptprca CD45.1+ CD3+ T cells (FL+T). At day 10 post-transplant absolute cell numbers 
were significantly reduced in the blood, BM and spleen compartments in the recipients of 
Atg5-/- FL+T compared to recipients of WT FL+T grafts (Figure 4.4A). To examine the 
impact of autophagy-deficiency within the donor graft in the setting of alloreactive T cell 
driven GVHD, we compared irradiated recipients of either WT or Atg5-/- FL+T cell grafts (to 
induce GVHD) to recipients of Atg5-/- FL cells only (non GVHD). Recipients of FL only (non 
GHVD) donor grafts survived long term (60+ days) while more than 75% of recipients 
given WT FL+T grafts succumbed to GVHD by day 60 (Figure 4.4B). However, we 
observed significantly (P< 0.0001) reduced survival in the Atg5-/- FL+T recipient group with 
the majority succumbing to GVHD by day 20 post-transplant. Next, we examined HSC 
engraftment in the BM of recipients early (day 10) post-transplant. Gating on lineage 
negative cells we separated these into cKit+ESAM+ (HSC) and cKit+ESAMneg (HSPC) 
populations (Figure 4.4C). Total lineage negative, HSC and progenitor populations were all 
significantly reduced in recipients of Atg5-/- FL+T grafts. Further sub-setting within the 
progenitor compartment revealed significantly reduced frequency and absolute numbers in 
the GMP, CMP and MEP populations in recipients of Atg5-/- FL+T grafts (Figure 4.4D). 
This result highlights the critical requirement for autophagy during HSC and HSPC 
engraftment after allogeneic SCT. To confirm the role of autophagy, and not derived from 
off target effects of Atg5 deficiency, we confirmed this result using a second model in 
which VAVcre promoter expression drives ablation of Atg7 in all haematopoietic cells. 
Again, we observed significantly reduced survival in mice receiving VAVcreAtg7fl/fl donor 
grafts (Figure 4.4B+D). In order to determine if this critical requirement for autophagy was 
restricted to HSC or additionally required by the more mature myeloid HSPC we examined 
the effect of ablating autophagy in myeloid cells, this time using the LysMcre promoter to 
ablate Atg7 from the GMP stage of myeloid differentiation onward. Lethally irradiated 
B6D2F1 recipients were administered a BM+T donor graft with either WT or LysMcreAtg7fl/fl 
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donor BM together with WT CD3+ T cell to induce GVHD. In this system we observed no 
significant difference in clinical scores or survival between recipients of WT versus 
LysMcreAtg7fl/fl donor grafts (Figure 4.4F), suggesting that autophagy is critical in earlier 
progenitor subsets in addition to the HSCs for successful primary engraftment post-
transplant in the context of GVHD but is dispensable in more mature myeloid cells. 
4.2.6 Dampening the allogeneic cytokine storm restores engraftment in 
HSC and HSPC 
Having observed a critical requirement for autophagy in HSC and HSPC specifically in the 
setting of GVHD, we next examined whether the inflammatory milieu was imparting an 
increased requirement for autophagy in the donor graft. To test this, we utilized 
Cyclosporine (CsA), an agent which dampens T-cell cytokine production, to examine the 
impact on autophagic activity in the HSC graft. Here, BM+T grafts from LC3-GFP donors 
were transferred into lethally irradiated B6D2F1 recipients, and treated daily with either 
saline or CsA (Figure 4.5A). Analysis of serum cytokines at day 7, confirmed elevated 
levels of inflammatory cytokines including: IFN, TNF, IL-6 and MCP-1 in recipient BM+T 
mice treated with saline, compared to TCD controls and BM+T recipients treated with CsA 
(Figure 4.5B). This demonstrated that CsA effectively reduced T cell production 
proinflammatory cytokines in vivo. Next, we used flow cytometry analysis to measure LC3-
GFP expression in lineage negative (HSC/HSPC) cells at day 7 post-transplant. BM+T 
recipients that were administered CsA over the early post-transplant period displayed 
significantly reduced LC3-GFP signal compared to saline treated BM+T recipients (Figure 
4.5C). Strikingly, CsA administration reduced LC3-GFP signals to levels equivalent to non-
GVHD controls. To examine the contribution of elevated pro-inflammatory cytokines to the 
graft failure observed in recipients of autophagy-deficient donor grafts. Cohorts of mice 
received FL+T grafts from WT or Atg5-/- donors, followed by either saline or CsA for the 
first 14 days post-transplant. Day 7 serum cytokine analysis confirmed elevated cytokine 
levels (IFN, TNF, IL-6 and also MCP-1) in both (WT or Atg5-/-) recipient groups treated 
with saline while cytokine levels were significantly reduced in mice administered CsA 
(Figure 4.5D). Moreover, monitoring of survival demonstrated CsA treatment significantly 
increased survival of Atg5-/- BM+T graft recipients (Figure 4.5E). To address which specific 
cytokine(s) were responsible for driving autophagy activity in HSC lineages we performed 
in vitro cytokine stimulation assays. Freshly isolated LC3-GFP BM was cultured for 4 hours 
in media supplemented with or without recombinant cytokine: TNF, IL-1, G-CSF, IFN, 
MCP-1 or IL-6 (each at 10mg/mL). Flow cytometric analysis demonstrated TNF, IL-1 and 
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to a lesser extent G-CSF elicited significantly increased LC3-GFP fluorescence, in LKSneg, 
ST-HSC, LT-HSC, GMP and CMP populations (Figure 4.5F). IFN treatment also 
increased LC3-GFP in LKSneg, GMP, CMP and MEP populations. Notably, simultaneous 
treatment with IL-1 and TNF resulted in the greatest increase in LC3-GFP fluorescence in 
LKSneg, ST-HSC, LT-HSC, GMP and CMP populations demonstrating the cumulative 
impact of cytokine exposure on autophagy activity in both HSC and HSPC populations. 
This result confirms that the pro-inflammatory cytokines released during GVHD contribute 
to the increased requirement for autophagy in HSC and HSPC during the period of 
engraftment and haematopoietic reconstitution. Thus, dampening systemic cytokine levels 
in the early post-transplant period enhances survival of autophagy-deficient HSPC and 
HSC and improves recipient engraftment. 
 Discussion 4.3
Efficient engraftment post-transplant is critical to protect the recipient from infection and to 
permit the effective T-cell mediated clearance of tumour burden via GVL. Studies to date 
have identified a key role for T cell derived, pro-inflammatory cytokines, including 
TNF[259], IL-1[260] as negative regulators of haematopoiesis, and which induce the 
production of reactive oxygen species (ROS) in HSPC and have been linked to bone 
marrow failure syndromes [261-263]. In the setting of aplastic anaemia (AA), excessive 
production of TNF by BM lymphocytes in tandem with higher expression of TNFRs on 
stem cell populations in AA patients, resulted in BM failure [261]. This demonstrates that 
HSC are highly responsive to pro-inflammatory cytokine stimulation and susceptible to BM 
failure in response. 
Further to this, a recent study identified that median plasma levels of pro-inflammatory 
cytokines, including IL-1 and IL-6, were significantly elevated in paediatric patients with 
engraftment complications compared to isolated aGVHD. This supports a role for pro-
inflammatory cytokines as stressors in the haematopoietic compartment during the early 
post-transplant period [264]. 
It is well established that myeloablative pre-conditioning and the presence of alloreactive T 
cells in the setting of GVHD elicits a cytokine storm resulting in systemic increase in pro-
inflammatory cytokines including TNF, IL-1 and IFN [13, 265]. Our findings demonstrate 
that several pro-inflammatory cytokines, but most significantly TNF and IL-1, induce 
autophagy in vitro in HSC and HSPC in the steady state. Furthermore, we demonstrate in 
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vivo that allogeneic T cells induce an increase in autophagy activity in murine HSPC by 
day 7 post-transplant.  
When autophagy is ablated in the donor stem cell graft, donor HSC/HSPC fail to support 
haematopoietic recovery resulting in significantly reduced reconstitution of all three 
lineages of the haematopoietic compartment and recipient mice succumb to engraftment 
failure by day 10 post-transplant. Furthermore, our experiments using LysMcreAtg7fl/fl stem 
cell grafts, which restrict autophagy-deficiency to more terminally differentiated myeloid 
progenitor cells, failed to replicate the significantly reduced survival observed when 
autophagy was ablated in all haematopoietic cells (using VAVcreAtg7fl/fl and Atg5-/- mice). 
This finding supports a critical role for autophagy in HSC and early progenitor populations 
(CMP and MEP) during primary engraftment in the setting of GVHD. 
We confirmed that development of the HSC pool in autophagy (Atg5)-deficient mice is 
comparable to that of WT mice. Following transplantation, in the absence of a pro-
inflammatory milieu, the autophagy-deficient graft is indeed capable of functional 
engraftment and long-term haematopoietic recovery.  
However, during GVHD and the inflammatory cytokine storm, we demonstrated a critical 
requirement for autophagy in the donor HSC graft for primary engraftment and 
haematopoietic recovery. Furthermore, treatment with cyclosporine (CsA) during days 0-
14 post-transplant reduced serum levels of donor T-cell derived cytokines including IL-1 
and TNF and rescued autophagy-deficient donor HSC from primary graft failure.  
These findings support a role for autophagy in HSC and progenitor survival in the setting 
of alloreactive GVHD. We demonstrate that IL-1 and TNF are potent inducers of 
autophagy in HSC and HSPC and that without autophagy activity these populations fail to 
engraft. A direct role for IL-1 in accelerating HSC cell division and myeloid differentiation 
was recently described, reporting that chronic exposure to IL-1 restricts HSC proliferation 
and self-renewal causing IL-1-exposed HSC to fail large scale replicative demands such 
as transplantation [266]. Similarly, neutralizing donor T cell-derived TNF in vivo is 
demonstrated to increase short-term stem and progenitor cell engraftment and to 
accelerate haematopoietic recovery [267]. We demonstrate that in response to these 
cytokine stressors, HSC and progenitor cells critically require autophagy to survive and 
engraft and that in the absence of autophagy recipients succumb to primary graft failure. 
These findings identify IL-1 and TNF as key pro-inflammatory mediators of HSC/HSPC 
stress during the early post-transplant period and highlight the potential benefits of 
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promoting autophagy activity within the donor graft or attenuating cytokine signalling to 
promote primary engraftment following SCT.  
Two biopharmaceutical agents currently employed in the clinic for the suppression of pro-
inflammatory cytokines include: (1) Anakinra, which is a recombinant and slightly modified 
version of the human interleukin 1 receptor antagonist protein (IL-1RAP) [268]; and (2) 
Enbrel / Etanercept, which is a TNF-receptor fusion protein [269]. 
Anakinra is an effective agent for the inhibition of both IL-1 and IL-1 dependent 
signalling and is currently used in the clinic for the treatment of chronic inflammatory 
diseases such as rheumatoid arthritis and has an excellent safety profile [270, 271]. 
Importantly for SCT, IL-1RAP is dispensable for normal HSC function, even under 
conditions of haematopoietic stress suggesting that treatment with Anakinra following SCT 
could indeed improve engraftment outcome by reducing IL-1 signals to the donor HSC 
graft [266]. 
Recent studies have reported improved engraftment outcomes when stem cell harvest is 
performed under hypoxic conditions [272]. Using a competitive transplant assay in which 
the donor grafts comprised a 1:1 ration of donor cells harvested under either hypoxic 
conditions or ambient air conditions and demonstrated a 2.5 fold increased in the 
repopulating ability of HSC prepared under hypoxic conditions compared to ambient air 
competitors. They identified that ambient air exposure decreased the recovery of LT-HSC 
and increased the proportion of HSPC. This was linked to increased production of ROS 
and the induction of mitochondrial permeability, both of which are factors that induce 
autophagy in HSC. Furthermore, this study demonstrated a reversal in the deleterious 
effects of ambient air exposure when BM was harvested in the continuous presence of 
cyclosporine (CsA).  
In summary, we have identified candidate cytokine stressors that trigger the requirement 
for autophagy in the donor HSC graft. Further investigation into the impact of both clinically 
available cytokine inhibitors and pre-transplant manipulation techniques (presented above) 
may provide improved strategies for the preparation of the HSC graft and post-transplant 
regimes to maximise donor engraftment. 
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Figure 4.1 LC3-GFP in naïve BM stem cell populations 
 
(A-D) Analysis of freshly isolated bone marrow (BM) cells from LC3-GFP mice. (A) 
Lineage negative (Linneg) cells were divided into cKit+Sca-1+ (LKS+) and cKit+Sca-1- 
(LKSneg) populations. (B) Representative histograms of flow cytometric analysis for LC3 
expression. Frequency of LC3+ cells in LKSneg, LKS+, long-term HSC (LT-HSC; Flt3-
CD150+CD48-) and short-term HSC (ST-HSC; Flt3-CD150-CD48-) (Representative of two 
independent experiments; n=6). (C) Representative images from imaging flow cytometry 
analysis of LC3-GFP BM. (D) Quantification of LC3-GFP punctae in LKSneg and LKS+ BM 
populations (n=7, from two independent experiments). Data is shown as mean +/- SEM. 
Statistical significance was determined using an unpaired 2-tailed Mann-Whitney test U 
test (***P=0.006). 
  
 54 
 
 
 
 
  
 55 
 
Figure 4.2 Analysis of Atg5-/- foetal liver phenotype and fitness 
  
(A-C) Analysis of freshly isolated Foetal Liver (FL) cells from embryonic day 17.5 (E17.5) 
(A) Absolute cell number in Atg5-/- FL compared to WT FL. (B) Comparison of absolute cell 
number in LSK+ cells between Atg5-/- and WT. (C) Absolute cell numbers of LKSneg cells 
compared between Atg5-/- and WT followed by LKSneg subsets: Granulocyte macrophage 
progenitors (GMP), common myeloid progenitors (CMP) and megakaryocyte erythroid 
progenitors (MEP). (D-E) Analysis of engraftment in chimeric mice. Recipients were 
lethally irradiated and reconstituted with FL cells in a 1:1 ratio comprised of WT.Ptprca 
(CD45.1+):Atg5-/- (CD45.2+) cells. (D) Analysis of competitive engraftment in BM, spleen 
and blood using flow cytometry to differentiate WT.Ptprca (CD45.1+) donor cells from  
Atg5-/- (CD45.2+) donor cells with relative donor frequencies (%) of total CD45+ cells 
displayed below (n=7 from two repeat experiments). (E) Representative plots of 
competitive engraftment between WT.Ptprca (CD45.1+) and either Atg5-/- (total KO) or 
Atg5+/- (heterozygous KO) both (CD45.2+) followed by relative donor frequencies (n=4 
representative of results from two repeat experiments). Data is shown as mean +/- SEM. 
Statistical significance was determined using an unpaired 2-tailed Mann-Whitney test U 
test (*P=0.0286; ***P=0.0006; ****P<0.0001). 
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Figure 4.3 Analysis of LC3-GFP in HSC populations in GVHD and non-GVHD settings 
 
(A) Lethally irradiated B6D2F1 mice were transplanted with 5x106 BM + 2x106 CD3+ T 
cells (GVHD) or without T cells (non-GVHD) from LC3-GFP mice. BM was harvested at 
day 7 post-transplant. (B) Flow cytometry was used to identify lineage negative (Linneg) BM 
cells and compare LC3-GFP expression between non-GVHD versus GVHD groups. 
Representative histograms comparing LC3-GFP MFI between non-GVHD and GVHD 
groups (n=3; representative of two experiments). (C) Representative pictures of imaging 
flow cytometry (AMNIS) analysis of LC3-GFP punctae in individual cells from the lineage 
negative BM population. (D) Mean spot count was quantified from imaging flow cytometric 
analysis. Post-transplant analysis uses the stem cell marker ESAM in place of Sca-1 to 
identify HSC and HSPC subsets. Thus LKE+ (previously LKS+); LKEneg (previously 
LKSneg); followed by progenitor subsets: GMP, CMP and MEP (n=6, representative of two 
repeat experiments). Data is shown as mean +/- SEM. Statistical significance was 
determined using an unpaired 2-tailed Mann-Whitney test U test (**P=0.0043; except MEP 
**P=0.0022). 
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Figure 4.4 Transplantation of autophagy-deficient stem cells in GVHD and non-GVHD 
settings 
 
(A-C) Lethally irradiated B6D2F1 mice were transplanted with WT or Atg5-/- foetal liver 
cells together with CD3+ T cells (GVHD) or without (non-GVHD).  (A) Engraftment, 
determined by total cell number of platelets, Hb (haemoglobin) and neutrophils in 
peripheral blood and total cell numbers together with CD11b+Ly6G+ (granulocytes) and 
CD11b+F480+ (macrophages) in BM and spleen (Blood n=14, representative of two repeat 
experiments; BM and Spleen n=4 taken from one representative experiment). Data is 
shown as mean +/- SEM. Statistical significance was determined using an unpaired 2-
tailed Mann-Whitney U test (*P=0.0286; **P=0.0437; ***P=0.0003; ****P<0.0001). (B) 
Survival analysis of transplant recipients given Atg5-/- or WT FL cells together with WT T 
cells (GVHD) or without (non-GVHD) (Atg5-/- GVHD n=21; WT GVHD n=16; Atg5-/- non-
GVHD n=10). (C) Flow cytometry analysis of HSC (LKE+: LinnegcKit+ESAM+) and myeloid 
HSPC (LKEneg: LinnegcKit+ESAMneg) populations: CMP, GMP and MEP from recipients of 
WT of Atg5-/- donor (GVHD) grafts at day 10 post-transplant (n=8 representative of two 
repeat experiments). (D) In a second model: Lethally irradiated B6D2F1 mice were 
transplanted with WT or VAVcreAtg7-/- BM together with WT T cells (GVHD) or without 
(non-GVHD). Survival analysis of transplant recipients given WT or VAVcreAtg7-/- donor 
grafts with WT T cells or without (GVHD n=10; non-GVHD n=6 representative of two 
repeat experiments). (E) In a third model: Lethally irradiated B6D2F1 mice were 
transplanted with WT or LysMcreAtg7-/- BM together with WT T cells (GVHD) or without 
(non-GVHD). Survival and clinical scores comparing WT GVHD and LysMcreAtg7-/- GVHD 
groups (n=11 and 12 respectively, representative of two repeat experiments). Transplant 
data is shown as mean +/- SEM. Statistical significance was determined using an unpaired 
2-tailed Mann-Whitney test U test (**P=0.0070; ***P=0.0003). Survival curves were 
analysed using a Log-rank (Mantel-Cox) test (****P<0.0001). 
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Figure 4.5 Analysis of the contribution made by cytokines to stem cell autophagy and 
engraftment 
 
(A) Lethally irradiated B6D2F1 mice were transplanted with 5x106 BM + T cells (GVHD) or 
without T cells (non-GVHD) from LC3-GFP mice. Recipients were treated with either saline 
or Cyclosporine (CsA) from day 0-6 post-transplant and BM was harvested at day 7 (D7) 
post-transplant. (B) Serum cytokine analysis at day 7 demonstrated that administration of 
CsA reduced serum concentrations of the cytokines IFN, TNF, IL-6 and MCP-1 to levels 
comparable to non-GVHD controls (n=4-6, representative of two repeat experiments). (C) 
Mean fluorescent intensity of LC3-GFP expression in HSPC. (D-E) Atg5-/- transplant 
model: Lethally irradiated B6D2F1 mice were transplanted with 5x106 Atg5-/- or WT FL 
cells + WT T cells (GVHD) or without T cells (non-GVHD). GVHD groups were 
administered either saline or CsA from day 0-6 post-transplant and non-GVHD controls 
received saline. (D) Day 7 serum cytokine analysis of GVHD and non-GVHD groups 
treated with either saline or CsA (n=5 per group). (E) Survival analysis of transplant 
recipients given Atg5-/- FL+T and treated with either Saline or CsA from day 0-14 
compared to saline treated non-GVHD controls (n=10 per group, representative of two 
repeat experiments). (F) Analysis of LC3-GFP expression in BM cells isolated from LC3-
GFP mice and stimulated in vitro with cytokines (TNF, IL-1, TNF+IL-1, G-CSF, IFN, 
MCP-1, IL-6) or saline (n=3-6, representative of two repeat experiments). Data is shown as 
mean +/- SEM. Statistical significance was determined using an unpaired 2-tailed Mann-
Whitney test U test (*P=0.0152; **P=0.0022) for treatment conditions: TNF, IL-1 and G-
CSF (n=6). A paired t test (*P=0.0188; **P=0.0027; ***P=0.0001; ****P<0.0001) was used 
for treatment conditions: TNF+IL-1, IFN, MCP-1 and IL-6. Survival curves were 
analysed using a Log-rank (Mantel-Cox) test (****P<0.0001). 
 62 
 
CHAPTER 5. THE ROLE OF COMMON BETA 
CHAIN CYTOKINE SIGNALS IN GVHD 
 Introduction 5.1
Although T cells contained within the donor graft are established critical mediators of both 
the acute and chronic forms of GVHD, it is increasingly appreciated that multiple myeloid 
populations contribute to GVHD pathophysiology. Through their potent capacity for antigen 
presentation both donor and host dendritic cells (DC) modulate GVHD severity. 
Paradoxically, early after transplant, host DC limit GVHD through overt activation and 
deletion of antigen specific T cells [273]. Indeed at this time point, host non-haematopoietic 
APC are the critical population driving detrimental GVHD inducing donor T cell responses 
[22]. However, the DC which eventually emerge from the donor graft promote pathogenic 
donor T cell expansion and thus exacerbate GVHD [274]. Donor and host macrophages 
equally have divergent contribution to GVHD outcomes. Early after transplant, CSF-1 
dependent host macrophages attenuate GVHD through their phagocytic sequestration of 
apoptotic donor T cells [126, 275]. Host macrophage ablation through CSF-1R signalling 
blockade results in hyperacute GVHD and rapid mortality. In contrast, CSF-1 dependent 
donor monocytes and macrophages have been demonstrated as critical mediators of 
chronic GVHD [33]. A recent study has demonstrated, using a novel photoconverter 
reporter system, that after tissue conditioning neutrophils migrate from the ilium to the 
mLN where they co-localized with T cells and present antigen via MHC II resulting in T cell 
expansion [118]. Thus, there remains a multitude of myeloid populations that contribute to 
priming alloreactive T cells in the early post-transplant period. The myeloid populations 
exhibit divergent roles and can either promote or inhibit GVHD. 
Common beta chain (c) cytokines, IL-3, IL-5 and Csf2 each play important roles in the 
development, differentiation and survival of myeloid populations including DC, monocytes, 
macrophages and neutrophils [130].  
IL-3 is produced by T cells, mast cells, eosinophils and B cells and has been identified as 
a regulator of HSC and a key inducer of emergency myelopoiesis [276]. To date little has 
been reported on the role of IL-3 in the setting of GVHD although there is some indirect 
evidence in mouse models that high-dosage IL-3 may accelerate GVHD and impair 
survival [277]. 
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IL-5 is produced by both haematopoietic and non-haematopoietic cells including T cells, 
granulocytes, and natural helper cells and impacts both proliferation and 
differentiation[153]. Major cellular sources of IL-5 include: Th2 cells, mast cells, group 2 
innate lymphoid cells (ILC2), CD34+progenitor cells, invariant natural killer (NK) T cells, 
together with eosinophils themselves [155]. IL-5 is reported to support a population of 
circulating eosinophils and blocking antibody studies suggest that IL-5 may play an 
important role in the lung during inflammation and disease [278]. 
Csf2 is produced by multiple cell types including those of the haematopoietic lineage: 
macrophages, fibroblasts, neutrophils, eosinophils, ILC and T cells but additionally by non-
haematopoietic epithelial cells, mesothelial cells, chondrocytes and Paneth cells [279]. In 
the setting of GVHD subsets of CD4 and CD8 T effector cells produce Csf2 after 
transplant [172] and these Csf2+ T cells were recently shown to be critical promoters of 
intestinal inflammation in GVHD [280]. Csf2 is produced by both haematopoietic and 
stromal cells in non-lymphoid tissues in the steady state and is established as a critical 
growth factor for the development of multiple myeloid populations including immature 
myeloid precursors and mature myeloid DC. Thus Csf2 is a potent cytokine for the 
development and function of myeloid populations that play critical roles in inflammatory 
responses. 
At present, the literature examining the role of c cytokines in the setting of aGVHD is 
limited. Using the mice that are globally deficient (c-/-) in the capacity to signal c 
cytokines, this study investigates the impact of ablating c cytokine signalling in the setting 
of allogeneic stem cell transplantation and its impact on the subsequent development of 
GVHD. 
 Results 5.2
5.2.1 Elevated c family cytokines in the recipient promote a pathogenic 
donor population. 
Although T cells contained within the donor graft are established critical mediators of both 
the acute and chronic forms of GVHD, it is increasingly appreciated that multiple myeloid 
populations contribute to GVHD pathophysiology. Through their potent capacity for antigen 
presentation both donor and host dendritic cells (DC) modulate GVHD severity. 
Paradoxically, early after transplant, host DC limit GVHD through overt activation and 
deletion of antigen specific T cells [273]. Indeed at this time point, host non-haematopoietic 
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APC are the critical population driving detrimental GVHD inducing donor T cell 
responses[22]. However, the DC which eventually emerge from the donor graft promote 
pathogenic donor T cell expansion and thus exacerbate GVHD [274, 281]. Donor and host 
macrophages equally have divergent contributions to GVHD outcomes. Early after 
transplant, CSF-1 dependent host macrophages attenuate GVHD through their phagocytic 
sequestration of apoptotic donor T cells [126, 275]. Host macrophage ablation through 
CSF-1R signalling blockade results in hyperacute GVHD and rapid mortality. In contrast, 
CSF-1 dependent donor monocytes and macrophages have been demonstrated as critical 
mediators of chronic GVHD [33]. Moreover, neutrophils represent an additional pathogenic 
myeloid population. A recent study has demonstrated, using a novel photoconverter 
reporter system, that after tissue conditioning neutrophils migrate from the ilium to the 
mLN where they co-localized with T cells and present antigen via MHC II resulting in T cell 
expansion [118, 232]. Thus, through divergent functionality, multiple myeloid populations 
contribute to shaping the immune landscape after SCT to either promote or inhibit GVHD. 
Common beta chain (c) cytokines, IL-3, IL-5 and colony stimulating factor 2 (Csf2, also 
known as granulocyte-macrophage colony stimulating factor) each play important roles in 
the development, differentiation and survival of myeloid populations including DC, 
monocytes, macrophages and neutrophils [130, 282]. IL-3 is produced by T cells, mast 
cells, eosinophils and B cells and has been identified as a regulator of HSC and a key 
inducer of emergency myelopoiesis [145, 276, 283]. To date little has been reported on the 
role of IL-3 in the setting of GVHD although elevated IL-3 was detected in sera of allograft 
recipients with extensive cGVHD [284] while IL-3 was undetectable in patients prior to the 
onset of GVHD nor in syngeneic or autologous recipient groups. There is also some 
evidence in mouse models that high-dosage IL-3 may accelerate GVHD and impair 
survival [277]. IL-5 is produced by both haematopoietic and non-haematopoietic cells and 
exerts pleiotropic effects its target which include B cells, eosinophils and basophils [153]. 
Major cellular sources of IL-5 include: Th2 cells, mast cells, group 2 innate lymphoid cells 
(ILC2), CD34+progenitor cells, invariant natural killer (NK) T cells, together with eosinophils 
themselves [155] and bronchial epithelial cells [285, 286]. IL-5 supports a population of 
circulating eosinophils and neutralization studies suggest that IL-5 may play an important 
role in the lung during inflammation and disease [278]. Csf2 is produced by both 
haematopoietic and stromal cells in non-lymphoid tissues in the steady state and is 
established as a critical growth factor for the development of multiple myeloid populations 
including immature myeloid precursors and mature myeloid DC [127, 169, 170, 194, 279, 
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287, 288]. In the setting of GVHD subsets of CD4 and CD8 T effector cells produce Csf2 
after transplant [171, 172] and these Csf2+ T cells were recently shown to be critical 
promoters of intestinal inflammation in GVHD [280]. Thus Csf2 is a potent cytokine for the 
development and function of myeloid populations that play critical roles in inflammatory 
responses including GVHD. 
At present, the literature examining the role of c cytokines in the setting of aGVHD is 
limited. Using the mice that are globally deficient in the common beta chain receptor 
subunit (c-/-) where the capacity to signal c cytokines is ablated, this study investigates 
the contribution of c cytokine signalling to GHVD outcomes following allogeneic stem cell 
transplantation. 
5.2.2 Ablation of recipient c signalling exacerbates GVHD 
In initial experiments we examined the contribution of c signalling within the host to 
transplant outcomes. Thus, using our well established BALB/c to B6 model of acute GVHD 
we transferred BALB/c BM supplemented with (or without) purified splenic T cells into 
lethally irradiated (1000 cGy) wild type B6 (B6.WT) and B6.c-/- recipients (Figure 5.1A). In 
the absence of GVHD inducing T cells, the majority (75-80%) of B6.WT and B6.c-/- 
recipients survived long term demonstrating that the ablation of host c signalling does not 
perturb the success of transplantation in the absence of alloreactive T cells (Figure 5.1B). 
In contrast, B6.c-/- recipients of BM grafts supplemented with T cells displayed 
significantly elevated clinical scores compared to B6.WT recipients and succumbed more 
rapidly to GVHD. Strikingly, all c-/- recipients succumbed by day 10 post-transplant 
whereas mortality in the WT recipient cohorts was significantly delayed. Notably, although 
TCD c-/- recipients displayed elevated clinical scores compared to WT TCD recipients, 
evidence of GVHD pathology remained minimal and GVHD histopathology scoring 
parameters suggested these noted differences were not the result of GVHD pathology. 
5.2.3 Ablation of c signalling in the recipient drives aGVHD 
histopathology in GVHD target organs 
To gain insight into the mechanisms driving early mortality in the B6.c-/- recipients of 
BM+T grafts, we first we first performed blood counts to examine the impact on 
haematological recovery. HEMAVET quantification of blood cells at D7 post-transplant 
revealed a small but significant decrease in whole blood counts in c recipients which was 
accounted for by a similar decrease in neutrophil numbers. However, monocytes, platelets, 
 66 
 
red blood cells (RBC) numbers were unperturbed thus indicating that early mortality in 
B6.c-/- recipients was not due to failed engraftment (Figure 5.2A). We therefore next 
undertook histological analysis of the gut and lung, which represent early GVHD target 
organs. On D7 post-transplant we examined the small intestine, colon and lung from 
recipients of either BM+T or TCD donor grafts (Figure 5.2B). Clinical pathology scores 
revealed significantly elevated disease in both the small intestine and colon and to a lesser 
extent lung, of c-/- recipients compared to WT. In B6.WT and B6.c-/- recipients, pathology 
was a result of alloreactive T cell driven aGVHD as recipients of TCD donor grafts 
displayed no evidence of GVHD pathology. Taken together, these data demonstrate that 
c cytokine signalling in the host early after transplant attenuates aGVHD. 
5.2.4 Ablation of host c signalling promotes donor graft expansion 
during aGVHD 
To examine the impact of recipient c deficiency on the donor graft expansion and tissue 
homing we transplanted donor grafts from BALB/c-luciferase mice, which ubiquitously 
express luciferase driven off the CMV-Actin promoter [232], permitting us to track and 
quantify donor graft expansion. Whole body imaging at D7 post-transplant revealed 
significantly increased expansion of donor cells in B6.c-/- recipients of BM+T grafts, but 
not TCD grafts, compared to WT recipients (Figure 5.3A). Imaging of individual organs at 
this time point demonstrated significantly increased bioluminescence in the gut, lung, liver 
and spleen of the B6.c-/- recipients (Figure 5.3B+C). Again, this was T cell dependent, as 
there was no difference in bioluminescence signals in these organs in B6.WT or B6.c-/- 
recipients of TCD BM grafts. As both the BM and T cell compartments of the donor graft 
were derived from BALB/c.luciferase donor, the compartment contributing to the elevated 
signal could not be determined. We therefore undertook flow cytometric analysis of the 
splenic T cell compartment of recipients of BM+T grafts at D7 post-transplant, which 
demonstrated a significant increase in CD4+ T cell frequency and a trend toward increased 
CD4+ T cells and CD4+FoxP3+ Treg in B6.c-/- recipients (Figure 5.3D). 
5.2.5 Host c deficiency results in elevated c cytokines early after 
transplant 
Since the c chain is a common receptor subunit for IL-3, IL-5 and Csf2 signalling, we next 
examined the circulating levels of these cytokine in WT and c-/- recipients early after 
transplant.  At both day 4 and day 7 post-transplant, IL-3, IL-5 and Csf2 serum levels were 
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elevated in recipients of GVHD inducing grafts (BM+T) compared to non-GVHD controls 
(TCD). Notably, serum levels of all three cytokines were significantly higher in the B6.c-/- 
recipients compared to WT recipients. We attribute this cytokine accumulation to ablation 
of c signalling in the recipient and thus the inability for the host cells to consume cytokine. 
However, while both IL-3 and IL-5 levels remained elevated in B6.c-/- recipients at D7 
post-transplant, at this time point Csf2 levels had diminished in the B6.c-/- recipients, and 
were equivalent to levels detected in B6.WT recipients (Figure 5.4) Thus, at D4 after 
transplant all three c cytokines appear to be consumed through c signalling by host 
tissues. At day 7 however, Csf2, but not IL-3 nor IL-5, appears to be consumed by c 
signalling in the donor graft. 
5.2.6 c signalling in recipient haematopoietic and non-haematopoietic 
compartments modulates GVHD 
As c cytokine signalling can occur in cells of either haematopoietic or non-haematopoietic 
origin, we next sought to determine the host compartment where c signalling serves to 
attenuate aGVHD. We thus generated B6 chimeras in which non-haematopoietic tissue 
was WT or c-/- in conjunction with haematopoietic tissue that was either WT or c-/- as 
outlined in Figure 5.5A.  Mice were provided a 3-4 month reconstitution period, after which 
recipient haematopoietic chimerism is >95% donor origin [22]. Chimeric recipients were 
then transplanted with 10x106 BM and 3.5x106 CD3+ T cells from BALB/c donors, and 
monitored weekly for clinical scores and survival (Figure 5.5A). As anticipated, chimeric 
recipients in which both the haematopoietic and non-haematopoietic compartments were 
c-/- (c-/-/c-/-) displayed significantly increased clinical scores and reduced survival (100% 
mortality at D15 post-transplant) compared to WT/WT chimera recipients (Fig5B). Notably, 
in comparison c-/-/c-/- chimera recipients: Restricted ablation of c signalling to either the 
haematopoietic (c-/-/WT) or the non-haematopoietic (WT/c-/-) compartment significantly 
improved recipient survival. In comparison to WT/WT chimera recipients: Ablation in either 
haematopoietic or non-haematopoietic compartments resulted in reduced survival 
although this was only statistically significant in the non-haematopoietic (WT/c-/-) recipient 
group.  Taken together these data demonstrate that early after transplant, c signalling in 
the recipient haematopoietic and non-haematopoietic compartments attenuates GVHD, 
potentially through limiting cytokine availability to the donor graft. 
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5.2.7 Ablation of donor T cell c signalling reduces GVHD 
Our cumulative data suggests c signalling in the donor graft may promote GVHD. To test 
this we next used the B6 into B6D2F1 model of chronic GVHD, enabling us to use B6.c-/- 
as donors (Figure 5.6A). We first confirmed elevated serum IL-3, IL-5 and Csf2 levels in 
GVHD recipients in this model (Figure 5.6B). We then transplanted BM±T grafts from WT 
or c-/- donors into lethally irradiated (1100cGy) recipients. In this model, where a low dose 
of T cells is used, recipients of WT grafts all survive out long term with minimal aGVHD 
[274, 289].  Notably, while transplantation of B6.c-/- grafts did not alter survival, by D28 
after transplant clinical scores were significantly reduced (Figure 5.6C), thus, confirming 
that c signalling in the donor graft after transplant exacerbates GVHD. To determine on 
which donor graft compartment c signalling was exerting pathogenic effects, we next 
performed transplants where we restricted c deficiency to either the donor BM or T cell 
compartment and monitored clinical scores. Surprisingly, ablation of c signalling in the 
BM cell compartment alone resulted in similar clinical scores compared to recipients of 
complete WT grafts. In contrast, recipients of B6.WT BM supplemented with B6.c-/- T 
cells displayed improved clinical scores that were significantly lower than recipients of 
grafts containing WT T cells by day 35 post-transplant (Figure 5.6C). Thus, we 
demonstrate the pathogenic role of direct c signalling in donor T cells in a model of 
chronic GVHD. 
To extend these findings, we returned to the BALB/c into B6.WT vs B6/c-/- model to 
confirm the pathogenic role of c signalling in the donor graft in the acute GVHD setting. 
Thus, we performed a pilot experiment where B6.WT and B6.c-/- recipient groups were 
transplanted with either BALB/c.WT or BALB/c.c-/- donor BM+T grafts (Figure 5.7A). BM 
and T cell mixing was not permitted in this transplant due to restricted donor BALB/c 
numbers. By day 14, the clinical scores of B6.c-/- mice receiving a BALB/c c-/- donor graft 
were significantly reduced compared to B6.c-/- mice receiving a WT donor graft (Figure 
5.7B). In addition, comparing survival between c-/- recipients of WT grafts to those of c-/- 
grafts revealed significantly improved survival when the donor graft lacked the capacity for 
c signalling. Thus, we have identified a pathogenic role for c signalling in the donor graft, 
and specifically in the T cell compartment, which serves as a mediator for both acute and 
chronic forms of GVHD pathology. 
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 Discussion 5.3
Acute GVHD (aGVHD) is a pro-inflammatory syndrome that occurs during the early post-
transplant period and is initiated when transplanted naïve T cells are primed against host 
antigens and subsequently initiate a pro-inflammatory cytokine response. Activated T cells 
contribute to tissue damage through the release of pro-inflammatory cytokines, or directly 
through cytolytic effector function [12, 16, 290]. During this acute phase the dominant 
impact of type 1 T helper (Th1) cells is well established, however Th2 cells, which produce 
IL-4, IL-5, IL-10 and IL13 are traditionally describe for their role in allergy and host defence 
against infection, are also implicated in aGVHD pathology [291, 292]. Elevated IL-5 has 
been reported during aGVHD and proposed as a sensitive diagnostic marker for the 
disease [293]. More recently, studies have identified elevated Csf2 during the early stages 
of GVHD produced by a pathogenic effector T cell population reported to be critical for the 
promotion of intestinal GVHD inflammation [33, 280]. Intriguingly, Csf2 and IL-5 together 
with IL-3, signal through a common c receptor subunit and are thus known as the c 
family cytokines [133]. Here we demonstrate that functional c signalling contributes 
significantly to GVHD outcome and elicits effects that are both protective and pathogenic 
depending on their cellular targets. 
Although studies have demonstrated that c cytokines are elevated after allogeneic SCT, 
little has been addressed regarding the role for these cytokines in GVHD responses [33, 
280, 284, 293]. Here we show a protective role for c cytokine signalling in the recipient 
following allogenetic SCT. Indeed, recipients of alloreactive BM+T grafts that lack c 
signalling display significantly elevated clinical scores and succumb to GVHD more rapidly 
than WT recipients. Using BMC, where c deficiency was limited to the host 
haematopoietic or non-haematopoietic compartments, we demonstrated c signalling in 
both compartments contributed in an additive manner, to this effect. Mechanistically we 
found significantly elevated systemic levels of Csf2, IL-3 and IL-5 very early after 
transplant in c-/- recipients, suggesting that that functional c signalling in the host serves 
to actively consume c cytokines. This consumption appears to be protective in that it 
limits the systemic availability of c cytokines to the incoming donor graft. In further 
support of this, we demonstrated that lethal aGVHD in the c-/- recipient could be rescued 
by the total ablation of c signalling capacity in the donor graft. 
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Our studies demonstrate that c signalling in the donor T cell compartment is 
unequivocally pathogenic. This is particularly interesting considering that although Csf2 is 
indeed produced by pathogenic T cells during GVHD [171, 280] and transgenic 
overexpression of Csf2 in T cells leads to increased inflammatory infiltrate and cytokine 
production [175], T cells are largely considered to lack expression of the Csf2R receptor 
[173, 174]. Although we have identified that functional signalling in donor T cells is 
pathogenic in both acute and chronic GVHD models, the mechanism by which c 
signalling in the donor compartment is eliciting pathogenicity remains to be elucidated. 
Future experiments using the acute BALB/c to B6 model will require the restricted ablation 
of c signalling to donor BM and T cell compartments individually in order to determine 
whether naïve donor T cells are indeed responding to c cytokine directly or whether 
signalling in the donor BM compartment is driving expansion of a pathogenic population 
early post-transplant. Importantly, the function of T cells in response to c cytokines should 
also be evaluated in the WT recipient setting where c cytokines are not artificially 
elevated.  
Indeed, we identified that Csf2 was the first c cytokine to display significantly elevated 
levels in c-/- recipients post-transplant (by day 4) and that Csf2 levels in these same 
recipients were equalized to levels comparable to WT recipients by day 7, suggesting that 
this elevated systemic Csf2 had found an alternate target, presumably that of the WT 
donor graft. Taken together, Csf2 presents as a key candidate for the inflammatory signals 
driving GVHD pathology. However, while our pilot study demonstrates that ablation of c 
signalling in the donor graft indeed rescues c-/- recipients from aGVHD, the clinical scores 
and survival of these recipients was not significantly improved in comparison to WT 
recipients of WT grafts. This may suggest that c signalling in the recipient is neither 
protective nor pathogenic and rather that elevated cytokine availability to the donor graft 
was responsible for driving the increased pathology observed in c-/- recipients of WT 
donor grafts. Alternately, the BALB/c c-/- donor into B6 c-/- recipient group does display a 
trend toward improved clinical scores and reduced weight loss following SCT, which may 
suggest c signalling in the recipient is indeed pathogenic. This remains to be clarified in 
repeat experiments but does highlight that further analysis into the functional requirement 
for c signalling in host populations. 
Indeed, the long term survival of c-/- recipients given TCD donor grafts confirm that GVHD 
pathology in this study was attributable to alloreactive donor T cells. Of note, elevated 
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clinical scores were observed in TCD c-/- recipients which may be attributable to the 
pulmonary defects reported in Csf2-/- mice [294]. Indeed this further supports a role for c 
signalling during development and / or maintenance of protective host populations. Indeed 
multiple immune cells are known to require Csf2 for their development and function and as 
such require c signalling [130, 295, 296]. Thus, it is possible that Csf2-dependent 
populations may also serve to maintain GI tract health and integrity and may be impacted 
in c-/- recipients following transplantation. Thus a detailed examination of myeloid 
populations in the lung and GI tissues of naive c-/- mice is warranted. 
In total, this study supports a duplicitous role for c signalling that is both pathogenic (in 
the donor graft) and protective in the recipient. The data suggests a previously 
underappreciated role for c signalling in the donor T cell graft and further suggests that 
these T cells indeed play a persistent role in GVHD pathology. Furthermore, this study 
provides a strong basis for the extended analysis of c cytokine signalling in both the 
donor and recipient compartments following allogeneic SCT and the development of 
GVHD. 
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Figure 5.1 Clinical scores and survival of WT and c-/- recipients following SCT 
(A) The BALB/c into B6 model of acute GVHD. Recipient mice were lethally irradiated at a 
dose of 1000 cGy and administered a donor graft comprised of 10x106 BM + 3.5-5x106 
CD3+ T cells and monitored for GVHD clinical scores. (B) Clinical scores and survival 
following allogeneic SCT. Blue lines indicate B6.WT recipients (n=12), Yellow lines 
indicate B6.c-/- recipients (n=13), Black lines indicate B6.WT TCD recipients (n=6), 
Burgundy lines indicate B6.c-/- TCD recipients (n=3). Results taken from two independent 
experiments. Data is shown as mean +/- SEM. Statistical significance was determined for 
clinical scores using a Mann-Whitney U test (**P=0.024) and for survival curves using a 
Log-rank (Mantel-Cox) test (****P<0.0001). 
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Figure 5.2 Analysis of WT and c-/- recipients at day 7 post-transplant 
(A) Total cell quantification of peripheral blood at day 7 post-transplant. Engraftment, 
determined by total cell number of white blood cells (WBC), neutrophils, monocytes, red 
blood cells (RBC), platelets and haemoglobin (Hb) in peripheral blood (B) Histology of 
small intestine (SI), colon and lung stained with H&E taken at day 7 post-transplant 
together with clinical pathology scores. Pathology scores are from one experiment (n=5 
per group for SI and colon and n=4 per group for lung). Representative of two repeat 
experiments. Data is shown as mean +/- SEM. Statistical significance was determined 
using a Mann-Whitney U test (**P=0.024). SI and colon images were captured at 200x 
magnification. Lung images were captured at 100x magnification. Scale bars are 
representative of 200mm.  
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Figure 5.3 Analysis of luciferase+ donor cells at day 7 post-transplant  
(A) Recipient whole body luciferase signal following BM+T (GVHD) or TCD (non-GVHD) 
SCT from B6.luciferase mice. B6.WT recipients are shown in blue, B6.c-/- recipients in 
orange, B6.WT TCD recipients in white/hashed and B6.c-/- TCD recipients in 
grey/hashed. (B) Representative images of luciferase signal in recipient organs from WT 
and c-/- GVHD groups. (C) MFI of luciferase signal in recipient organs including: gut, lung, 
liver and spleen and mLN. (D) Analysis of splenic T cells at day 7 post-transplant 
displaying frequency and total cell counts between c-/-  and WT recipient GHVD groups. 
Data is shown as mean +/- SEM. (n=5 per BM+T group and n=3 per TCD group, images 
are taken from one experiment and are representative of two independent experiments. 
Statistical analysis was performed using a Mann-Whitney U test (*P=0.0159; **P=0.0079). 
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Figure 5.4 Analysis of serum cytokines at day 4 and day 7 post-transplant 
(A) Serum cytokine analysis comparing Csf2, IL-3 and IL-5 at day 4 (top panel) and day 7 
(bottom panel) following BM+T SCT. B6 recipients are displayed in black and c-/- 
recipients displayed in grey. 
Data are shown as mean +/- SEM. (Day 4, n=4; representative of one experiment 
*P=0.0286). Day 7 data is from two repeat experiments with n=9 per group. Data is shown 
as mean +/- SEM. Statistical analysis was performed using a Mann-Whitney U test. Day 4: 
n=4, representative of one experiment (*P=0.0286). Day 7: n=9, representative of two 
independent experiments (*P=0.0106; **P=0.0019). 
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Figure 5.5 Generation of chimeric mice 
B6 Recipient mice were lethally irradiated with a dose of 1000 cGy. Recipients received a 
donor graft comprised of 10x106 BM and rested for 12 weeks in order to reconstitute their 
haematopoietic compartments to generate (haematopoietic / non-haematopoietic) chimeric 
mice. B6.WT recipient groups were reconstituted with B6.WT (WT / WT) or B6.c-/- (c-/- / 
WT) grafts respectively. B6.c-/- recipients were reconstituted with B6.WT (WT / c-/-) or 
B6.c-/- (c-/- / c-/-) grafts respectively. 
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Figure 5.6 Analysis of post-transplant cytokines, clinical scores and survival in the B6 into 
B6D2F1 model of GVHD 
(A) Chimeric recipient mice were lethally irradiated at a dose of 1000 cGy and 
administered a donor graft comprised of 10x106 BM + 5x106 CD3+ T cells and monitored 
for GVHD clinical scores. (B) Chimeric WT / WT recipients are displayed in blue, chimeric 
c-/- / c-/- recipients are displayed in yellow, chimeric c-/- / B6 recipients (in which 
haematopoietic cells only are c-/-) are displayed in blue, and chimeric B6 / c-/- recipients 
(in which non-haematopoietic cells only are c-/-) are displayed in red. Data is shown as 
mean +/- SEM. (n=13, representative of two independent experiments. Statistical analysis 
was performed for clinical scores using a Mann-Whitney U test (**P=0.0049). Statistical 
analysis for survival curves was performed using a Log-rank (Mantel-cox) test 
(**P=0.0085) (****P<0.0001).  
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Figure 5.7 Analysis of clinical scores and survival in the BALB/c into B6 model of GVHD 
(A) Recipient B6 or c-/- mice were lethally irradiated at a dose of 1100 cGy and 
administered a donor BALB/c WT or c-/- graft comprised of 10x106 BM + 5x106 T cells to 
induce GVHD and monitored for clinical scores and survival post-transplant. (B) Clinical 
scores and survival curves with B6 recipients of BALB/c WT grafts displayed in black, c-/-  
recipients of BALB/c WT grafts displayed in yellow, and c-/-  recipients of BALB/c c-/- 
grafts displayed in green (n=4-5, representative of one experiment). Data is shown as 
mean +/- SEM. Statistical analysis of clinical scores at day 14 were performed using a 
Mann-Whitney U test (**p=0.0079) and from day 21 onward using an unpaired t test 
(*p=0.0226) (**p=0.0030). 
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CHAPTER 6. UBIQUITIN LIGASE MARCH8 
ATTENUATES GVHD VIA REGULATION OF 
MHC II SURFACE EXPRESSION IN GUT 
EPITHELIAL CELLS  
 Introduction 6.1
Following allogeneic stem cell transplantation (SCT) donor T cells, which are primed 
against host tissue antigens, are critical mediators of GVHD. Recently we reported that 
MHC class II-dependent priming of donor CD4+ T cells by host non-haematopoietic cells is 
sufficient to elicit GVHD and that early after SCT the intestinal tract represents the primary 
site of alloantigen presentation [22].  
The membrane-associated really interesting new gene (RING)-CH (MARCH) family of E3 
ubiquitin ligases function as immune regulators by limiting the expression of key immune 
receptors. MARCH proteins ubiquitinate lysine residues of membrane proteins to direct 
their endocytosis and inclusion into intraluminal vesicles of multivesicular bodies and 
subsequent delivery to the lysosome for degradation [209]. While previous findings 
demonstrate that MARCH1 serves as a regulator of antigen presentation in DC, B cells 
and monocytes [214], studies recently demonstrate that MARCH8 serves to limit the 
expression of MHC II on non-haematopoietic thymic epithelial cells (TEC) cells by 
ubiquitinating MHC II and thus targeting it for degradation through the endocytic lysosomal 
degradation pathway [205]. In this study we use March1-/- mice [297] and March8-/- mice 
[205] to examine the relative contribution of MARCH1 and MARCH8 in the regulation of 
MHC II trafficking in haematopoietic and non-haematopoietic lineages and additionally, the 
role of MARCH8 and MHC II expression during initiation of GVHD in the GI tract. 
 Results 6.2
6.2.1 MARCH1 and MARCH8 show distinct tissue expression in 
haematopoietic and non-haematopoietic APC 
Through MHC II presentation, host antigen presenting cells (APC) of both haematopoietic 
and non-haematopoietic origins contribute to shaping the donor T cell response to host 
antigens early after transplant, and thus impact the intensity of ensuing acute GVHD. As 
both MARCH1 and MARCH8 are established regulators of MHC II expression, we sought 
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to establish their relative contribution to the control of MHC II expression in haematopoietic 
and non-haematopoietic APC. A role for MARCH1 in regulating MHC II expression on 
haematopoietic APC is established and so we compared the relative contribution of 
MARCH1 and MARCH8 to cell surface MHC II levels on DC, B cells and monocytes 
isolated from the spleens of March1-/- or March8-/- mice. Flow cytometric analysis 
demonstrated elevated surface expression of MHC II in dendritic cells (DC), macrophages 
and B cells of MARCH1-/- mice. In contrast, surface expression of MHC II in these same 
APC populations was unchanged in March8-/- mice (Figure 6.1A). Consistent with previous 
findings for MARCH1, these results suggest that MARCH1 but not MARCH8 ubiquitin 
ligase is involved in regulating MHC II turnover and cell surface expression in 
haematopoietic APC.  
MARCH8 has recently been shown to control surface expression of MHC II in thymic 
epithelial cells, and to limit the expansion of CD4+ T cells in the thymus [205, 223]. Having 
already confirmed that MARCH8 does not contribute to the regulation of MHC II in 
haematopoietic APC, we next examined the role of MARCH8 in regulating MHC II 
expression in epithelial cells isolated from GVHD target organs. Lung and small intestine 
(SI) from naïve mice were dissociated and CD45negCD326+ epithelial cells were examined 
for MHC II expression. We found elevated expression of MHC II on CD236+ epithelial cells 
in the lung and small intestine (SI) in March8-/- mice compared to WT (Figure 6.1B). Thus 
we demonstrate MARCH8 regulation of MHC II surface expression in at least two other 
epithelial tissues in addition to TEC. Taken together, our results suggest that MARCH1 
and MARCH8 negatively regulate MHC II cell surface presentation on APC of distinct 
origins, with MARCH1 controlling surface MHC II levels in haematopoietic APC and 
MARCH8 in epithelial tissues. 
To examine if differences in tissue specificity between MARCH1 and MARCH8 result from 
differences in their expression patterns, we compared mRNA levels in non-haematopoietic 
and haematopoietic cells of the gastrointestinal tract. Haematopoietic (CD45+) and non-
haematopoietic (CD45neg) cells were isolated from the SI of C57Bl/6 WT mice and 
examined for MARCH1 and MARCH8 expression (Figure 6.2A). MARCH1 was only 
expressed in CD45+ cells and was non-detectable (ND) in CD45neg cells. In comparison, 
MARCH8 expression was significantly elevated in CD45neg cells in comparison to the low 
level expression observed in CD45+ cells from the SI. To confirm this preferential gene 
expression between haematopoietic (CD45+) and non-haematopoietic (CD45neg) 
compartments we also examined MARCH1 and MARCH8 expression in myeloid-derived 
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murine bone marrow-derived macrophages. RT-PCR results confirmed that in these 
haematopoietic-derived cells, MARCH1 expression was elevated in comparison to 
MARCH8 mRNA expression (Figure 6.2B). These results demonstrate a distinct tissue 
expression pattern for MARCH1 and MARCH8, which underpins their distinct roles in 
regulating MHC II surface levels in divergent cell types. 
6.2.2 Ablation of MARCH8 does not impact intestinal tissue integrity 
Previous studies by the lab have demonstrated that non-haematopoietic APC in the GI 
tract are sufficient to drive CD4+ T cell mediated acute GVHD [21]. Following our 
observation that MARCH8 is expressed in non-haematopoietic cells from the SI we set out 
to determine if MARCH8 expression varied between proximal and distal regions of the GI 
tract. Expression of MARCH8 was compared to the house-keeper gene Hypoxanthine 
Phosphoribosyltransferase 1 (HPRT) and the mRNA expression levels in different regions 
of the gastrointestinal were compared. RT-PCR confirmed that MARCH8 was consistently 
expressed throughout the duodenum (most proximal), jejunum (middle) and ilium (most 
distal) portions of the SI and similarly expressed in the colon (Figure 6.3A). Naïve splenic 
cells were used as a baseline control as the spleen is predominantly comprised of cells of 
haematopoietic origin and thus expected to have relatively low MARCH8 expression. 
As MARCH8 was found to be constitutively expressed and functional in gut epithelial cells, 
which play an integral role in gut homeostasis, we next sought to determine if MARCH8 
deficiency in these cells compromised gut integrity. Thus, SI and colon samples were 
harvested from naïve C57Bl/6 WT and March8-/- mice and prepared for histological 
analysis. Paraffin embedded sections were stained with Hematoxylin and Eosin (H&E) to 
compare tissue architecture and inflammatory infiltrate and also with Alcian Blue/PAS to 
identify the mucin producing goblet cells (Figure 6.3B).  Blinded analysis by an 
independent pathologist, demonstrated that histological samples from the SI and colon of 
March8-/- mice displayed no obvious differences to those of WT mice. Intestinal integrity 
was measured by signs of ulceration, lamina propria (LP) inflammation and damage to 
intestinal villi structure (including: intestinal blunting, surface sloughing, apoptosis, crypt 
loss and regeneration). 
In further studies we examined whether the ablation of MARCH8 impacted the 
development of the gastrointestinal epithelial cells. Thus, crypt organoid cultures were 
derived from proximal and distal portions of the SI from WT and March8-/- littermate 
controls. Crypt cultures were re-plated over four passages and RNA samples collected at 
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early and later passages. Crypt cultures generated from WT and March8-/- SI were 
photographed at each passage and displayed comparable organoid growth rate and 
structure, suggesting similar cellular expansion regardless of the ablation of MARCH8 
(Figure 6.3C). 
RNA was extracted from crypt culture cells from passage 1 and passage 4 to examine 
gene expression of MARCH8. RT-PCR confirmed expression of MARCH8 in WT crypts 
and confirmed ablation of MARCH8 expression in March8-/- crypt cultures from both 
proximal and distal regions of the SI (Figure 6.3D). These results demonstrate that 
March8-/- epithelial cells derived from the gastrointestinal tract are capable of generating 
intestinal crypts in vitro that are phenotypically similar to those of WT samples suggesting 
MARCH8 deficiency does not impact the developmental potential of gut epithelial stem 
cells.  
6.2.3 MARCH8 expression is protective during acute GVHD onset 
MHC II antigen presentation by recipient non-haematopoietic cells in the gastrointestinal 
tract is sufficient to elicit GVHD [22]. Therefore, considering the increased MHC II 
expression observed in the SI of March8-/- mice, we next wanted to investigate the impact 
of this elevated MHC II expression in the initiation of aGVHD. Using the BALB/c into B6 
model, lethally irradiated recipients were given a donor graft comprised of BALB/c BM 
together with CD3+ T cells (GVHD) or a TCD BM graft (non-GVHD) (Figure 6.4A). We 
demonstrated that March8-/- recipients display significantly increased clinical scores at day 
7 post-transplant with (100%) succumbing to aGVHD by day 10 post-transplant. In 
comparison, WT recipients displayed significantly improved survival with 60% surviving 
beyond day 40 post-transplant (Figure 6.4B). Thus MARCH8 expression is protective 
during the early onset of aGVHD. 
To attribute this early demise of March8-/- recipients to GVHD we examined tissue 
pathology in the SI, colon and lung at day 7 post-transplant (Figure 6.5A).  Histological 
analysis using H&E and Alcian Blue / PAS staining confirmed significantly increased tissue 
pathology and reduced goblet cell numbers in March8-/- recipients together, indicative of 
GVHD pathology. Thus, the ablation of MARCH8 leads to exacerbated GVHD pathology in 
the gastrointestinal tract in the early post-transplant period. 
Considering that MARCH8 is constitutively expressed throughout the gastrointestinal tract 
in the steady state, we next asked if MARCH8 expression is modulated post-transplant in 
 89 
 
the inflammatory setting of aGVHD. Using qRT-PCR, MARCH8 levels in the duodenum, 
jejunum, ileum and colon at day 7 post-transplant were examined and mRNA expression 
levels were compared between GHVD (e.g. mice receiving BM+CD3+ T cells) and TCD 
BM graft recipients (Figure 6.6A). Expression between GVHD and TCD groups showed no 
significant difference, although a trend towards increased MARCH8 expression in the 
duodenum of GVHD recipients was noted. 
Using the same BALB/c into B6 model of acute GHVD, we next transplanted lethally 
irradiated WT or March8-/- recipients with BM from BALB/c WT donors supplemented with 
T cells from BALB/c GFP-luciferase+ donors to permit tracking and quantification of donor 
T cell expansion in vivo using bioluminescence imaging (Xenogen, IVIS Spectrum) (Figure 
6.6B). At day 7 post-transplant, total body imaging was performed followed by imaging of 
individual organs. Whole body images revealed that March8-/- recipients displayed 
significantly increased luciferase signal indicative of increased T cell expansion in these 
recipients (Figure 6.6C). Organ imaging revealed significantly increased luciferase signal 
in the small intestine and colon together with the thymus and spleen of March8-/- 
recipients. Taken together this data supports a requirement for MARCH8 expression by 
IEC of the GI tract, to attenuate MHC II expression and subsequently limit donor T cell 
expansion following SCT. 
6.2.4 March8-/- recipients display elevated pro-inflammatory cytokines in 
the gastrointestinal tract 
To further investigate T cell activity in the recipient day 7 cytokine levels were analysed in 
both serum and gastrointestinal tract tissue samples by CBA Flex (BD) and RT-PCR 
respectively. Serum TNF was significantly increased in March8-/- recipients compared to 
WT recipients but surprisingly, serum concentrations of other pro-inflammatory cytokines 
analysed: (IFN, IL-6 and MCP-1) revealed no difference between March8-/- and WT 
recipients (Figure 6.7A). To examine the production of pro-inflammatory cytokines in the 
GI tract, mRNA expression of TNF, IFN and IL-6 in the SI was assessed by qRT-PCR. 
Consistent with the GI tract being the primary site of T cell priming during early GVHD [21], 
PCR results showed elevated expression of IFN, IL-6 and TNF in the SI of March8-/- 
recipients compared to WT recipients at day 7 (Figure 6.7B).  
Taken together, our transplant data indicate that the ablation of MARCH8 in recipients 
leads to marked expansion in donor T cell numbers and is associated with significantly 
increased pathology and pro-inflammatory cytokine secretion in GVHD target tissues. 
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6.2.5 Chimeric recipients confirm MARCH8 ablation in non-
haematopoietic cells is sufficient to induce aGVHD. 
To demonstrate that expression of MARCH8 in recipient non-haematopoietic APC, and 
subsequent regulation of MHC II expression in the gastrointestinal tract serves to mitigate 
T cell expansion during aGVHD onset, we generated chimeric recipients. Recipients 
included March8-/- and also MHC II K>R mutant mice (KR-/-), in which the capacity to 
ubiquitinate the MHC II β-chain is completely abolished [298]. Animals were lethally 
irradiated and their haematopoietic compartment reconstituted with a 10x106 Ptprca BM 
graft (Figure 6.8A). Chimeric mice were allowed to reconstitute for a minimum of eight 
weeks prior to use as recipients. Allogeneic BM + T transplants were conducted using the 
same BALB/c into B6 model and chimeric (B6) recipients were transplanted with a donor 
graft comprised of 10x106 BM together with a T cell dose of 4-5x106 CD3+ T cells to induce 
GVHD. These chimeric recipient experiments demonstrate that ablation of the E3-
ubiquitin-ligase MARCH8 in the non-haematopoietic recipient compartment results in 
significantly elevated clinical scores at day 21 post-transplant (Figure 6.8B). Similarly, the 
ablation of MHC II ubiquitination (KR-/-) in the non-haematopoietic recipient compartment, 
resulted in significantly elevated clinical scores at day 7 and day 14 post-transplant (Figure 
6.8C). This data supports a role for MARCH8-mediated ubiquitination of MHC II in the non-
haematopoietic compartment of recipient mice in regulating T cell-mediated aGVHD. 
 Discussion 6.3
The functional role of non-haematopoietic antigen presentation in steady state and as a 
driver of inflammation is increasingly appreciated. Multiple non-haematopoietic lineages 
including fibroblasts [299-301], endothelial cells [302, 303], and epithelial cells [304-306] 
have been reported to express MHC II and to contribute toward T effector responses. 
Importantly, studies demonstrate that non-haematopoietic MHC II antigen presentation, 
rather than conventional APC (e.g. DC), plays a dominant role in GHVD initiation [22, 307]. 
In this study we demonstrate that expression of the ubiquitinase MARCH8 in non-
haematopoietic APC functions to limit MHC II expression on epithelial cells, and following 
SCT serves to attenuate T effector cell expansion and the severity of GVHD. Importantly, 
MARCH8 appears to regulate epithelial cell MHC II expression in multiple target organs 
including the gut, lung and thymus, and likely serves to dampen T effector cell expansion 
and pathology at these tissue sites. Thus, our findings highlight the broad contribution of 
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epithelial cell MHC II antigen presentation, which is regulated by MARCH8 in both steady 
state and during post-transplant inflammation, to the initiation and perpetuation GVHD. 
Our initial experiments, using naïve March8-/- mice as transplant recipients, demonstrated 
a critical role for MARCH8 in controlling GVHD. Importantly, we confirmed disruption of 
MHC II regulation within the non-haematopoietic compartment as a driver of this response 
using BMC recipients to restrict MARCH8 deficiency to the non-haematopoietic 
compartment. Although GVHD severity and mortality was significantly increased in the 
March8-/- BMC, it was not as striking as in the naïve March8-/- recipients. Note that 
historically, and for reasons that remain unclear, in multiple preclinical models (including 
infection and GVHD), immune mediated pathology is variably attenuated in BMC hosts 
compared to naïve hosts. Thus, whether the less abrupt mortality noted in the March8-/- 
BMC was due to the model, or indicative of an additional contribution of MARCH8 activity 
in the haematopoietic compartment requires further investigation. This will be clarified in 
future experiments using BMC in which MARCH8 function is ablated in both 
compartments, or restricted to either the haematopoietic or non-haematopoietic 
compartment alone in parallel with control BMC in which MARCH8 function is unperturbed 
in both haematopoietic and non-haematopoietic compartments.   
The MARCH8 family regulates the trafficking of cell surface molecules in addition to MHC 
II including, TRAIL-R1 (CD253) [220], Transferrin receptor (TfR) [221], interleukin-1 
receptor accessory protein (IL-1RAP) [219] and B7.2 (CD86) [215, 308]. To address MHC 
II specifically we generated BMC from KR-/- mice [298], which have a K225 residue 
substitution that renders them non-susceptible to K225 ubiquitination-mediated 
degradation of MHC II, and demonstrated that perturbation of MHC II ubiquitination in 
the non-haematopoietic compartment indeed leads to enhanced GHVD. Notably, 
because MARCH1 regulates MHC II expression in haematopoietic APC via the same 
ubiquitination site, limiting K>R ablation to non-haematopoietic cells permitted the 
unaltered maintenance of MARCH1 activity and MHC II presentation in profession APC. 
Although mortality at day 30 was minimal and equal between groups, clinical scores were 
elevated in the KR-/- BMC recipients, indicative of enhanced GVHD. This demonstrates a 
role for class II ubiquitination in dampening the GVHD response, and parallels the 
phenotype observed in March8-/- BMC recipients. As such, these two models implicate 
MARCH8-driven ubiquitin regulation of MHC II cell surface expression in non-
haematopoietic cells, as a protective control during aGVHD. As GVHD was notably milder 
in this transplant, likely due to the inherent variability associated with using BMC, this 
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experiment requires repeating. Additionally, to circumvent the use of BMC, and better 
assess the degree to which MARCH8 regulation of MHC II  is contributing, we will 
compare GVHD outcomes between WT, March1-/-, March8-/- and KR-/- transplant 
recipients. 
The gastrointestinal tract is well established as the initiating site of GVHD responses [14]. 
In steady state, the gut is constantly bombarded with foreign antigens of both microbial 
and food origin. To combat this, the local immune system has evolved a series of 
mechanisms to promote tolerance to avoid aberrant inflammation. Gut resident regulatory 
T cells (Treg) which recognize intestinal antigens represent one strategy employed to 
prevent inappropriate immune responses [309]. Notably, antigen specific Treg are 
expanded in the gut through IEC MHC II presentation, independent of DC, highlighting a 
critical role for gut IEC in the maintenance of intestinal homeostasis [310]. However, in 
inflammatory conditions such as ulcerative colitis and Crohn's disease, IEC MHC II 
expression is upregulated and promotes T effector expansion and differentiation that 
contributes to pathology [311, 312]. Following SCT, gut non-haematopoietic cells express 
high levels of MHC II expression [22, 313], and importantly, elevated expression levels of 
MHC II are associated with increased GVHD severity [314]. Thus our demonstration of 
increased expression of MHC II on IEC in the absence MARCH8 implicates a regulatory 
role for M8 in controlling MHC II mediated gut immune responses as supported by the 
observed T effector expansion and exacerbation of GVHD pathology at this site.  
MARCH8 has recently been shown to represent the major E3 ubiquitin ligase responsible 
for MHC II trafficking in thymic epithelial cells (TEC), which is required for efficient thymic 
CD4+ T cell selection.  Here, in addition to the GI tract, we show increased expansion of 
donor T cells in the lung, spleen and thymus of March8 deficient recipients, indicative of 
elevated MHC II expression at these tissue sites. In addition we demonstrate increased 
pathology within GVHD target organs in March8-/- recipients demonstrating a role for 
MARCH8 in both initiation and progression of GVHD. This data identifies MARCH8 as a 
beneficial regulator of MHC II during GHVD and suggests that promotion of MARCH8 may 
be beneficial for controlling T cell expansion following SCT.  
 
Currently, little is known about the transcriptional control of MARCH proteins. Importantly, 
many of the MARCH proteins, including MARCH8, undergo autoubiquitination [215, 315-
318] indicating that they regulate their own activity. Studies demonstrate that IL-10 
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regulates MARCH1 to induce intracellular sequestration of MHC II in monocytes and 
macrophages but not in DC [207, 229, 319]. Of functional importance, studies demonstrate 
that the timing of MARCH protein expression is quite specific. For example in DC, 
MARCH1 expression is transcriptionally regulated during DC maturation. Expression is 
high in immature DC and is downregulated as they mature, which enables the increased 
expression and stabilization of MHC II at the surface of mature and activated DCs [224, 
320]. A very recent study demonstrated that expression of MARCH2 (but not other 
MARCH family members) is upregulated by infection with HIV-1 and serves to inhibit viral 
production and infection [321]. IFNg is known to be to induce the upregulation of MHC II 
expression by IEC [322] however, although IFN is elevated post-transplant, we observed 
no difference in MARCH8 expression suggesting that IFN does not drive IEC MHC II 
expression via the inhibition of MARCH8.  
 
Identifying the mechanisms which control MARCH8 expression should lead to the ability to 
modulate this pathway for therapeutic benefit.  For the attenuation of MHC II mediated 
pathology in inflammatory settings such as GVHD and inflammatory bowel disease, 
identifying the signals that drive March8 expression is required. Interestingly, one study 
has already demonstrated that genetic transfer of MARCH8 into synovial tissues in a 
mouse model of rheumatoid arthritis (RA) displayed a therapeutic improvement. In vitro 
studies attributed this improvement to reduced IL-6 production from synovial fibroblasts 
following stimulation with TNF and IL-1 impaired IL-6 and TNF production from BMDM 
and DC following LPS stimulation [323]. This study demonstrates that induction of 
MARCH8 can indeed inhibit inflammatory cytokine production in fibroblasts, macrophages 
and DC but also highlights the broader impact of targeting MARCH8 expression in the 
haematopoietic compartment.  
 
Conversely, and more therapeutically approachable, the suppression or ablation of 
MARCH8 may be favourable in a setting where the promotion of T effector function would 
be favourable, such as cancer. Importantly, two opposing roles for MARCH family 
members have been reported in the regulation of cancer cells. Recently, March7 was 
reported to be oncogenic for its role in the regulation of E-cadherin protein levels leading to 
progression of epithelial ovarian cancer [324]. Conversely, MARCH8 was found to supress 
cancer cell properties including invasion, migration and colony forming ability in 
oesophageal cancer cells [325]. Taken together, it appears that MARCH8 provides 
beneficial regulatory control in the setting of cancer and inflammation, such as that elicited 
 94 
 
by GVHD. As such, further investigation into the regulatory controls and tissue specific 
targets of MARCH8 are warranted. 
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Figure 6.1 Analysis of MHC II surface expression 
 
(A) Flow cytometry analysis of MHC II expression on haematopoietic APC including DC, 
macrophages and B cells from March1-/- (blue line) and March8-/- (red line) naïve animals 
with isotype control (grey) (n=1, representative of three independent experiments). (B) 
Flow cytometry analysis of MHC II expression on non-haematopoietic epithelial cells from 
small intestine and lung. Histograms show the MFI of MHC II in March8-/- (black line) and 
isotype (grey) control (n=2, representative of two independent experiments).  
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Figure 6.2 Analysis of MARCH1 and MARCH8 expression in haematopoietic and non-
haematopoietic tissues  
 
(A) QRT-PCR analysis of MARCH1 (blue) and MARCH8 expression in CD45+ (red) versus 
CD45neg (red with black lines) cells isolated from the small intestine (n=6, taken from two 
independent experiments). (B) QRT-PCR analysis of MARCH1 (blue) and MARCH8 (red) 
in bone marrow-derived macrophages (BMDM) (n=4).  Data is shown as mean +/- SEM. 
Statistical significance was determined using a Mann-Whitney U test (**P=0.0095, 
*P=0.0242, *P=0.0286). 
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Figure 6.3 Phenotypic analysis of naïve March8-/- gastrointestinal tissues 
 
(A) qRT-PCR showing MARCH8 expression throughout the gastrointestinal tract including 
SI: duodenum, jejenum, ileum and the colon with comparative low level expression in 
splenic cells. (B) H&E and Alcian Blue/PAS histological analysis of naïve SI and colon 
tissue samples. (C) Representative images displaying crypt morphology of SI epithelial 
crypt cultures at in vitro passage 4. (D) qRT-PCR analysis of MARCH8 mRNA expression 
in crypt cultures. Displaying proximal SI (blue) and distal SI (red) cultured crypts at 
passage 1 and passage 4 (n=1).  
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Figure 6.4 Comparison of March8-/- and WT recipients following SCT in the GVHD setting  
(A) The BALB/c into B6 model of acute GVHD. Recipient mice were lethally irradiated at a 
dose of 1000 cGy and administered a donor graft comprised of BALB/c WT BM together 
with CD3+ T cells (GVHD) or without T cells (non-GVHD). (B) Clinical scores and survival 
outcomes for WT versus March8-/- recipients of BM+T (GVHD) and TCD (non-GVHD) 
donor grafts (n=5-8, representative of two independent experiments with n=8 for GVHD 
groups and n=5 for TCD). Data is shown as mean +/- SEM. Statistical significance for 
clinical scores was performed using a Mann-Whitney U test (**p=0.0011). Statistical 
significant for survival outcomes was performed using a Log-rank (Mantel-Cox) test 
(****p<0.0001). 
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Figure 6.5 Histological analysis of WT and March8-/- recipients at day 7 post-transplant 
(A) Histological analysis displaying H&E and Alcian Blue/PAS stains in WT and MARCH8-/- 
recipient tissue at day 7 post-transplant together with GVHD pathology scores (n=4, taken 
from one experiment, representative of two independent experiments).  Data is shown as 
mean +/- SEM. Statistical analysis was performed using a Mann-Whitney U test 
(*p=0.0286). 
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Figure 6.6 Analysis of T cell expansion in March8-/- and WT recipients in aGVHD 
 
(A) qRT-PCR examining MARCH8 expression in the SI of GVHD versus non-GVHD 
recipient mice at day 7 post-transplant (n=5 (GVHD) and n=3 (TCD), from a single 
experiment). (B) The BALB/c into B6 model of acute GVHD. Recipient mice were lethally 
irradiated at a dose of 1000 cGy and administered a donor graft comprised of BALB/c WT 
BM and luciferase+ (luci+) T cell graft. (C) Luciferase T cell signal in recipient whole body 
and organs: SI, colon, lung, thymus, spleen and liver (n=7, representative of two 
independent experiments). Data is shown as mean +/- SEM. Statistical analysis was 
performed using a Mann-Whitney U test (*p=0.0262, **p=0.0070, ***p=0.0006). 
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Figure 6.7 Comparison of serum cytokines between March8-/- and WT recipients 
 
(A) Day 7 serum cytokine analysis of IFN, TNF, IL-6, MCP-1, IL-5 (n=8-9, representative 
of two independent experiments) and IL-10 (n=4-5, taken from one experiment). (B) QRT-
PCR of IFN, TNF and IL-6 cytokine expression in SI at day 7 post-transplant (n=2-4, 
taken from one experiment). Data is shown as mean +/- SEM. Statistical significance for 
clinical scores was performed using a Mann-Whitney U test (***p=0.0003). 
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Figure 6. 8 Generation of chimeric mice and analysis of chimeric recipient GVHD 
(A) Generation of chimeric recipient mice. B6 recipient WT, March8-/-, or KR-/- mice were 
lethally irradiated with a dose of 1000 cGy and administered a donor graft comprised of 
10x106 Ptprca (WT) BM before being for 8-12 weeks in order to reconstitute their 
haematopoietic compartments. Three groups of chimeric recipients were generated: (WT / 
WT) and (WT / March8-/-) and (WT / KR-/-). (B) Clinical scores and survival outcomes for 
chimeric recipient WT / WT and WT / MARCH8-/- mice following allogeneic transplant with 
CD3+ T cells to induce GVHD (n=6, from a single experiment). (C) Clinical scores and 
survival outcomes for chimeric recipient WT / WT and WT / KR-/- mice following allogeneic 
transplant with CD3+ T cells to induce GVHD (n=5 WT / WT and n=6 WT / KR-/- from a 
single experiment). Data is shown as mean +/- SEM. Statistical significance for clinical 
scores was performed using a Mann-Whitney U test (*p=0.0333) and statistical 
significance for survival outcomes were performed using a Log-rank (Mantel Cox) test (P). 
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CHAPTER 7. FINAL DISCUSSION 
 
Allogeneic haematopoietic SCT is a well-established treatment currently employed for a 
number of haematological diseases that cannot be cured by conventional chemotherapy. 
The most common and life-threatening complication associated with this therapy is acute 
GVHD, the incidence of which remains high and as such presents the primary limitation to 
its success. GHVD results from interplay between APC and donor derived T cells, resulting 
in the expansion of inflammatory populations that target recipient tissues leading to tissue 
damage and dysfunction. The fundamental aim of this thesis was to identify the cellular 
mechanisms employed by both donor and recipient cells during the early post-transplant 
period to identify targetable pathways that underpin the transplant related complications of 
graft failure and GVHD. 
This thesis has identified a critical requirement for autophagy in the donor graft HSC pool 
to facilitate primary engraftment in the highly inflammatory setting of GHVD. We have 
confirmed that in the absence of autophagy, donor HSC and HSPC fail to engraft and 
proliferate to provide short-term haematopoiesis and this in turn leads to primary graft 
failure by day 10 post-transplant. We confirmed that the in vivo stressor that induces these 
cells to fail is T cell derived pro-inflammatory cytokines, in particular TNF and IL-1, which 
are known to be elevated early post-transplant as part of the GVHD cytokine storm. 
Recipient treatment with cyclosporine (CsA) both reduced pro-inflammatory cytokine levels 
in GVHD recipients and was sufficient to rescue the autophagy deficient HSC graft and 
permit successful engraftment and proliferation leading to long-term recipient survival, 
similar to that observed in non-GVHD recipients. This study identifies the critical 
requirement for autophagy in the donor HSC graft and highlights two potential approaches 
for targeted improvement of donor graft efficacy. (1) Pharmacological interventions that 
either suppress recipient derived IL-1 and/or TNF and (2) Pre-transplant manipulation of 
the donor HSC graft in order to promote autophagy and reduce HSC oxidative stress. Both 
should ultimately lead to improved donor HSC survival and engraftment and thus improved 
recipient survival. 
Next, to further investigate the role of cytokine signals during the early post-transplant 
period and their contribution to GVHD, this study examined the requirement for common 
beta chain (c) family of cytokine signalling. We identified that in the GVHD setting, 
functional c signalling in the recipient consumes systemic Csf2, IL-3 and IL-5. In the 
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absence of c signalling serum levels of these cytokines accumulate in the recipient with 
Csf2 displaying the earliest significant increase compared to the WT recipient system, in 
which c signalling is intact. We further identified that c signalling in the donor graft drives 
GHVD, and that c ablation in the donor T cell compartment significantly improved GVHD. 
This finding challenges previous reports that T cells lack the receptors for signalling c 
family cytokines. In addition, the data support a continuing, and c dependant, role for the 
donor T cells contained within the graft in late phase chronic GVHD.  
Taken together the data suggest that c signalling is pathogenic in the donor graft but may 
serve a protective role in the recipient either by consuming c cytokines and preventing 
their accumulation or by signalling the development and maintenance of tissue resident 
populations that provide protection following SCT. 
From here, we propose additional investigation to assess the infiltrating effector 
populations and to elucidate which subset(s) of cells are responsive to c signals. We 
propose phenotypical analysis of both the inflammatory and patrolling populations within 
the GI tract during aGVHD onset. Two recent publications have identified pathogenic T 
effector populations that are believed to target the GI tract and have identified additional 
markers of interest including: Csf2, IL-7R, BATF, IL-23R, RORt and CD11c [280, 326]. A 
review of the literature identified Csf2 and to a lesser extent IL-5, as the prevalent c 
cytokines that signal in the GI tract and as such ablation of c signalling in the recipient 
may be impacting c responsive myeloid populations in the GI tract including: granulocytes 
(eosinophils and neutrophils) in addition to ILC, macrophages and DCs. 
The final chapter of this thesis identifies a novel role for the E3 ubiquitin ligase MARCH8 
as a regulator of MHC II expression on non-haematopoietic APC in the GI tract. We report 
that MARCH8 is expressed in CD45neg non-haematopoietic cells in the GI tract while 
expression of the closely related MARCH1 family member is restricted to CD45+ 
haematopoietic cells in this same tissue. We further demonstrate that ablation of MARCH8 
results in elevated MHC II expression in epithelial cells of the GI tract and lung. Following 
transplantation with BM+T cell to induce GVHD, March8-/- recipients displayed significantly 
elevated clinical scores and succumbed to aGVHD by day 10 post-transplant. We confirm 
that this outcome is the result of alloreactive T cell driven GVHD as March8-/- recipients of 
TCD depleted (non-GVHD) donor grafts survive long term. Histological analysis and 
GVHD pathology scores of the GI tract and lung confirmed significantly increased GHVD 
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pathology in March8-/- recipients compared to WT. Using a luciferase+ T cell and WT BM 
donor graft we demonstrate significant expansion of donor T cells by day 7 post-transplant 
in March8-/- compared to WT recipient mice. We propose additional time point studies to 
identify and phenotype these T effector populations that are being expanded in response 
to the elevated MHC II in March8-/- recipients. Using BMC in which MARCH8 ablation is 
restricted to recipient non-haematopoietic cells (WT / March8-/-) we demonstrate a similarly 
reduced survival in comparison to WT / WT BMC recipients of BM+T (GVHD) SCT. This 
finding confirmed that elevated MHC II expression by non-haematopoietic APC is sufficient 
to induce exacerbated GVHD following SCT. To further demonstrate that this was the 
result of ubiquitination in non-haematopoietic cells we used BMC in which non-
haematopoietic cells were derived from MHC II K>R (KR-/-) mice which, due to a residue 
substitution on the cytoplasmic domain of MHC II, entirely lack the ability to ubiquitinate 
MHC II and thus regulate its removal from the cell membrane. Using these WT / KR-/- mice 
as recipients we demonstrate reduced body weight and increased clinical scores indicative 
of enhance GVHD compared to WT / WT BMC recipients of BM+T SCT. BMC transplant 
studies have been performed once and will be repeated to confirm these results. As GVHD 
was notably milder in this transplant, likely due to the inherent variability associated with 
using BMC, this experiment requires repeating. Additionally, to circumvent the use of 
BMC, and better assess the degree to which M8 regulation of MHC II  is contributing, we 
will compare GVHD outcomes between WT, March1-/-, March8-/- and MHCII.K>R 
transplant recipients. In conclusion this study identifies a novel role for MARCH8 in 
regulating MHC II presentation and T cell activation in the GI tract during aGVHD onset.  
In summary, this thesis presents a novel analysis of early cellular mechanisms that 
contribute to complications associated with allogeneic stem cell transplantation, including 
autophagy, cytokine signals and antigen presentation. We have identified several novel 
mechanisms that present novel therapeutic opportunities to improve patient outcomes in 
the clinic following allogeneic stem cell transplantation. 
  
 113 
 
REFERENCES 
 
1. Becker, A.J., C.E. Mc, and J.E. Till, Cytological demonstration of the clonal nature of 
spleen colonies derived from transplanted mouse marrow cells. Nature, 1963. 197: p. 
452-4. 
2. Till, J.E. and C.E. Mc, A direct measurement of the radiation sensitivity of normal 
mouse bone marrow cells. Radiat Res, 1961. 14: p. 213-22. 
3. Doulatov, S., et al., Hematopoiesis: a human perspective. Cell Stem Cell, 2012. 
10(2): p. 120-36. 
4. Ferrara, J.L., et al., Graft-versus-host disease. Lancet, 2009. 373(9674): p. 1550-61. 
5. Imus, P.H., et al., Major Histocompatibility Mismatch and Donor Choice for Second 
Allogeneic Bone Marrow Transplantation. Biol Blood Marrow Transplant, 2017. 
23(11): p. 1887-1894. 
6. Chang, Y.J., et al., Haploidentical allograft is superior to matched sibling donor 
allograft in eradicating pre-transplantation minimal residual disease of AML patients 
as determined by multiparameter flow cytometry: a retrospective and prospective 
analysis. J Hematol Oncol, 2017. 10(1): p. 134. 
7. Toubai, T., Y. Sun, and P. Reddy, GVHD pathophysiology: is acute different from 
chronic? Best Pract Res Clin Haematol, 2008. 21(2): p. 101-17. 
8. Anasetti, C., et al., Peripheral-blood stem cells versus bone marrow from unrelated 
donors. N Engl J Med, 2012. 367(16): p. 1487-96. 
9. Hill, G.R., et al., Interleukin-11 promotes T cell polarization and prevents acute graft-
versus-host disease after allogeneic bone marrow transplantation. J. Clin. Invest., 
1998. 102: p. 115-123. 
10. Hill, G.R. and J.L. Ferrara, The primacy of the gastrointestinal tract as a target organ 
of acute graft-versus-host disease: rationale for the use of cytokine shields in 
allogeneic bone marrow transplantation. Blood, 2000. 95(9): p. 2754-9. 
11. Morris, E.S. and G.R. Hill, Advances in the understanding of acute graft-versus-host 
disease. Br J Haematol, 2007. 137(1): p. 3-19. 
12. Hill, G.R., et al., Total body irradiation and acute graft versus host disease. The role 
of gastrointestinal damage and inflammatory cytokines. Blood, 1997. 90: p. 3204-
3213. 
13. Henden, A.S. and G.R. Hill, Cytokines in Graft-versus-Host Disease. J Immunol, 
2015. 194(10): p. 4604-12. 
 114 
 
14. Hill, G.R. and J.L.M. Ferrara, The primacy of the gastrointestinal tract as a target 
organ of graft-versus-host disease: Rationale for the use of cytokine shields in 
allogeneic bone marrow transplantation. Blood, 2000. 95: p. 2754-9. 
15. Ferrara, J.L., K.R. Cooke, and T. Teshima, The pathophysiology of acute graft-
versus-host disease. Int J Hematol, 2003. 78(3): p. 181-7. 
16. Teshima, T., et al., Acute graft-versus-host disease does not require alloantigen 
expression on host epithelium. Nat Med, 2002. 8(6): p. 575-81. 
17. Duffner, U.A., et al., Host dendritic cells alone are sufficient to initiate acute graft-
versus-host disease. J Immunol, 2004. 172(12): p. 7393-8. 
18. Shlomchik, W.D., et al., Prevention of graft versus host disease by inactivation of 
host antigen-presenting cells. Science, 1999. 285(5426): p. 412-5. 
19. Zhang, Y., et al., Preterminal host dendritic cells in irradiated mice prime CD8+ T cell-
mediated acute graft-versus-host disease. J Clin Invest, 2002. 109(10): p. 1335-44. 
20. Li, H., et al., Profound depletion of host conventional dendritic cells, plasmacytoid 
dendritic cells, and B cells does not prevent graft-versus-host disease induction. J 
Immunol, 2012. 188(8): p. 3804-11. 
21. Koyama, M., et al., Recipient nonhematopoietic antigen-presenting cells are sufficient 
to induce lethal acute graft-versus-host disease. Nat Med, 2012. 18(1): p. 135-42. 
22. Koyama, M., et al., Recipient nonhematopoietic antigen-presenting cells are sufficient 
to induce lethal acute graft-versus-host disease. Nat Med, 2011. 18(1): p. 135-42. 
23. Martin, P.J., et al., A retrospective analysis of therapy for acute graft-versus-host 
disease: initial treatment. Blood, 1990. 76(8): p. 1464-72. 
24. Shlomchik, W.D., et al., Transplantation's greatest challenges: advances in chronic 
graft-versus-host disease. Biol Blood Marrow Transplant, 2007. 13(1 Suppl 1): p. 2-
10. 
25. Teshima, T., et al., Flt3 ligand therapy for recipients of allogeneic bone marrow 
transplants expands host CD8 alpha(+) dendritic cells and reduces experimental 
acute graft-versus-host disease. Blood, 2002. 99(5): p. 1825-32. 
26. Hill, G.R., et al., Total body irradiation and acute graft-versus-host disease: the role of 
gastrointestinal damage and inflammatory cytokines. Blood, 1997. 90(8): p. 3204-13. 
27. Shlomchik, W.D., Graft-versus-host disease. Nat Rev Immunol, 2007. 7(5): p. 340-
52. 
 115 
 
28. Carlens, S., et al., Risk factors in bone marrow transplant recipients with leukaemia. 
Increased relapse risk in patients treated with ciprofloxacin for gut decontamination. 
Clin Transplant, 1998. 12(2): p. 84-92. 
29. Baird, K. and S.Z. Pavletic, Chronic graft versus host disease. Curr Opin Hematol, 
2006. 13(6): p. 426-35. 
30. Higman, M.A. and G.B. Vogelsang, Chronic graft versus host disease. Br J 
Haematol, 2004. 125(4): p. 435-54. 
31. Champlin, R.E., et al., Blood stem cells compared with bone marrow as a source of 
hematopoietic cells for allogeneic transplantation. IBMTR Histocompatibility and 
Stem Cell Sources Working Committee and the European Group for Blood and 
Marrow Transplantation (EBMT). Blood, 2000. 95(12): p. 3702-9. 
32. Morris, E.S., K.P. MacDonald, and G.R. Hill, Stem cell mobilization with G-CSF 
analogs: a rational approach to separate GVHD and GVL? Blood, 2006. 107(9): p. 
3430-5. 
33. Alexander, K.A., et al., CSF-1-dependant donor-derived macrophages mediate 
chronic graft-versus-host disease. J Clin Invest, 2014. 124(10): p. 4266-80. 
34. Yin, T. and L. Li, The stem cell niches in bone. J Clin Invest, 2006. 116(5): p. 1195-
201. 
35. Eliasson, P., et al., Hypoxia mediates low cell-cycle activity and increases the 
proportion of long-term-reconstituting hematopoietic stem cells during in vitro culture. 
Exp Hematol, 2010. 38(4): p. 301-310 e2. 
36. Hirao, A., F. Arai, and T. Suda, Regulation of cell cycle in hematopoietic stem cells by 
the niche. Cell Cycle, 2004. 3(12): p. 1481-3. 
37. Cheshier, S.H., et al., In vivo proliferation and cell cycle kinetics of long-term self-
renewing hematopoietic stem cells. Proc Natl Acad Sci U S A, 1999. 96(6): p. 3120-5. 
38. Yamazaki, S., et al., Cytokine signals modulated via lipid rafts mimic niche signals 
and induce hibernation in hematopoietic stem cells. EMBO J, 2006. 25(15): p. 3515-
23. 
39. Yoshihara, H., et al., Thrombopoietin/MPL signaling regulates hematopoietic stem 
cell quiescence and interaction with the osteoblastic niche. Cell Stem Cell, 2007. 
1(6): p. 685-97. 
40. Sharpless, N.E. and R.A. DePinho, How stem cells age and why this makes us grow 
old. Nat Rev Mol Cell Biol, 2007. 8(9): p. 703-13. 
41. Osawa, M., et al., Long-term lymphohematopoietic reconstitution by a single CD34-
low/negative hematopoietic stem cell. Science, 1996. 273(5272): p. 242-5. 
 116 
 
42. Uchida, N., et al., Different in vivo repopulating activities of purified hematopoietic 
stem cells before and after being stimulated to divide in vitro with the same kinetics. 
Exp Hematol, 2003. 31(12): p. 1338-47. 
43. Camargo, F.D., et al., Hematopoietic stem cells do not engraft with absolute 
efficiencies. Blood, 2006. 107(2): p. 501-7. 
44. Wagers, A.J., J.L. Christensen, and I.L. Weissman, Cell fate determination from stem 
cells. Gene Ther, 2002. 9(10): p. 606-12. 
45. Matsuzaki, Y., et al., Unexpectedly efficient homing capacity of purified murine 
hematopoietic stem cells. Immunity, 2004. 20(1): p. 87-93. 
46. Morrison, S.J., D.E. Wright, and I.L. Weissman, Cyclophosphamide/granulocyte 
colony-stimulating factor induces hematopoietic stem cells to proliferate prior to 
mobilization. Proc Natl Acad Sci U S A, 1997. 94(5): p. 1908-13. 
47. Randall, T.D. and I.L. Weissman, Phenotypic and functional changes induced at the 
clonal level in hematopoietic stem cells after 5-fluorouracil treatment. Blood, 1997. 
89(10): p. 3596-606. 
48. Chambers, I., The molecular basis of pluripotency in mouse embryonic stem cells. 
Cloning Stem Cells, 2004. 6(4): p. 386-91. 
49. Uchida, N., et al., ABC transporter activities of murine hematopoietic stem cells vary 
according to their developmental and activation status. Blood, 2004. 103(12): p. 
4487-95. 
50. Klionsky, D.J., et al., A comprehensive glossary of autophagy-related molecules and 
processes. Autophagy, 2010. 6(4): p. 438-48. 
51. Kuma, A., et al., The role of autophagy during the early neonatal starvation period. 
Nature, 2004. 432(7020): p. 1032-6. 
52. Scherz-Shouval, R. and Z. Elazar, ROS, mitochondria and the regulation of 
autophagy. Trends Cell Biol, 2007. 17(9): p. 422-7. 
53. Yue, Z., et al., Beclin 1, an autophagy gene essential for early embryonic 
development, is a haploinsufficient tumor suppressor. Proc Natl Acad Sci U S A, 
2003. 100(25): p. 15077-82. 
54. Deretic, V. and B. Levine, Autophagy, immunity, and microbial adaptations. Cell Host 
Microbe, 2009. 5(6): p. 527-49. 
55. Levine, B. and D.J. Klionsky, Development by self-digestion: molecular mechanisms 
and biological functions of autophagy. Dev Cell, 2004. 6(4): p. 463-77. 
 117 
 
56. Mizushima, N., The pleiotropic role of autophagy: from protein metabolism to 
bactericide. Cell Death Differ, 2005. 12 Suppl 2: p. 1535-41. 
57. Rubinsztein, D.C., The roles of intracellular protein-degradation pathways in 
neurodegeneration. Nature, 2006. 443(7113): p. 780-6. 
58. Mizushima, N. and B. Levine, Autophagy in mammalian development and 
differentiation. Nat Cell Biol, 2010. 12(9): p. 823-30. 
59. Maiuri, M.C., et al., Self-eating and self-killing: crosstalk between autophagy and 
apoptosis. Nat Rev Mol Cell Biol, 2007. 8(9): p. 741-52. 
60. Klionsky, D.J., A.J. Meijer, and P. Codogno, Autophagy and p70S6 kinase. 
Autophagy, 2005. 1(1): p. 59-60; discussion 60-1. 
61. Nakatogawa, H., et al., Dynamics and diversity in autophagy mechanisms: lessons 
from yeast. Nat Rev Mol Cell Biol, 2009. 10(7): p. 458-67. 
62. Karanasios, E., et al., Autophagy initiation by ULK complex assembly on ER 
tubulovesicular regions marked by ATG9 vesicles. Nat Commun, 2016. 7: p. 12420. 
63. Kundu, M., et al., Ulk1 plays a critical role in the autophagic clearance of 
mitochondria and ribosomes during reticulocyte maturation. Blood, 2008. 112(4): p. 
1493-502. 
64. Gan, B., et al., Role of FIP200 in cardiac and liver development and its regulation of 
TNFalpha and TSC-mTOR signaling pathways. J Cell Biol, 2006. 175(1): p. 121-33. 
65. Geng, J. and D.J. Klionsky, Quantitative regulation of vesicle formation in yeast 
nonspecific autophagy. Autophagy, 2008. 4(7): p. 955-7. 
66. Mizushima, N., et al., In vivo analysis of autophagy in response to nutrient starvation 
using transgenic mice expressing a fluorescent autophagosome marker. Mol Biol 
Cell, 2004. 15(3): p. 1101-11. 
67. Tanida, I., et al., Lysosomal turnover, but not a cellular level, of endogenous LC3 is a 
marker for autophagy. Autophagy, 2005. 1(2): p. 84-91. 
68. Djeddi, A., et al., Induction of autophagy in ESCRT mutants is an adaptive response 
for cell survival in C. elegans. J Cell Sci, 2012. 125(Pt 3): p. 685-94. 
69. Simonsen, A. and S.A. Tooze, Coordination of membrane events during autophagy 
by multiple class III PI3-kinase complexes. J Cell Biol, 2009. 186(6): p. 773-82. 
70. Tanida, I., T. Ueno, and E. Kominami, LC3 and Autophagy. Methods Mol Biol, 2008. 
445: p. 77-88. 
 118 
 
71. Mizushima, N. and T. Yoshimori, How to interpret LC3 immunoblotting. Autophagy, 
2007. 3(6): p. 542-5. 
72. Mizushima, N. and A. Kuma, Autophagosomes in GFP-LC3 Transgenic Mice. 
Methods Mol Biol, 2008. 445: p. 119-24. 
73. Shvets, E., E. Fass, and Z. Elazar, Utilizing flow cytometry to monitor autophagy in 
living mammalian cells. Autophagy, 2008. 4(5): p. 621-8. 
74. Phadwal, K., et al., A novel method for autophagy detection in primary cells: impaired 
levels of macroautophagy in immunosenescent T cells. Autophagy, 2012. 8(4): p. 
677-89. 
75. Blommaart, E.F., et al., The phosphatidylinositol 3-kinase inhibitors wortmannin and 
LY294002 inhibit autophagy in isolated rat hepatocytes. Eur J Biochem, 1997. 243(1-
2): p. 240-6. 
76. Wu, Y., et al., Synthesis and screening of 3-MA derivatives for autophagy inhibitors. 
Autophagy, 2013. 9(4): p. 595-603. 
77. Klionsky, D.J., et al., Does bafilomycin A1 block the fusion of autophagosomes with 
lysosomes? Autophagy, 2008. 4(7): p. 849-950. 
78. Mizushima, N., Methods for monitoring autophagy. Int J Biochem Cell Biol, 2004. 
36(12): p. 2491-502. 
79. Homewood, C.A., et al., Lysosomes, pH and the anti-malarial action of chloroquine. 
Nature, 1972. 235(5332): p. 50-2. 
80. Guan, J.L., et al., Autophagy in stem cells. Autophagy, 2013. 9(6): p. 830-49. 
81. Yousefi, S. and H.U. Simon, Autophagy in cells of the blood. Biochim Biophys Acta, 
2009. 1793(9): p. 1461-4. 
82. Leveque, L., et al., Autophagy and haematopoietic stem cell transplantation. Immunol 
Cell Biol, 2015. 93(1): p. 43-50. 
83. Valcourt, J.R., et al., Staying alive: metabolic adaptations to quiescence. Cell Cycle, 
2012. 11(9): p. 1680-96. 
84. Kohli, L. and E. Passegue, Surviving change: the metabolic journey of hematopoietic 
stem cells. Trends Cell Biol, 2014. 24(8): p. 479-87. 
85. Yilmaz, O.H., M.J. Kiel, and S.J. Morrison, SLAM family markers are conserved 
among hematopoietic stem cells from old and reconstituted mice and markedly 
increase their purity. Blood, 2006. 107(3): p. 924-30. 
 119 
 
86. Gan, B., et al., mTORC1-dependent and -independent regulation of stem cell 
renewal, differentiation, and mobilization. Proc Natl Acad Sci U S A, 2008. 105(49): p. 
19384-9. 
87. Ho, T.T., et al., Autophagy maintains the metabolism and function of young and old 
stem cells. Nature, 2017. 543(7644): p. 205-210. 
88. Liu, F., et al., FIP200 is required for the cell-autonomous maintenance of fetal 
hematopoietic stem cells. Blood, 2010. 116(23): p. 4806-14. 
89. Mortensen, M., et al., The autophagy protein Atg7 is essential for hematopoietic stem 
cell maintenance. J Exp Med, 2011. 208(3): p. 455-67. 
90. Suda, T., K. Takubo, and G.L. Semenza, Metabolic regulation of hematopoietic stem 
cells in the hypoxic niche. Cell Stem Cell, 2011. 9(4): p. 298-310. 
91. Kuznetsov, A.V., et al., Mitochondrial ROS production under cellular stress: 
comparison of different detection methods. Anal Bioanal Chem, 2011. 400(8): p. 
2383-90. 
92. Mortensen, M., D.J. Ferguson, and A.K. Simon, Mitochondrial clearance by 
autophagy in developing erythrocytes: clearly important, but just how much so? Cell 
Cycle, 2010. 9(10): p. 1901-6. 
93. Bigarella, C.L., et al., FOXO3 Transcription Factor Is Essential for Protecting 
Hematopoietic Stem and Progenitor Cells from Oxidative DNA Damage. J Biol Chem, 
2017. 292(7): p. 3005-3015. 
94. Ito, K., et al., Reactive oxygen species act through p38 MAPK to limit the lifespan of 
hematopoietic stem cells. Nat Med, 2006. 12(4): p. 446-51. 
95. Jang, Y.Y. and S.J. Sharkis, A low level of reactive oxygen species selects for 
primitive hematopoietic stem cells that may reside in the low-oxygenic niche. Blood, 
2007. 110(8): p. 3056-63. 
96. Tothova, Z. and D.G. Gilliland, FoxO transcription factors and stem cell homeostasis: 
insights from the hematopoietic system. Cell Stem Cell, 2007. 1(2): p. 140-52. 
97. Watson, A.S., et al., Autophagy limits proliferation and glycolytic metabolism in acute 
myeloid leukemia. Cell Death Discov, 2015. 1. 
98. Cao, Y., et al., Autophagy regulates the cell cycle of murine HSPCs in a nutrient-
dependent manner. Exp Hematol, 2015. 43(3): p. 229-42. 
99. Warr, M.R., et al., FOXO3A directs a protective autophagy program in 
haematopoietic stem cells. Nature, 2013. 494(7437): p. 323-7. 
 120 
 
100. Kalaitzidis, D., et al., Amino acid-insensitive mTORC1 regulation enables nutritional 
stress resilience in hematopoietic stem cells. J Clin Invest, 2017. 127(4): p. 1405-
1413. 
101. Lin, W., et al., Autophagy confers DNA damage repair pathways to protect the 
hematopoietic system from nuclear radiation injury. Sci Rep, 2015. 5: p. 12362. 
102. Delgado, M., et al., Neuropeptides kill African trypanosomes by targeting intracellular 
compartments and inducing autophagic-like cell death. Cell Death Differ, 2009. 16(3): 
p. 406-16. 
103. Xu, Y., et al., Toll-like receptor 4 is a sensor for autophagy associated with innate 
immunity. Immunity, 2007. 27(1): p. 135-44. 
104. Mazzuca, P., et al., Role of Autophagy in HIV-1 Matrix Protein p17-Driven 
Lymphangiogenesis. J Virol, 2017. 91(16). 
105. Wan, Y., et al., Autophagy promotes osteogenic differentiation of human bone 
marrow mesenchymal stem cell derived from osteoporotic vertebrae. Biochem 
Biophys Res Commun, 2017. 488(1): p. 46-52. 
106. Williams, A., et al., Aggregate-prone proteins are cleared from the cytosol by 
autophagy: therapeutic implications. Curr Top Dev Biol, 2006. 76: p. 89-101. 
107. Cohen-Kaplan, V., A. Ciechanover, and I. Livneh, Stress-induced polyubiquitination 
of proteasomal ubiquitin receptors targets the proteolytic complex for autophagic 
degradation. Autophagy, 2017. 13(4): p. 759-760. 
108. Husak, Z. and M.N. Dworzak, Chronic stress induces CD99, suppresses autophagy, 
and affects spontaneous adipogenesis in human bone marrow stromal cells. Stem 
Cell Res Ther, 2017. 8(1): p. 83. 
109. Leveque-El Mouttie, L., et al., Autophagy is required for stem cell mobilization by G-
CSF. Blood, 2015. 125(19): p. 2933-6. 
110. Zeiser, R., G. Socie, and B.R. Blazar, Pathogenesis of acute graft-versus-host 
disease: from intestinal microbiota alterations to donor T cell activation. Br J 
Haematol, 2016. 175(2): p. 191-207. 
111. Woltman, A.M., et al., The effect of calcineurin inhibitors and corticosteroids on the 
differentiation of human dendritic cells. Eur J Immunol, 2000. 30(7): p. 1807-12. 
112. Zelante, T., et al., Impaired calcineurin signaling in myeloid cells results in 
downregulation of pentraxin-3 and increased susceptibility to aspergillosis. Mucosal 
Immunol, 2017. 10(2): p. 470-480. 
113. Koyama, M., et al., Donor colonic CD103+ dendritic cells determine the severity of 
acute graft-versus-host disease. J Exp Med, 2015. 212(8): p. 1303-21. 
 121 
 
114. Socie, G., et al., Prognostic value of apoptotic cells and infiltrating neutrophils in 
graft-versus-host disease of the gastrointestinal tract in humans: TNF and Fas 
expression. Blood, 2004. 103(1): p. 50-7. 
115. Schwab, L., et al., Neutrophil granulocytes recruited upon translocation of intestinal 
bacteria enhance graft-versus-host disease via tissue damage. Nat Med, 2014. 20(6): 
p. 648-54. 
116. Fischer, J.C., et al., Assessment of mucosal integrity by quantifying neutrophil 
granulocyte influx in murine models of acute intestinal injury. Cell Immunol, 2017. 
316: p. 70-76. 
117. Klambt, V., et al., A Novel Function for P2Y2 in Myeloid Recipient-Derived Cells 
during Graft-versus-Host Disease. J Immunol, 2015. 195(12): p. 5795-804. 
118. Hulsdunker, J., et al., Neutrophils provide cellular communication between ileum and 
mesenteric lymph nodes at graft-versus-host disease onset. Blood, 2018. 
119. Ginhoux, F. and M. Merad, Ontogeny and homeostasis of Langerhans cells. Immunol 
Cell Biol, 2010. 88(4): p. 387-92. 
120. Hashimoto, D., et al., Tissue-resident macrophages self-maintain locally throughout 
adult life with minimal contribution from circulating monocytes. Immunity, 2013. 38(4): 
p. 792-804. 
121. Schulz, C., et al., A lineage of myeloid cells independent of Myb and hematopoietic 
stem cells. Science, 2012. 336(6077): p. 86-90. 
122. Yona, S., et al., Fate mapping reveals origins and dynamics of monocytes and tissue 
macrophages under homeostasis. Immunity, 2013. 38(1): p. 79-91. 
123. Bain, C.C., et al., Constant replenishment from circulating monocytes maintains the 
macrophage pool in the intestine of adult mice. Nat Immunol, 2014. 15(10): p. 929-
937. 
124. Bogunovic, M., et al., Origin of the lamina propria dendritic cell network. Immunity, 
2009. 31(3): p. 513-25. 
125. Varol, C., S. Yona, and S. Jung, Origins and tissue-context-dependent fates of blood 
monocytes. Immunol Cell Biol, 2009. 87(1): p. 30-8. 
126. MacDonald, K.P., et al., An antibody against the colony-stimulating factor 1 receptor 
depletes the resident subset of monocytes and tissue- and tumor-associated 
macrophages but does not inhibit inflammation. Blood, 2010. 116(19): p. 3955-63. 
127. Mortha, A., et al., Microbiota-dependent crosstalk between macrophages and ILC3 
promotes intestinal homeostasis. Science, 2014. 343(6178): p. 1249288. 
 122 
 
128. Zhan, Y., Y. Xu, and A.M. Lew, The regulation of the development and function of 
dendritic cell subsets by GM-CSF: more than a hematopoietic growth factor. Mol 
Immunol, 2012. 52(1): p. 30-7. 
129. Martinez-Moczygemba, M. and D.P. Huston, Biology of common beta receptor-
signaling cytokines: IL-3, IL-5, and GM-CSF. J Allergy Clin Immunol, 2003. 112(4): p. 
653-65; quiz 666. 
130. Hercus, T.R., et al., Role of the beta Common (betac) Family of Cytokines in Health 
and Disease. Cold Spring Harb Perspect Biol, 2017. 
131. Dijkers, P.F., et al., Regulation and function of protein kinase B and MAP kinase 
activation by the IL-5/GM-CSF/IL-3 receptor. Oncogene, 1999. 18(22): p. 3334-42. 
132. Martinez-Moczygemba, M., et al., Distinct STAT structure promotes interaction of 
STAT2 with the p48 subunit of the interferon-alpha-stimulated transcription factor 
ISGF3. J Biol Chem, 1997. 272(32): p. 20070-6. 
133. Hercus, T.R., et al., Signalling by the betac family of cytokines. Cytokine Growth 
Factor Rev, 2013. 24(3): p. 189-201. 
134. Nishinakamura, R., et al., The pulmonary alveolar proteinosis in granulocyte 
macrophage colony-stimulating factor/interleukins 3/5 beta c receptor-deficient mice 
is reversed by bone marrow transplantation. J Exp Med, 1996. 183(6): p. 2657-62. 
135. Stanley, E., et al., Granulocyte/macrophage colony-stimulating factor-deficient mice 
show no major perturbation of hematopoiesis but develop a characteristic pulmonary 
pathology. Proc Natl Acad Sci U S A, 1994. 91(12): p. 5592-6. 
136. Nishinakamura, R., et al., Hematopoiesis in mice lacking the entire granulocyte-
macrophage colony-stimulating factor/interleukin-3/interleukin-5 functions. Blood, 
1996. 88(7): p. 2458-64. 
137. Hirata, Y., et al., GM-CSF-facilitated dendritic cell recruitment and survival govern the 
intestinal mucosal response to a mouse enteric bacterial pathogen. Cell Host 
Microbe, 2010. 7(2): p. 151-63. 
138. Broughton, S.E., et al., The GM-CSF/IL-3/IL-5 cytokine receptor family: from ligand 
recognition to initiation of signaling. Immunol Rev, 2012. 250(1): p. 277-302. 
139. Mach, N., et al., Involvement of interleukin-3 in delayed-type hypersensitivity. Blood, 
1998. 91(3): p. 778-83. 
140. Nicola, N.A., et al., Functional inactivation in mice of the gene for the interleukin-3 (IL-
3)-specific receptor beta-chain: implications for IL-3 function and the mechanism of 
receptor transmodulation in hematopoietic cells. Blood, 1996. 87(7): p. 2665-74. 
 123 
 
141. Lantz, C.S., et al., Role for interleukin-3 in mast-cell and basophil development and in 
immunity to parasites. Nature, 1998. 392(6671): p. 90-3. 
142. Shen, T., et al., T cell-derived IL-3 plays key role in parasite infection-induced 
basophil production but is dispensable for in vivo basophil survival. Int Immunol, 
2008. 20(9): p. 1201-9. 
143. Neel, N.F., et al., Absence of interleukin-3 does not affect the severity of local and 
systemic anaphylaxis but does enhance eosinophil infiltration in a mouse model of 
allergic peritonitis. Immunol Lett, 2004. 95(1): p. 37-44. 
144. Srivastava, R.K., et al., IL-3 attenuates collagen-induced arthritis by modulating the 
development of Foxp3+ regulatory T cells. J Immunol, 2011. 186(4): p. 2262-72. 
145. Eder, M., G. Geissler, and A. Ganser, IL-3 in the clinic. Stem Cells, 1997. 15(5): p. 
327-33. 
146. Jordan, C.T., et al., The interleukin-3 receptor alpha chain is a unique marker for 
human acute myelogenous leukemia stem cells. Leukemia, 2000. 14(10): p. 1777-84. 
147. Testa, U., et al., Elevated expression of IL-3Ralpha in acute myelogenous leukemia 
is associated with enhanced blast proliferation, increased cellularity, and poor 
prognosis. Blood, 2002. 100(8): p. 2980-8. 
148. Vergez, F., et al., High levels of CD34+CD38low/-CD123+ blasts are predictive of an 
adverse outcome in acute myeloid leukemia: a Groupe Ouest-Est des Leucemies 
Aigues et Maladies du Sang (GOELAMS) study. Haematologica, 2011. 96(12): p. 
1792-8. 
149. Jin, L., et al., Monoclonal antibody-mediated targeting of CD123, IL-3 receptor alpha 
chain, eliminates human acute myeloid leukemic stem cells. Cell Stem Cell, 2009. 
5(1): p. 31-42. 
150. Busfield, S.J., et al., Targeting of acute myeloid leukemia in vitro and in vivo with an 
anti-CD123 mAb engineered for optimal ADCC. Leukemia, 2014. 28(11): p. 2213-21. 
151. Al-Hussaini, M., et al., Targeting CD123 in acute myeloid leukemia using a T-cell-
directed dual-affinity retargeting platform. Blood, 2016. 127(1): p. 122-31. 
152. Tettamanti, S., et al., Targeting of acute myeloid leukaemia by cytokine-induced killer 
cells redirected with a novel CD123-specific chimeric antigen receptor. Br J 
Haematol, 2013. 161(3): p. 389-401. 
153. Takatsu, K., Interleukin-5 and IL-5 receptor in health and diseases. Proc Jpn Acad 
Ser B Phys Biol Sci, 2011. 87(8): p. 463-85. 
154. Yanagibashi, T., et al., Allergic diseases: From bench to clinic - Contribution of the 
discovery of interleukin-5. Cytokine, 2017. 98: p. 59-70. 
 124 
 
155. Nussbaum, J.C., et al., Type 2 innate lymphoid cells control eosinophil homeostasis. 
Nature, 2013. 502(7470): p. 245-8. 
156. Kolbeck, R., et al., MEDI-563, a humanized anti-IL-5 receptor alpha mAb with 
enhanced antibody-dependent cell-mediated cytotoxicity function. J Allergy Clin 
Immunol, 2010. 125(6): p. 1344-1353 e2. 
157. Kopf, M., et al., IL-4-deficient Balb/c mice resist infection with Leishmania major. J. 
Exp. Med., 1996. 184: p. 1127-1136. 
158. Matthaei, K.I., P. Foster, and I.G. Young, The role of interleukin-5 (IL-5) in vivo: 
studies with IL-5 deficient mice. Mem Inst Oswaldo Cruz, 1997. 92 Suppl 2: p. 63-8. 
159. Yoshida, T., et al., Defective B-1 cell development and impaired immunity against 
Angiostrongylus cantonensis in IL-5R alpha-deficient mice. Immunity, 1996. 4(5): p. 
483-94. 
160. Hiroi, T., et al., Deficiency of IL-5 receptor alpha-chain selectively influences the 
development of the common mucosal immune system independent IgA-producing B-
1 cell in mucosa-associated tissues. J Immunol, 1999. 162(2): p. 821-8. 
161. Moro, K., et al., Innate production of T(H)2 cytokines by adipose tissue-associated c-
Kit(+)Sca-1(+) lymphoid cells. Nature, 2010. 463(7280): p. 540-4. 
162. Neill, D.R., et al., Nuocytes represent a new innate effector leukocyte that mediates 
type-2 immunity. Nature, 2010. 464(7293): p. 1367-70. 
163. Saenz, S.A., et al., IL25 elicits a multipotent progenitor cell population that promotes 
T(H)2 cytokine responses. Nature, 2010. 464(7293): p. 1362-6. 
164. Yamada, Y., et al., The FIP1L1-PDGFRA fusion gene cooperates with IL-5 to induce 
murine hypereosinophilic syndrome (HES)/chronic eosinophilic leukemia (CEL)-like 
disease. Blood, 2006. 107(10): p. 4071-9. 
165. Wenzel, S., Severe asthma: from characteristics to phenotypes to endotypes. Clin 
Exp Allergy, 2012. 42(5): p. 650-8. 
166. Varricchi, G. and G.W. Canonica, The role of interleukin 5 in asthma. Expert Rev Clin 
Immunol, 2016. 12(9): p. 903-5. 
167. Becher, B., S. Tugues, and M. Greter, GM-CSF: From Growth Factor to Central 
Mediator of Tissue Inflammation. Immunity, 2016. 45(5): p. 963-973. 
168. Metcalf, D., Hematopoietic cytokines. Blood, 2008. 111(2): p. 485-91. 
169. Shi, Y., et al., Granulocyte-macrophage colony-stimulating factor (GM-CSF) and T-
cell responses: what we do and don't know. Cell Res, 2006. 16(2): p. 126-33. 
 125 
 
170. Codarri, L., et al., RORgammat drives production of the cytokine GM-CSF in helper T 
cells, which is essential for the effector phase of autoimmune neuroinflammation. Nat 
Immunol, 2011. 12(6): p. 560-7. 
171. Gartlan, K.H., et al., Tc17 cells are a proinflammatory, plastic lineage of pathogenic 
CD8+ T cells that induce GVHD without antileukemic effects. Blood, 2015. 126(13): 
p. 1609-20. 
172. Gartlan, K.H., et al., Th17 plasticity and transition toward a pathogenic cytokine 
signature are regulated by cyclosporine after allogeneic SCT. Blood Adv, 2017. 1(6): 
p. 341-351. 
173. Wada, H., et al., T cell functions in granulocyte/macrophage colony-stimulating factor 
deficient mice. Proc Natl Acad Sci U S A, 1997. 94(23): p. 12557-61. 
174. Rosas, M., S. Gordon, and P.R. Taylor, Characterisation of the expression and 
function of the GM-CSF receptor alpha-chain in mice. Eur J Immunol, 2007. 37(9): p. 
2518-28. 
175. van Nieuwenhuijze, A.E., et al., Transgenic expression of GM-CSF in T cells causes 
disseminated histiocytosis. Am J Pathol, 2014. 184(1): p. 184-99. 
176. Campbell, I.K., et al., Protection from collagen-induced arthritis in granulocyte-
macrophage colony-stimulating factor-deficient mice. J Immunol, 1998. 161(7): p. 
3639-44. 
177. McQualter, J.L., et al., Granulocyte macrophage colony-stimulating factor: a new 
putative therapeutic target in multiple sclerosis. J Exp Med, 2001. 194(7): p. 873-82. 
178. Ghosh, D., et al., Depletion of CD4+ CD25+ regulatory T cells confers susceptibility 
to experimental autoimmune encephalomyelitis (EAE) in GM-CSF-deficient Csf2-/- 
mice. J Leukoc Biol, 2016. 100(4): p. 747-760. 
179. Vlahos, R., et al., Neutralizing granulocyte/macrophage colony-stimulating factor 
inhibits cigarette smoke-induced lung inflammation. Am J Respir Crit Care Med, 
2010. 182(1): p. 34-40. 
180. Botelho, F.M., et al., A mouse GM-CSF receptor antibody attenuates neutrophilia in 
mice exposed to cigarette smoke. Eur Respir J, 2011. 38(2): p. 285-94. 
181. Yamashita, N., et al., Attenuation of airway hyperresponsiveness in a murine asthma 
model by neutralization of granulocyte-macrophage colony-stimulating factor (GM-
CSF). Cell Immunol, 2002. 219(2): p. 92-7. 
182. Fahy, J.V., Eosinophilic and neutrophilic inflammation in asthma: insights from clinical 
studies. Proc Am Thorac Soc, 2009. 6(3): p. 256-9. 
 126 
 
183. Griseri, T., et al., Granulocyte Macrophage Colony-Stimulating Factor-Activated 
Eosinophils Promote Interleukin-23 Driven Chronic Colitis. Immunity, 2015. 43(1): p. 
187-99. 
184. Bernasconi, E., et al., Critical role of the GM-CSF signaling pathway in macrophage 
pro-repair activities. Pathobiology, 2014. 81(4): p. 183-9. 
185. Koenderman, L., et al., Eosinophil priming by cytokines: from cellular signal to in vivo 
modulation. Eur Respir J Suppl, 1996. 22: p. 119s-125s. 
186. Sehmi, R., et al., Interleukin-5 selectively enhances the chemotactic response of 
eosinophils obtained from normal but not eosinophilic subjects. Blood, 1992. 79(11): 
p. 2952-9. 
187. Koenderman, L., et al., Granulocyte-macrophage colony-stimulating factor induces 
sequential activation and deactivation of binding via a low-affinity IgG Fc receptor, 
hFc gamma RII, on human eosinophils. Blood, 1993. 81(9): p. 2413-9. 
188. Masterson, J.C., et al., Eosinophil-mediated signalling attenuates inflammatory 
responses in experimental colitis. Gut, 2015. 64(8): p. 1236-47. 
189. Pearson, C., et al., ILC3 GM-CSF production and mobilisation orchestrate acute 
intestinal inflammation. Elife, 2016. 5: p. e10066. 
190. Drumm, B. and D. Vaughan, Granulocyte-macrophage colony-stimulating factor for 
Crohn's disease. Lancet, 2003. 361(9371): p. 1830; author reply 1830-1. 
191. Sainathan, S.K., et al., Granulocyte macrophage colony-stimulating factor 
ameliorates DSS-induced experimental colitis. Inflamm Bowel Dis, 2008. 14(1): p. 88-
99. 
192. Han, X., et al., Granulocyte-macrophage colony-stimulating factor autoantibodies in 
murine ileitis and progressive ileal Crohn's disease. Gastroenterology, 2009. 136(4): 
p. 1261-71, e1-3. 
193. Han, X., et al., Loss of GM-CSF signalling in non-haematopoietic cells increases 
NSAID ileal injury. Gut, 2010. 59(8): p. 1066-78. 
194. Egea, L., et al., GM-CSF produced by nonhematopoietic cells is required for early 
epithelial cell proliferation and repair of injured colonic mucosa. J Immunol, 2013. 
190(4): p. 1702-13. 
195. Joshi, P.C., et al., GM-CSF receptor expression and signaling is decreased in lungs 
of ethanol-fed rats. Am J Physiol Lung Cell Mol Physiol, 2006. 291(6): p. L1150-8. 
196. Sennikov, S.V., et al., Effects of granulocyte-macrophage colony-stimulating factor 
produced by intestinal epithelial cells on functional activity of hemopoietic stem cells. 
Bull Exp Biol Med, 2002. 134(6): p. 548-50. 
 127 
 
197. Paine, R., 3rd, et al., Transgenic overexpression of granulocyte macrophage-colony 
stimulating factor in the lung prevents hyperoxic lung injury. Am J Pathol, 2003. 
163(6): p. 2397-406. 
198. Penn, D.J., Major Histocompatibility Complex (MHC). Encyclopedia of life sciences, 
2002. 
199. Rock, K.L., A New Foreign Policy: MHC Class I Molecules Monitor the Outside 
World. Immunology  Today, 1996. 17(3): p. 131-137. 
200. Harding, C.V., Class I MHC presentation of exogenous antigens. J Clin Immunol, 
1996. 16(2): p. 90-6. 
201. Bevan, M.J., Cross-priming for a secondary cytotoxic response to minor H antigens 
with H-2 congenic cells which do not cross-react in the cytotoxic assay. J Exp Med, 
1976. 143(5): p. 1283-8. 
202. Rock, K.L., S. Gamble, and L. Rothstein, Presentation of exogenous antigen with 
class I major histocompatibility complex molecules. Science, 1990. 249(4971): p. 
918-21. 
203. Ostrand-Rosenberg, S., Tumor immunotherapy: the tumor cell as an antigen-
presenting cell. Curr Opin Immunol, 1994. 6(5): p. 722-7. 
204. Kambayashi, T. and T.M. Laufer, Atypical MHC class II-expressing antigen-
presenting cells: can anything replace a dendritic cell? Nat Rev Immunol, 2014. 
14(11): p. 719-30. 
205. Liu, H. and R. Jain, Ubiquitin ligase MARCH 8 cooperates with CD83 to control 
surface MHC II expression in thymic epithelium and CD4 T cell selection. 2016. 
213(9): p. 1695-703. 
206. Sconocchia, G., et al., HLA class II antigen expression in colorectal carcinoma 
tumors as a favorable prognostic marker. Neoplasia, 2014. 16(1): p. 31-42. 
207. Thibodeau, J., et al., Interleukin-10-induced MARCH1 mediates intracellular 
sequestration of MHC class II in monocytes. Eur J Immunol, 2008. 38(5): p. 1225-30. 
208. Hershko, A. and A. Ciechanover, The ubiquitin system. Annu Rev Biochem, 1998. 
67: p. 425-79. 
209. MacGurn, J.A., P.C. Hsu, and S.D. Emr, Ubiquitin and membrane protein turnover: 
from cradle to grave. Annu Rev Biochem, 2012. 81: p. 231-59. 
210. Pickart, C.M., Mechanisms underlying ubiquitination. Annu Rev Biochem, 2001. 70: 
p. 503-33. 
 128 
 
211. Cho, K.J. and P.A. Roche, Regulation of MHC Class II-Peptide Complex Expression 
by Ubiquitination. Front Immunol, 2013. 4: p. 369. 
212. Moffat, J.M., J.D. Mintern, and J.A. Villadangos, Control of MHC II antigen 
presentation by ubiquitination. Curr Opin Immunol, 2013. 25(1): p. 109-14. 
213. Villadangos, J.A., P. Schnorrer, and N.S. Wilson, Control of MHC class II antigen 
presentation in dendritic cells: a balance between creative and destructive forces. 
Immunol Rev, 2005. 207: p. 191-205. 
214. Samji, T., S. Hong, and R.E. Means, The Membrane Associated RING-CH Proteins: 
A Family of E3 Ligases with Diverse Roles through the Cell. Int Sch Res Notices, 
2014. 2014: p. 637295. 
215. Goto, E., et al., c-MIR, a human E3 ubiquitin ligase, is a functional homolog of 
herpesvirus proteins MIR1 and MIR2 and has similar activity. J Biol Chem, 2003. 
278(17): p. 14657-68. 
216. Bartee, E., et al., Downregulation of major histocompatibility complex class I by 
human ubiquitin ligases related to viral immune evasion proteins. J Virol, 2004. 78(3): 
p. 1109-20. 
217. Liu, H., et al., Ubiquitin ligase MARCH 8 cooperates with CD83 to control surface 
MHC II expression in thymic epithelium and CD4 T cell selection. J Exp Med, 2016. 
213(9): p. 1695-703. 
218. Tze, L.E., et al., CD83 increases MHC II and CD86 on dendritic cells by opposing IL-
10-driven MARCH1-mediated ubiquitination and degradation. J Exp Med, 2011. 
208(1): p. 149-65. 
219. Chen, R., et al., The E3 ubiquitin ligase MARCH8 negatively regulates IL-1beta-
induced NF-kappaB activation by targeting the IL1RAP coreceptor for ubiquitination 
and degradation. Proc Natl Acad Sci U S A, 2012. 109(35): p. 14128-33. 
220. van de Kooij, B., et al., Ubiquitination by the membrane-associated RING-CH-8 
(MARCH-8) ligase controls steady-state cell surface expression of tumor necrosis 
factor-related apoptosis inducing ligand (TRAIL) receptor 1. J Biol Chem, 2013. 
288(9): p. 6617-28. 
221. Fujita, H., et al., Membrane-associated RING-CH (MARCH) 8 mediates the 
ubiquitination and lysosomal degradation of the transferrin receptor. J Cell Sci, 2013. 
126(Pt 13): p. 2798-809. 
222. Tada, T., et al., MARCH8 inhibits HIV-1 infection by reducing virion incorporation of 
envelope glycoproteins. Nat Med, 2015. 21(12): p. 1502-7. 
 129 
 
223. von Rohrscheidt, J., et al., Thymic CD4 T cell selection requires attenuation of 
March8-mediated MHCII turnover in cortical epithelial cells through CD83. J Exp 
Med, 2016. 213(9): p. 1685-94. 
224. Galbas, T., et al., MARCH1 down-regulation in IL-10-activated B cells increases MHC 
class II expression. Cytokine, 2012. 59(1): p. 27-30. 
225. De Gassart, A., et al., MHC class II stabilization at the surface of human dendritic 
cells is the result of maturation-dependent MARCH I down-regulation. Proc Natl Acad 
Sci U S A, 2008. 105(9): p. 3491-6. 
226. Corcoran, K., et al., Ubiquitin-mediated regulation of CD86 protein expression by the 
ubiquitin ligase membrane-associated RING-CH-1 (MARCH1). J Biol Chem, 2011. 
286(43): p. 37168-80. 
227. Oh, J., et al., MARCH1-mediated MHCII ubiquitination promotes dendritic cell 
selection of natural regulatory T cells. J Exp Med, 2013. 210(6): p. 1069-77. 
228. Chattopadhyay, G. and E.M. Shevach, Antigen-specific induced T regulatory cells 
impair dendritic cell function via an IL-10/MARCH1-dependent mechanism. J 
Immunol, 2013. 191(12): p. 5875-84. 
229. Mittal, S.K., et al., Interleukin 10 (IL-10)-mediated Immunosuppression: MARCH-I 
INDUCTION REGULATES ANTIGEN PRESENTATION BY MACROPHAGES BUT 
NOT DENDRITIC CELLS. J Biol Chem, 2015. 290(45): p. 27158-67. 
230. Ishikawa, R., M. Kajikawa, and S. Ishido, Loss of MHC II ubiquitination inhibits the 
activation and differentiation of CD4 T cells. Int Immunol, 2014. 26(5): p. 283-9. 
231. Robb, L., et al., Hematopoietic and lung abnormalities in mice with a null mutation of 
the common beta subunit of the receptors for granulocyte-macrophage colony-
stimulating factor and interleukins 3 and 5. Proc Natl Acad Sci U S A, 1995. 92(21): 
p. 9565-9. 
232. Cao, Y.A., et al., Molecular imaging using labeled donor tissues reveals patterns of 
engraftment, rejection, and survival in transplantation. Transplantation, 2005. 80(1): 
p. 134-9. 
233. Burman, A.C., et al., IFNgamma differentially controls the development of idiopathic 
pneumonia syndrome and GVHD of the gastrointestinal tract. Blood, 2007. 110(3): p. 
1064-72. 
234. Cooke, K.R., et al., An experimental model of idiopathic pneumonia syndrome after 
bone marrow transplantation: I. The roles of minor H antigens and endotoxin. Blood, 
1996. 88(8): p. 3230-9. 
 130 
 
235. Livak, K.J. and T.D. Schmittgen, Analysis of relative gene expression data using real-
time quantitative PCR and the 2(-Delta Delta C(T)) Method. Methods, 2001. 25(4): p. 
402-8. 
236. Weissman, I.L., Stem cells: units of development, units of regeneration, and units in 
evolution. Cell, 2000. 100(1): p. 157-68. 
237. Eaves, C.J., Hematopoietic stem cells: concepts, definitions, and the new reality. 
Blood, 2015. 125(17): p. 2605-13. 
238. Purton, L.E. and D.T. Scadden, Limiting factors in murine hematopoietic stem cell 
assays. Cell Stem Cell, 2007. 1(3): p. 263-70. 
239. Schoedel, K.B., et al., The bulk of the hematopoietic stem cell population is 
dispensable for murine steady-state and stress hematopoiesis. Blood, 2016. 
240. Na Nakorn, T., et al., Myeloerythroid-restricted progenitors are sufficient to confer 
radioprotection and provide the majority of day 8 CFU-S. J Clin Invest, 2002. 109(12): 
p. 1579-85. 
241. Mattsson, J., O. Ringden, and R. Storb, Graft failure after allogeneic hematopoietic 
cell transplantation. Biol Blood Marrow Transplant, 2008. 14(1 Suppl 1): p. 165-70. 
242. Walasek, M.A., R. van Os, and G. de Haan, Hematopoietic stem cell expansion: 
challenges and opportunities. Ann N Y Acad Sci, 2012. 1266: p. 138-50. 
243. Reddy, P., R. Negrin, and G.R. Hill, Mouse models of bone marrow transplantation. 
Biol Blood Marrow Transplant, 2008. 14(1 Suppl 1): p. 129-35. 
244. Holmfeldt, P., et al., Functional screen identifies regulators of murine hematopoietic 
stem cell repopulation. J Exp Med, 2016. 213(3): p. 433-49. 
245. Rossi, L., et al., Less is more: unveiling the functional core of hematopoietic stem 
cells through knockout mice. Cell Stem Cell, 2012. 11(3): p. 302-17. 
246. Sun, J., et al., Clonal dynamics of native haematopoiesis. Nature, 2014. 514(7522): 
p. 322-7. 
247. Busch, K., et al., Fundamental properties of unperturbed haematopoiesis from stem 
cells in vivo. Nature, 2015. 518(7540): p. 542-6. 
248. Markey, K.A., K.P. MacDonald, and G.R. Hill, The biology of graft-versus-host 
disease: experimental systems instructing clinical practice. Blood, 2014. 124(3): p. 
354-362. 
249. Harris, J., Autophagy and cytokines. Cytokine, 2011. 56(2): p. 140-4. 
 131 
 
250. Yorimitsu, T. and D.J. Klionsky, Autophagy: molecular machinery for self-eating. Cell 
Death Differ, 2005. 12 Suppl 2: p. 1542-52. 
251. Cuervo, A.M., Autophagy: many paths to the same end. Mol Cell Biochem, 2004. 
263(1-2): p. 55-72. 
252. Mizushima, N., Autophagy: process and function. Genes Dev, 2007. 21(22): p. 2861-
73. 
253. Chen, Y. and D.J. Klionsky, The regulation of autophagy - unanswered questions. J 
Cell Sci, 2011. 124(Pt 2): p. 161-70. 
254. Yang, Z. and D.J. Klionsky, Eaten alive: a history of macroautophagy. Nat Cell Biol, 
2010. 12(9): p. 814-22. 
255. Yang, Z. and D.J. Klionsky, An overview of the molecular mechanism of autophagy. 
Curr Top Microbiol Immunol, 2009. 335: p. 1-32. 
256. Mortensen, M., A.S. Watson, and A.K. Simon, Lack of autophagy in the 
hematopoietic system leads to loss of hematopoietic stem cell function and 
dysregulated myeloid proliferation. Autophagy, 2011. 7(9): p. 1069-70. 
257. Pua, H.H., et al., A critical role for the autophagy gene Atg5 in T cell survival and 
proliferation. J Exp Med, 2007. 204(1): p. 25-31. 
258. Mombaerts, P., et al., RAG-1-deficient mice have no mature B and T lymphocytes. 
Cell, 1992. 68(5): p. 869-77. 
259. Dybedal, I., et al., Tumor necrosis factor (TNF)-mediated activation of the p55 TNF 
receptor negatively regulates maintenance of cycling reconstituting human 
hematopoietic stem cells. Blood, 2001. 98(6): p. 1782-91. 
260. Imamura, M., et al., In vitro expansion of murine hematopoietic progenitor cells by 
leukemia inhibitory factor, stem cell factor, and interleukin-1 beta. Exp Hematol, 
1996. 24(11): p. 1280-8. 
261. Hara, T., et al., Excessive production of tumor necrosis factor-alpha by bone marrow 
T lymphocytes is essential in causing bone marrow failure in patients with aplastic 
anemia. Eur J Haematol, 2004. 73(1): p. 10-6. 
262. Sejas, D.P., et al., Inflammatory reactive oxygen species-mediated hemopoietic 
suppression in Fancc-deficient mice. J Immunol, 2007. 178(8): p. 5277-87. 
263. Niho, Y. and Y. Asano, Fas/Fas ligand and hematopoietic progenitor cells. Curr Opin 
Hematol, 1998. 5(3): p. 163-5. 
 132 
 
264. Khandelwal, P., et al., Cytokine Profile of Engraftment Syndrome in Pediatric 
Hematopoietic Stem Cell Transplant Recipients. Biol Blood Marrow Transplant, 2016. 
22(4): p. 690-697. 
265. Hill, G.R., W. Krenger, and J.L. Ferrara, The role of cytokines in acute graft-versus-
host disease. Cytokines Cell Mol Ther, 1997. 3(4): p. 257-66. 
266. Pietras, E.M., et al., Chronic interleukin-1 exposure drives haematopoietic stem cells 
towards precocious myeloid differentiation at the expense of self-renewal. Nat Cell 
Biol, 2016. 18(6): p. 607-18. 
267. Wang, W. and H. Fujii, Enhanced human hematopoietic stem and progenitor cell 
engraftment by blocking donor T cell-mediated TNFalpha signaling. 2017. 9(421). 
268. Arend, W.P., Interleukin-1 receptor antagonist. Adv. Immunol., 1993. 54: p. 167-227. 
269. Jarvis, B. and D. Faulds, Etanercept: a review of its use in rheumatoid arthritis. 
Drugs, 1999. 57(6): p. 945-66. 
270. Zhang, B., et al., Inhibition of interleukin-1 signaling enhances elimination of tyrosine 
kinase inhibitor-treated CML stem cells. Blood, 2016. 128(23): p. 2671-2682. 
271. Fleischmann, R.M., et al., Safety of extended treatment with anakinra in patients with 
rheumatoid arthritis. Ann Rheum Dis, 2006. 65(8): p. 1006-12. 
272. Mantel, C.R., et al., Enhancing Hematopoietic Stem Cell Transplantation Efficacy by 
Mitigating Oxygen Shock. Cell, 2015. 161(7): p. 1553-65. 
273. Koyama, M., et al., Plasmacytoid dendritic cells prime alloreactive T cells to mediate 
graft-versus-host disease as antigen-presenting cells. Blood, 2009. 113(9): p. 2088-
95. 
274. Leveque-El Mouttie, L., et al., Corruption of dendritic cell antigen presentation during 
acute GVHD leads to regulatory T-cell failure and chronic GVHD. 2016. 128(6): p. 
794-804. 
275. Hashimoto, D., et al., Pretransplant CSF-1 therapy expands recipient macrophages 
and ameliorates GVHD after allogeneic hematopoietic cell transplantation. J Exp 
Med, 2011. 208(5): p. 1069-82. 
276. Weber, G.F., et al., Interleukin-3 amplifies acute inflammation and is a potential 
therapeutic target in sepsis. Science, 2015. 347(6227): p. 1260-5. 
277. Atkinson, K., et al., Effect of in vivo administration of IL-3 and IL-6, alone and in 
combination with G-CSF, GM-CSF or IL-1, on haematopoiesis, graft-versus-host 
disease and survival after murine haematopoietic stem cell transplantation. Cytokines 
Mol Ther, 1995. 1(1): p. 47-55. 
 133 
 
278. Johansson, M.W., et al., Anti-IL-5 attenuates activation and surface density of beta(2) 
-integrins on circulating eosinophils after segmental antigen challenge. Clin Exp 
Allergy, 2013. 43(3): p. 292-303. 
279. Fukuzawa, H., et al., Identification of GM-CSF in Paneth cells using single-cell RT-
PCR. Biochem Biophys Res Commun, 2003. 312(4): p. 897-902. 
280. Ullrich, E., et al., BATF-dependent IL-7RhiGM-CSF+ T cells control intestinal graft-
versus-host disease. J Clin Invest, 2018. 128(3): p. 916-930. 
281. MacDonald, K.P., et al., Effector and regulatory T-cell function is differentially 
regulated by RelB within antigen-presenting cells during GVHD. Blood, 2007. 
109(11): p. 5049-57. 
282. Bronte, V., et al., Identification of a CD11b(+)/Gr-1(+)/CD31(+) myeloid progenitor 
capable of activating or suppressing CD8(+) T cells. Blood, 2000. 96(12): p. 3838-46. 
283. Frendl, G., Interleukin 3: from colony-stimulating factor to pluripotent 
immunoregulatory cytokine. Int J Immunopharmacol, 1992. 14(3): p. 421-30. 
284. Valent, P., et al., Detection of circulating endogenous interleukin-3 in extensive 
chronic graft-versus-host disease. Bone Marrow Transplant, 1992. 9(5): p. 331-6. 
285. Salvi, S., et al., Interleukin-5 production by human airway epithelial cells. Am J Respir 
Cell Mol Biol, 1999. 20(5): p. 984-91. 
286. Wu, C.A., et al., Bronchial epithelial cells produce IL-5: implications for local immune 
responses in the airways. Cell Immunol, 2010. 264(1): p. 32-41. 
287. Hamilton, J.A., GM-CSF in inflammation and autoimmunity. Trends Immunol, 2002. 
23(8): p. 403-8. 
288. Fleetwood, A.J., et al., Granulocyte-macrophage colony-stimulating factor (CSF) and 
macrophage CSF-dependent macrophage phenotypes display differences in cytokine 
profiles and transcription factor activities: implications for CSF blockade in 
inflammation. J Immunol, 2007. 178(8): p. 5245-52. 
289. Le Texier, L., K.E. Lineburg, and K.P. MacDonald, Harnessing bone marrow resident 
regulatory T cells to improve allogeneic stem cell transplant outcomes. Int J Hematol, 
2017. 105(2): p. 153-161. 
290. Carlson, M.J., et al., In vitro-differentiated TH17 cells mediate lethal acute graft-
versus-host disease with severe cutaneous and pulmonary pathologic 
manifestations. Blood, 2009. 113(6): p. 1365-74. 
291. Nurieva, R.I. and Y. Chung, Understanding the development and function of T 
follicular helper cells. Cell Mol Immunol, 2010. 7(3): p. 190-7. 
 134 
 
292. Nikolic, B., et al., Th1 and Th2 mediate acute graft-versus-host disease, each with 
distinct end-organ targets. J Clin Invest, 2000. 105(9): p. 1289-98. 
293. Fujii, N., et al., Serum cytokine concentrations and acute graft-versus-host disease 
after allogeneic peripheral blood stem cell transplantation: concurrent measurement 
of ten cytokines and their respective ratios using cytometric bead array. Int J Mol 
Med, 2006. 17(5): p. 881-5. 
294. LeVine, A.M., et al., GM-CSF-deficient mice are susceptible to pulmonary group B 
streptococcal infection. J Clin Invest, 1999. 103(4): p. 563-9. 
295. Bhattacharya, P., et al., GM-CSF: An immune modulatory cytokine that can suppress 
autoimmunity. Cytokine, 2015. 75(2): p. 261-71. 
296. Wicks, I.P. and A.W. Roberts, Targeting GM-CSF in inflammatory diseases. Nat Rev 
Rheumatol, 2016. 12(1): p. 37-48. 
297. Matsuki, Y., et al., Novel regulation of MHC class II function in B cells. EMBO J, 
2007. 26(3): p. 846-54. 
298. Shin, J.S., et al., Surface expression of MHC class II in dendritic cells is controlled by 
regulated ubiquitination. Nature, 2006. 444(7115): p. 115-8. 
299. Saada, J.I., et al., Subepithelial myofibroblasts are novel nonprofessional APCs in the 
human colonic mucosa. J Immunol, 2006. 177(9): p. 5968-79. 
300. Kundig, T.M., et al., Fibroblasts as efficient antigen-presenting cells in lymphoid 
organs. Science, 1995. 268(5215): p. 1343-7. 
301. Powell, D.W., et al., Mesenchymal cells of the intestinal lamina propria. Annu Rev 
Physiol, 2011. 73: p. 213-37. 
302. Card, C.M., S.S. Yu, and M.A. Swartz, Emerging roles of lymphatic endothelium in 
regulating adaptive immunity. J Clin Invest, 2014. 124(3): p. 943-52. 
303. Abrahimi, P., et al., Blocking MHC class II on human endothelium mitigates acute 
rejection. JCI Insight, 2016. 1(1). 
304. Hershberg, R.M., et al., Intestinal epithelial cells use two distinct pathways for HLA 
class II antigen processing. J Clin Invest, 1997. 100(1): p. 204-15. 
305. Hershberg, R.M., et al., Highly polarized HLA class II antigen processing and 
presentation by human intestinal epithelial cells. J Clin Invest, 1998. 102(4): p. 792-
803. 
306. Beers, C., et al., Cathepsin S Controls MHC Class II-Mediated Antigen Presentation 
by Epithelial Cells In Vivo. The Journal of Immunology, 2005. 174(3): p. 1205-1212. 
 135 
 
307. Toubai, T., et al., Induction of acute GVHD by sex-mismatched H-Y antigens in the 
absence of functional radiosensitive host hematopoietic-derived antigen-presenting 
cells. Blood, 2012. 119(16): p. 3844-53. 
308. Baravalle, G., et al., Ubiquitination of CD86 is a key mechanism in regulating antigen 
presentation by dendritic cells. J Immunol, 2011. 187(6): p. 2966-73. 
309. Powrie, F., et al., Phenotypically distinct subsets of CD4+ T cells induce or protect 
from chronic intestinal inflammation in C. B-17 scid mice. Int Immunol, 1993. 5(11): p. 
1461-71. 
310. Westendorf, A.M., et al., CD4+Foxp3+ regulatory T cell expansion induced by 
antigen-driven interaction with intestinal epithelial cells independent of local dendritic 
cells. Gut, 2009. 58(2): p. 211-9. 
311. Dotan, I., et al., Intestinal epithelial cells from inflammatory bowel disease patients 
preferentially stimulate CD4+ T cells to proliferate and secrete interferon-gamma. Am 
J Physiol Gastrointest Liver Physiol, 2007. 292(6): p. G1630-40. 
312. Bisping, G., et al., Patients with inflammatory bowel disease (IBD) reveal increased 
induction capacity of intracellular interferon-gamma (IFN-gamma) in peripheral CD8+ 
lymphocytes co-cultured with intestinal epithelial cells. Clin Exp Immunol, 2001. 
123(1): p. 15-22. 
313. Stevanovic, S., et al., HLA class II upregulation during viral infection leads to HLA-
DP-directed graft-versus-host disease after CD4+ donor lymphocyte infusion. Blood, 
2013. 122(11): p. 1963-73. 
314. Petersdorf, E.W., et al., High HLA-DP Expression and Graft-versus-Host Disease. N 
Engl J Med, 2015. 373(7): p. 599-609. 
315. Bourgeois-Daigneault, M.C. and J. Thibodeau, Autoregulation of MARCH1 
expression by dimerization and autoubiquitination. J Immunol, 2012. 188(10): p. 
4959-70. 
316. Yonashiro, R., et al., A novel mitochondrial ubiquitin ligase plays a critical role in 
mitochondrial dynamics. EMBO J, 2006. 25(15): p. 3618-26. 
317. Hassink, G., et al., TEB4 is a C4HC3 RING finger-containing ubiquitin ligase of the 
endoplasmic reticulum. Biochem J, 2005. 388(Pt 2): p. 647-55. 
318. Iyengar, P.V., et al., Membrane-associated RING-CH 10 (MARCH10 protein) is a 
microtubule-associated E3 ubiquitin ligase of the spermatid flagella. J Biol Chem, 
2011. 286(45): p. 39082-90. 
319. Hunt, D., et al., Francisella tularensis elicits IL-10 via a PGE(2)-inducible factor, to 
drive macrophage MARCH1 expression and class II down-regulation. PLoS One, 
2012. 7(5): p. e37330. 
 136 
 
320. Ohmura-Hoshino, M., et al., Cutting edge: requirement of MARCH-I-mediated MHC II 
ubiquitination for the maintenance of conventional dendritic cells. J Immunol, 2009. 
183(11): p. 6893-7. 
321. Zhang, Y., J. Lu, and X. Liu, MARCH2 is upregulated in HIV-1 infection and inhibits 
HIV-1 production through envelope protein translocation or degradation. Virology, 
2018. 518: p. 293-300. 
322. Thelemann, C., et al., Interferon-gamma induces expression of MHC class II on 
intestinal epithelial cells and protects mice from colitis. PLoS One, 2014. 9(1): p. 
e86844. 
323. Toyomoto, M., et al., Anti-arthritic effect of E3 ubiquitin ligase, c-MIR, expression in 
the joints. Int Immunol, 2011. 23(3): p. 177-83. 
324. Zhang, L., et al., Expression of USP7 and MARCH7 Is Correlated with Poor 
Prognosis in Epithelial Ovarian Cancer. Tohoku J Exp Med, 2016. 239(3): p. 165-75. 
325. Singh, S., et al., Increased expression of MARCH8, an E3 ubiquitin ligase, is 
associated with growth of esophageal tumor. Cancer Cell Int, 2017. 17: p. 116. 
326. Zhou, V., et al., A colitogenic memory CD4+ T cell population mediates 
gastrointestinal graft-versus-host disease. J Clin Invest, 2016. 126(9): p. 3541-55. 
 
  
 137 
 
Appendix 1 
 
 
 
QIMR Berghofer Medical Research Institute Animal Ethical Approval for Project P2096 – 
Autophagy and stem cell transplantation (2015 – 2019). 
